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Obesity and type 2 diabetes mellitus (T2DM) are among the most common and costly health-related issues 
worldwide, and both have been declared a global epidemic by the World Health Organization. A key 
characteristic of these conditions is disturbed leptin signalling. Leptin, named after the Greek word for 
‘lean’ (λεπτός), is a hormone that plays a key role in energy homeostasis. Although known best for its 
adipostatic role in mammals, leptin also regulates glucose homeostasis independent of effects on 
adipostasis. To date, the mechanism through which leptin exerts its glucoregulatory actions remains largely 
unknown. This thesis investigates whether leptin regulates glucose homeostasis via the canonical 
WNT pathway in the zebrafish (Danio rerio). Non-mammalian leptin studies have been conducted for 
only a little bit over a decade, and still comprise but a tiny fraction (<2%) of the total research in this field. 
However, these studies are needed not only to answer comparative questions, but uncovering the 
evolutionary origins of leptin function will clarify our understanding of how this hormone functions in the 
human body.  
Using the CRISPR/Cas9 mutagenesis system, stable mutant zebrafish lines were successfully generated 
(chapter 2). These fish had a homozygous knockout of either the leptin-a gene (lepa), the leptin-b gene 
(lepb) or the leptin receptor gene (lepr). Next, protocols were established to investigate glucose homeostasis 
in adult zebrafish (chapter 3). Existing procedures for intraperitoneal injection and blood sampling were 
adapted to create a protocol for intraperitoneal glucose tolerance tests in adult zebrafish. In addition to this 
acute hyperglycaemic challenge, a glucose-immersion protocol was established to allow for the 
investigation of artificially-induced persistent hyperglycaemia as well.  
Combining the mutant fish generated in chapter 2 with the protocols established in chapter 3, the effects of 
leptin- and leptin receptor deficiency were characterized in adult zebrafish (chapter 4). It was confirmed 
that under normal feeding conditions, leptin regulates glucose homeostasis but not adipostasis in the 




zebrafish. However, in times of nutrient excess leptin was found to regulate body weight and standard 
length, and glucose homeostasis was impaired.  
Next, the canonical WNT pathway was investigated as a potential mediator of the glucoregulatory effects 
of leptin. Taking advantage of the optical transparency of zebrafish larvae, a transgenic zebrafish line 
expressing fluorescence upon WNT pathway activation was used to demonstrate that leptin directly 
activates the canonical WNT pathway in vivo (chapter 5). Finally, various pharmacological manipulations 
of the canonical WNT pathway were performed in leptin-mutant fish and wild type controls to demonstrate 
that leptin regulates glucose homeostasis via the canonical WNT pathway (chapter 6).  
Together, these findings show a novel essential role of the canonical Wnt pathway in the neuroendocrine 
control of glucose homeostasis in zebrafish. Furthermore, these data highlight that leptin may primarily 
have evolved as a glucoregulatory hormone with its role of an adipostat acquired later in evolution. Finally, 
the glucoregulatory action of leptin is mediated via the Wnt pathway - an essential mechanism that appears 
preserved throughout the vertebrate phylum. 
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Abstract 
Leptin is a body weight regulatory hormone, but it is arguably even more potent at regulating blood glucose 
levels. The molecular mechanism by which leptin controls glucose homeostasis remains largely unknown. 
To further our understanding, we use a transgenic zebrafish model and conditional deletion of beta catenin 
in the mediobasal hypothalamus of adult mice to show that Wnt signalling mediates glucoregulatory effects 
of leptin. In zebrafish, under normal feeding conditions, leptin regulates glucose homeostasis but not 
adipostasis. In times of nutrient excess, we found that leptin also regulates body weight and size in this 
species. Using a Wnt signalling reporter fish, we show that leptin directly activates the canonical Wnt 
pathway in vivo. Pharmacological inhibition of this pathway prevented the leptin-induced improvement in 
glucose tolerance. In adult mice, conditional deletion of the key Wnt effector molecule, β-catenin, in the 
mediobasal hypothalamus of male mice confirmed the essential role of the Wnt pathway in mediating leptin 
action and neuroendocrine regulation of glucose homeostasis. Adult-onset β-catenin deletion in the 
mediobasal hypothalamus led to glucose intolerance, high fat diet-induced exacerbation of body weight 
gain and caloric intake as well as resistance to exogenous leptin. 
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Abstract 
Energy homeostasis is controlled by an intricate regulatory system centred in the brain. The peripheral 
adiposity signals insulin and leptin play a crucial role in this system by informing the brain of the energy 
status of the body and mediating their catabolic effects through signal transduction in hypothalamic areas 
that control food intake, energy expenditure and glucose metabolism. Disruptions of insulin and leptin 
signalling can result in diabetes and obesity. The central signalling crosstalk between insulin and leptin is 
essential for maintenance of normal healthy energy homeostasis. An important role of leptin in 
glucoregulation has been revealed. Typically regarded as controlled by insulin, the control of glucose 
homeostasis critically depends on functional leptin action. Leptin, on the other hand, is able to lower glucose 
levels in the absence of insulin, but insulin is necessary for long-term stabilization of euglycaemia. Evidence 
from rodent models and human patients suggests that leptin improves insulin sensitivity in type 1 diabetes. 
The signalling crosstalk between insulin and leptin is likely conveyed by the WNT/β-catenin pathway. 
Leptin activates WNT/β-catenin signalling, leading to inhibition of GSK-3β, a key inhibitor of insulin 
action, and thereby facilitating improved insulin signal transduction and sensitization of insulin action. 
Interestingly, insights into the roles of insulin and leptin in insects and fish indicate that leptin may have 
initially evolved as a glucoregulatory hormone and that its anorexigenic and body weight regulatory 
function was acquired throughout evolution. Furthermore, the regulation of both central and peripheral 
control of energy homeostasis is tightly controlled by the circadian clock, allowing adaptation of 
homeostatic processes to environmental cues. 
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LiCl lithium chloride 
LKB1 serine–threonine liver kinase B1 
LRP lipoprotein related protein 
MAP mitogen-activated protein 
MC3R melanocortin receptor 3 
MC4R melanocortin receptor 4 
mRNA messenger ribonucleic acid 
MS-222 tricaine mesylate 
mTORC2 mammalian target of rapamycin complex 2 
NF-kB nuclear factor kappa B 
NHEJ non-homologous end joining 




nls nuclear localization signal 
NPY neuropeptide Y 
NTP nucleoside triphosphate 
NTS nucleus of the solitary tract 
ob obese gene (leptin) 
ob-rgrp leptin receptor gene-related protein (endospanin) 
OD outer diameter 
PACAP pituitary adenyl cyclase activating protein 
PAM protospacer adjacent motif 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PDPK1 phosphoinositide dependent kinase 1 
PFA paraform aldehyde 
PI3K phosphoinositide 3-kinase 
PIP3 phosphatidylinositol-3,4,5trisphosphate 
POMC proopiomelanocortin 
PRKCQ protein kinase C θ-type 
Pten tumour suppressor phosphatase and tensin homolog 
PTP1B protein tyrosine phosphatase 1B  
PTU N-phenylthiourea  
PVN paraventricular nucleus 
Rab13 Ras-related protein 13 
Rab8 Ras-related protein 8 
RNA ribonucleic acid 
RNAseq ribonucleic acid sequencing 
RT-qPCR reverse transcription polymerase chain reaction 
S40V-polyA simian virus 40 polyadenylation 
SEM standard error of the mean 
SF1 steroidogenic factor 1 
sgRNA single guide RNA 
SH2 Src homology 2 domain 
SH2B1 SH2B adapter protein 1 
SLC2A5 Solute Carrier Family 2 Member 5 
sLEPR soluble leptin receptor 
SOCS3 supressor of cytokine signalling 3 
STAT signal transducer and activator of transcription 
T1DM type 1 diabetes mellitus 
T2DM type 2 diabetes mellitus 
TAE tris acetate EDTA 
TALEN transcription activator-like effector nuclease 
TCF T cell factor 
TCF7l2 transcription factor 7-like 2 




TCPTP T cell protein-tyrosine phosphatase  
TNFα tumour necrosis factor alpha 
TRAPseq translating ribosome affinity purification sequencing  
TRH thyrotropin-releasing hormone 
TYK2 non-receptor tyrosine-protein kinase 2 
Upd2 unpaired 2 
VMH ventromedial hypothalamic nucleus 
WNT wingless-integration1 
XbaI Xanthomonas badrii 1 
Y1077 leptin receptor tyrosine residue number 1077 
Y1138 leptin receptor tyrosine residue number 1138 
Y985 leptin receptor tyrosine residue number 985 
ZFIN zebrafish international network 
ZFN zinc-finger nuclease 
ZIRC zebrafish international resource center 
ZM Zebrafish Management Ltd. 













1.1 Societal Relevance 
1.1.1 Obesity and type 2 diabetes in numbers 
Obesity and type 2 diabetes (T2DM) are among the most common and costly chronic disorders worldwide 
[1], and both have been declared a global epidemic by the World Health Organization. Disrupted leptin 
signalling is one of the key characteristics of metabolic disorders like obesity and T2DM. Obesity is 
generally defined as having a body mass index ≥30 kg/m2. The risk of T2DM, generally defined as having 
a fasting plasma glucose ≥126mg/dl or a glucose tolerance ≥200mg/dl two hours post glucose injection, 
increases exponentially as body mass index increases above about 25kg/m2. A meta-analysis of 1698 studies 
on the prevalence of obesity estimated that in 1974, 105 million adults worldwide were obese. By 2014 that 
number had increased 6-fold to 640 million [2] (figure 1.1, figure 1.2). Likewise, a meta-analysis of 751 
studies showed that the prevalence of T2DM has quadrupled from 108 million individuals in 1980 to 422 
million in 2014 (figure 3, figure 4). It is estimated that half of these people are not aware of their condition 
and even more are not receiving any kind of treatment. One of the World Health Organization’s global 
health targets, endorsed by all member states, is to restrict the rise of obesity and T2DM for the year 2025 
to rates observed in 2010. At the current rise, chances of actually reaching this target have been deemed 
virtually zero [3].  
For the majority of endocrine disorders, effective therapeutic treatments have been developed, based on the 
underlying physiological mechanisms. For obesity and T2DM on the other hand, no curative treatment 
exists. Despite decades of research and billions of dollars spent on symptomatic management every year, 
no effective therapies exist [4]. Given the immense amount of time and effort that the scientific community 
has invested into understanding the pathogenesis of obesity and type 2 diabetes, we still have a surprisingly 
limited understanding of these conditions.  





Figure 1.1 Age-standardized mean BMI in men by country in 1975 and 2014. Adapted from [2]. 





Figure 1.2 Age-standardized mean BMI in women by country in 1975 and 2014. Adapted from [2]. 





Figure 1.3 Age-standardized prevalence of diabetes in adult men by country in 1980 and 2014. Adapted from [5]. 





Figure 1.4 Age-standardized prevalence of diabetes in adult women by country in 1980 and 2014. Adapted from [5]. 




1.1.2 Obesity in pre-modern times 
Life on earth has evolved under a constant struggle for existence. Throughout history, organisms have 
always had to compete for limited resources needed to survive [6]. Humans too have been chronically 
plagued by food shortage and malnutrition. Obesity was not seen as a pathological state until about a century 
ago [7]. Instead, the historical scarcity of food led to the belief that being obese was a sign of wealth and 
health. Even today, some traditional cultures still perceive diet-induced obesity as a sign of social status 
and aesthetic beauty. For example, young males of the Massa tribe from northern Cameroon take part in 
collective premarital ‘fattening sessions’, called Guru Walla, in order to increase their chances to find a 
partner. Over the course of about two months, participants voluntarily double or triple their habitual daily 
food intake, gaining 17 kilograms on average [8, 9]. Exceptions like these are mostly found in ancient 
societies that preserved their traditional lifestyle. In the modern world, where the majority of people have 
unlimited access to food and where exercise is seen as a pastime instead of a necessity of survival, obesity 
and related disorders like T2DM are considered medical conditions with well-defined pathologic 
consequences.  
The transformation of humankind from hunger-driven hunter-gatherers into saturated couch potatoes took 
an estimated 7000 generations [7], but this same transformation was attained by the Pima people over the 
course of only 3 generations [10]. Native to southern Arizona, this tribe settled and farmed the area 
surrounding the Gila and Salt rivers for many centuries. The construction of a dam upstream forced them 
to suddenly abandon their traditional diet and lifestyle, shifting from farmed crops to mainly processed 
foods, together with a decline in physical activity. The combination of a genetic makeup that is 
evolutionarily designed for an environment with limited food supplies and the sudden shift towards a rather 
incompatible lifestyle with food abundant both in terms of availability and energy density has resulted in 
the Pima people having the highest known prevalence of obesity and type 2 diabetes in the world [11]. In 




comparison, genetically similar native tribes from nearby Mexico were found to only have a slightly higher 
prevalence of type 2 diabetes than non-Pima Mexicans [12].  
1.2.3 Explaining the pandemic: thrifty versus drifty genes 
These findings are in support of the so called thrifty gene hypothesis. This hypothesis, proposed by James 
Neel in 1962, postulates that certain adaptive (‘thrifty’) genes that predispose certain ethnic groups towards 
obesity and T2DM were advantageous throughout evolution, but have become detrimental in the modern 
era [13]. These genes supposedly enable to process and store energy more efficiently during times of 
nutrient excess, in order to increase chances of survival during times of food shortage. This would explain 
why certain ethnic groups today are more prone to obesity and T2DM than others. However, it has been 
argued that if this hypothesis was true, natural selection should have shaped mankind in such a manner that 
would render all modern humans diabetic and obese [14].  As this is clearly not the case, several alternative 
hypotheses have been formed. The most highly cited alternative to the thrifty gene hypothesis was proposed 
by John Speakman in 2008. His ‘drifty gene hypothesis’ is fundamentally different because it rejects the 
idea of an evolutionarily selective advantage of the obese state. Instead, it postulates that the current obesity 
crisis is a result of genetic drift, the change in frequency of an existing allele, in the genes controlling the 
upper limit of human adiposity [15]. Such drift supposedly started when our ancestors removed the risk of 
predation, around 2 million years ago. By doing so, they simultaneously removed the main factor selecting 
against fatness. Recently developed molecular genetic tools allowed for the testing of these hypotheses. 
Two studies have looked for molecular signatures of positive selection for genes that are implicated in 
obesity [16] and type 2 diabetes [17], but neither of them found such signatures. Thus, these data argue 
against the adaptive thrifty gene hypothesis and instead support the non-adaptive drifty gene hypothesis.  
 




1.2 Regulation of energy homeostasis by leptin 
1.2.1 Leptin synthesis, structure, expression and clearance 
In 1994, positional cloning of the elusive obese gene identified the factor the caused the morbid obesity 
found in Lepob/ob mice [18]. This gene encodes a 16kDa protein of 167 amino acids that was named leptin, 
after the Greek word for ‘lean’ (λεπτός). Leptin is a member of the class-1 helical cytokine family. It 
characteristically consists of four antiparallel α-helices which are connected by two long crossover links 
and one short loop, arranged together in a left-hand twisted helical bundle. Two cysteine residues, Cys96 
and Cys146, form a disulphide bond between the beginning of the CD loop and the C terminus of the 
protein. This disulphide bond is important for structure folding and receptor binding [19] (figure 1.5).  
Figure 1.5 Structure of the human leptin protein. Four antiparallel α-helices, represented by four different colours, are 
connected by two long crossover links and one short loop, arranged together in a left-hand twisted helical bundle. Created 
with BioRender.com. 
 




1.2.1.1 Leptin expression 
In mammals, leptin is primarily, but not exclusively, produced by adipocytes [18]. Other tissues include the 
placenta, the endocrine cells of the gastrointestinal system, skeletal muscle, and the liver [20, 21]. The 
expression of leptin mRNA levels and rates of protein secretion are differentially regulated between the 
various fat depots found in mammals [22] [23]. Leptin gene expression is positively correlated with 
adipocyte volume, both in whole tissue in the fed state [24] and in isolate adipocytes from a single fat pad 
[25]. In both lean and obese humans, leptin mRNA levels are 3- to 5-fold higher in subcutaneous adipose 
tissue, the adipose tissue beneath the skin, compared to omental adipose tissue, the primary intraperitoneal 
reservoir [26]. In juvenile mice and rats, leptin gene expression is higher in gonadal and retroperitoneal fat 
depots compared to inguinal adipose tissue [27, 28]. These differences can be largely attributed to 
differences in adipocyte size, although it has furthermore been shown that different depots have varying 
sensitivities to other hormones like insulin and glucocorticoids [22, 29]. For example, overnight fasting of 
juvenile rats significantly decreased leptin gene expression in visceral depots, but not in inguinal adipose 
tissue [30]. Leptin is also expressed in brown adipose tissue [31]. Interestingly, brown adipose tissue is the 
main determinant of circulating leptin in neonatal rats, whereas in adult mice leptin mRNA levels are much 
lower in brown adipose tissue compared to white adipose tissue [27].  
1.2.1.2 Circulating leptin levels 
Fluctuating leptin levels correlate tightly with adiposity. However, leptin expression is also very sensitive 
to acute changes in energy balance, such as short-term fasting. For example, a 52-hour fast in normal and 
obese human subjects decreased leptin mRNA levels and plasma leptin concentrations by more than 50% 
[32]. Refeeding rapidly normalized leptin mRNA levels. Similar studies confirm these results, and showed 
that short-term fasting furthermore has no effect on individual adipocyte volume or total fat stores [33, 34]. 
On the other hand, an acute positive energy balance in humans, resulting from glucose or lipid infusion or 
consumption of high-fat diet, leads to a gradual increase of leptin mRNA expression proportional to the 




increase in adiposity [32, 35]. The differential response of leptin to acute positive and negative energy 
balance may suggest that leptin functions to protect the long-term energy stores, situated in the fat reserve, 
against weight loss [36]. Circulating leptin levels have furthermore been shown to follow a circadian 
rhythm. The nadir of this rhythm is found between Zeitgeber time (ZT) 6 and ZT9, and the zenith is between 
ZT 18 and ZT22 [37]. Within this circadian rhythm, plasma leptin levels oscillate in an ultradian manner 
with a frequency of 32 pulses per day on average [38]. Although the ultradian oscillation is similar in 
frequency between obese and lean subjects, or between males and females, the difference in pulse height 
explains the different concentrations of circulating leptin levels between these groups [39]. The underlying 
mechanism and physiological significance of these leptin oscillations remain poorly understood to date.  
1.2.1.3 Leptin clearance 
The half-life of circulating leptin is estimated to be about 25 minutes in humans, with no difference between 
lean and obese individuals [40]. Interestingly, although injection of leptin in Lepob/ob mice has no effect on 
suppression of food intake during the first 3 hours post-injection, food intake is significantly suppressed at 
6 hours following leptin injection and remains significantly lower at 24 hours post-injection, when 97% of 
the injected leptin has been cleared from the circulation [41]. Thus, the effect of leptin on food intake is 
more persistent than the presence of the protein itself. Leptin is cleared from the circulation primarily by 
the kidneys [42]. Hemodialysis patients have significantly elevated plasma leptin levels [43]. Moreover, 
rats with surgically removed kidneys have severely impaired clearance of intravenously injected 
recombinant leptin compared to control animals [42]. Leptin is not metabolized across the renal circulation. 
Instead, it is extracted intact at approximately 6.5 nanogram per minute for both kidneys, followed by 
metabolic degradation in the renal tubule [44]. Clearance kinetics studies showed that injection of 
radioactive leptin in leptin-deficient Lepob/ob mice and leptin receptor-deficient Lepdb/db mice lead to the 
highest accumulation of radioactivity in the liver and kidneys [41] [45].  




1.2.2 Structure and expression of the leptin receptor 
The leptin receptor is a member of the type I cytokine receptor family. Receptors in this family consist of 
an extracellular, trans-membrane and intracellular region, and share a conserved WSXWS motif in their 
extracellular amino acid domain that is essential for receptor activation [46]. Besides the leptin receptor, 
members include the interleukin receptors, the erythropoietin receptor, the growth hormone receptor, the 
prolactin receptor and the oncostatin M receptor. More specifically, the leptin receptor shares the 
glycoprotein 130 subunit responsible for signal transduction with the interleukin-6 receptor [47]. The 
extracellular component, responsible for recognizing and binding leptin, consists of 6 functional domains: 
an immunoglobulin-like domain, two cytokine receptor homology domains (CRH1 and CRH2), an N-
terminal domain, and two membrane-proximal fibronectin type III domains [48].  The immunoglobulin-
like domain interacts with leptin and is important for the conformational change in the receptor upon ligand 
binding. The CRH2 domain is essential for leptin binding, whereas the CRH1 domain appears to have more 
of a regulatory role. The fibronectin domains regulate receptor activation upon binding of leptin.  
1.2.2.1 Leptin receptor isoforms 
In mammals, six isoforms of the leptin receptor arise from alternative splicing of the C terminal exon 
(LEPRa-LEPRf; figure 1.6). Five of these isoforms are membrane-bound and share the same extracellular 
domain but differ in their C-terminal sequence. One isoform, LEPRe or soluble leptin receptor (sLEPR), is 
the major leptin-binding protein in the circulation and modulates bioavailability of leptin. Expression 
pattern data of the ‘a’, ‘c’, ‘d’, and ‘f’ leptin receptor isoforms suggest that they are involved in blood-brain 
barrier transport and renal clearance. LEPRb is the major mediator of leptin’s physiological effects, as 
illustrated by the fact that the morbidly obese Lepdb/db mice have a mutation that only affects expression of 
the LEPRb isoform: a GT point mutation causes a 106-nucleotide insertion that leads to premature 
termination of the intracellular domain. LEPRb is the only isoform that contains complete intracellular 
tyrosine residues necessary to convey signals. The box1 motif of the intracellular domain of LEPRb is a 




critical component for activation by JAK2. The box1 motif contains a sequence found in all leptin receptor 
isoforms. LEPRb also has a cytokine box 2, which lacks the ability to activate JAK2. However, a 15 amino 
acid-long sequence downstream of box 1 can activate JAK2. The cytoplasmic domain of LEPRb consists 
of 302 amino acids and contains the binding sites for protein tyrosine kinase Janus kinas 2 (JAK2) and 
signal transducer and activator of transcription 3 (STAT3). Although low levels of expression have been 
detected in peripheral tissues like the lungs and the liver, LEPRb is expressed primarily in the brain, and 
especially in the hypothalamus [49]. The short isoforms on the other hand are expressed at high levels in 
kidney, lung and choroid plexus of adult mice [47]. It is not well understood how the expression, 
intracellular trafficking and post-translational modification of the leptin receptor is regulated. An important 
role in the processes appears to be played by endospanin.  
 
Figure 1.6 Overview of the six isoforms of the leptin receptor. In mammals, six isoforms of the leptin receptor arise from alternative 
splicing of the C terminal exon (LEPRa-LEPRf). Five of these isoforms are membrane-bound and share the same extracellular 
domain but differ in their C-terminal sequence. One isoform, LEPRe or soluble leptin receptor (sLEPR), is the major leptin-binding 
protein in the circulation and modulates bioavailability of leptin. The extracellular component, responsible for recognizing and 
binding leptin, consists of 6 functional domains: an immunoglobulin-like domain, two cytokine receptor homology domains (CRH1 
and CRH2), an N-terminal domain, and two membrane-proximal fibronectin type III domains Created with BioRender.com. 




1.2.2.2 Regulation of leptin receptor expression 
Soon after the discovery of leptin it was found that the LEPR gene also transcribes a second, non-leptin 
receptor gene product [50]. Initially named leptin receptor gene-related protein (OB-RGRP) or leptin 
receptor overlapping transcript (LEPROT), this protein is transcribed from an alternative start codon that is 
out of frame with the leptin receptor transcript, thus producing a protein that does not have primary sequence 
homology with LEPR [51]. Due to its topology and intracellular localization this protein was renamed 
endospanin-1, and a recently discovered paralogue was named endospanin-2 [52]. Knockdown of both 
endospanin-1 and -2 increases leptin receptor surface expression and improves leptin sensitivity in a cell 
culture system. Moreover, endospanin-1 knockout mice express significantly more leptin receptor on the 
cell surface compared to wild type mice, rendering them hyperresponsive to leptin and resistant to diet-
induced obesity [53]. Leptin receptor protein expression is negatively correlated with endospanin-1 in 
humans [54]. Endospanin-1 has furthermore been implicated in the control of tissue-specific leptin receptor 
expression [55]. Importantly, endospanin-1 and -2 have been shown to interact with the small G-proteins 
Rab13 and Rab8, which are essential for cellular trafficking between the trans-Golgi network and other 
compartments of the cell [56, 57]. Thus, endospanin regulates leptin receptor expression, but may have 
other roles beyond this.  
Another direct regulator of leptin receptor expression is tumour necrosis factor alpha (TNFα). TNFα is a 
cytokine involved in systemic inflammation [58]. Although primarily produced by macrophages, a wide 
range of tissues has been implicated in TNFα expression, including adipocytes. Dysregulation of TNFα is 
associated with a number of diseases, including obesity [59], type 2 diabetes [60], Alzheimer’s disease [61], 
cancer [62] and depression [63]. TNFα has been shown to increase production of sLEPR in a time- and 
dose-dependent manner, and surface expression and total cellular protein expression level of LEPRb in 
multiple cell types, by stimulating LEPR export via a protein kinase C (PKC)-dependent mechanism. Cell 
culture studies confirm these findings and furthermore show that the effects of TNFα on LEPRb are 
remarkably swift, requiring only 30 minutes to significantly increase surface expression and total cellular 




protein level. In the continuous presence of TNFα, these effects persist for up to 15 hours [64]. TNFα effects 
on leptin receptor expression are blocked by brefeldin-A, an antiviral that inhibits protein transport from 
the endoplasmic reticulum to the Golgi complex [65]. This suggests that TNFα acts in a post-endoplasmic 
reticulum cellular compartment. The mechanism behind TNFα-mediated leptin receptor expression 
regulation remains to be elucidated. Interestingly, TNFα is an essential early mediator of the inflammatory 
response [60]. Studies have shown that inflammation correlates with increased circulating leptin levels and 
sLEPR levels [66, 67], suggesting that inflammation may modulate leptin signalling through TNFα. 
  




1.3 Intracellular leptin signalling 
1.3.1 Tyrosine residues 
The cytoplasmic domain of the long isoform of the leptin receptor (LEPRb) is characterized by three 
tyrosine residues: tyrosine (Y)  985, Y1077 and Y1138. The Y1138 residue forms the STAT3 docking site 
that is necessary for initiating the downstream signalling cascade.  A mouse model with a tyrosine-to-
leucine mutation of Y1138 in mice, named the Leps/s mouse model, is characterized by an obese phenotype, 
to a degree similar to Lepdb/db mice [68]. Thus, Y1138 is essential for the regulation of the adipostatic effects 
of leptin. However, Y1138-mediated JAK/STAT signalling appears to play no role in either glucose 
homeostasis or reproduction. While Lepdb/db mice, which lack a functional cytoplasmic LEPRb domain, are 
extremely glucose intolerant and infertile, Y1138-mutant Leps/s mice are fertile and have only mildly 
impaired glucose homeostasis, despite being morbidly obese [69]. The Y985 residue appears to be involved 
in the feedback suppression of the leptin signal, functioning as a binding site for suppressor of cytokine 
signalling 3 (SOCS3) [70]. A tyrosine-to-leucine mutation of Y985 protects mice against high fat diet-
induced obesity, thereby emphasizing on the importance of SOCS3 feedback in the development of obesity 
and leptin resistance [71]. Finally, the Y1077 residue has been implicated in the binding of STAT5 [72], 
but its physiological significance remains not well understood.  
Interestingly, LEPRb has been shown to control energy homeostasis through tyrosine-independent 
mechanisms as well. Using 2 knockin mouse lines, expressing mutant leptin receptors with phenylalanine-
for-tyrosine substitutions either for all 3 tyrosine residues or for Y1138 alone, the spectrum of signalling 
actions through these residues was defined. Compared to Lepdb/db mice, both knockin lines displayed 
attenuated adiposity with reduced hyperphagia, significantly improved glucose tolerance, and upregulated 
physical activity and thermogenesis [73]. Further evidence for the STAT3-independent control of 
metabolism comes from a very recent study that used CRISPR/Cas9 to target the COOH-terminal of LEPRb 
[74]. It was found that CRISPR-mediated deletions between residues 921 and 960 significantly impair 




metabolic control and lead to altered hypothalamic function compared to smaller truncations. Furthermore, 
deletions of the regions including 960-1013, which contains Y985, and 1013-1053, which contains no 
tyrosine residue, both improved the obese phenotype compared to deletions that included additional 
residues of the COOH-terminal. Together, these studies show that the cytoplasmic domain of LEPRb 
mediates tyrosine-dependent, but also tyrosine-independent signals.  
1.3.2 JAK2-STAT3-SOCS3 signalling 
Upon binding of LEPRb by two leptin molecules, JAK2 is activated through autophosphorylation of the 
tyrosine residues described above. Three other JAK proteins have been described in mammals: JAK1, JAK 
3 and the non-receptor tyrosine-protein kinase 2 (TYK2) [75]. Originally these proteins were named ‘just 
another kinase #1 and #2’, because of their discovery in a PCR-based kinase screen that implicated 
numerous protein-tyrosine kinases [76]. However, they were published as ‘Janus kinase’, after the dual-
faced Roman god of beginnings and endings, due to their possession of two near-identical phosphate-
transferring domains. All members consist of a FERM domain that enables linkage to the plasma 
membrane, an SH2-related domain that is involved in docking the phosphorylated tyrosine residues (of 
LEPRb in the case of JAK2), a kinase domain that allows for phosphorylation of other proteins, and finally 
a pseudo-kinase that regulates normal kinase activity but lacking enzymatic activity [77]. The family of 
cytokine receptors that LEPRb belongs to are homodimeric and bind JAK2 exclusively. Subsequently, 
activated JAK2 phosphorylates the specific LEPRb tyrosine residues and then transphosphorylates onto 
downstream STAT proteins. 
 The STAT protein family consists of 7 members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B 
and STAT6 [78]. Although the various STAT proteins consists of a wide range of different domains, all 
members have an SH2 domain, allowing STAT’s to dock to phosphorylated tyrosine residues on other 
proteins [79]. A recent study used translating ribosome affinity purification sequencing (TRAPseq) to 
investigate through which STAT proteins LEPRb neurons exert their effects on energy homeostasis. It was 




found that ablation of STAT3, but not of the other STAT proteins, induced impairments of energy balance. 
Moreover, the expression of a constitutively-active STAT3 in LEPRb neurons ameliorated symptoms of 
metabolic syndrome in both leptin-deficient Lepob/ob mice and wild type mice [80]. Thus, STAT3 represents 
the sole STAT protein required for leptin-mediated regulation of energy homeostasis, and STAT3-mediated 
signalling suffices to enable leptin action in the absence of other LEPRb signals. Following the 
phosphorylation of LEPRb tyrosine residues by JAK2, STAT3 binds to these residues via the SH2 domain. 
Subsequently, JAK2 tyrosine-phosphorylates STAT3, causing it to dissociate and translocate to the nucleus 
[81]. Dimerized STAT3 moves from the cytosol into the nucleus by associating with importin α3 and 
importin α6 [82]. Once in the nucleus, the GTP-binding nuclear protein RAN binds the importins, detaching 
them from the STAT3 dimer [83]. STAT3 induces the transcription of several genes, of which SOCS3 is 
the most significant. 
The SOCS family consist of 8 members: cytokine-inducible SH2 domain-containing protein (CISH), and 
SOCS1-7 [84]. Each of these proteins contains an SH2 domain and a specific site for interaction with JAK 
members named the SOCS box [85]. The SOCS box can form a complex with the regulatory protein 
ubiquitin to target JAK2 for proteasomal degradation [86]. It is through this mechanism that SOCS3 inhibits 
JAK2, thereby creating a negative feedback loop in the leptin signalling cascade. SOCS3 can inhibit JAK2-
STAT3 signalling furthermore by binding JAK2 using kinase inhibitory regions, thus preventing the 
binding of JAK2 to other proteins [87]. Mutation of the SOCS3-binding site on the leptin receptor elevates 
leptin sensitivity and confers resistance to diet-induced obesity [88]. 
1.3.3 IRS-PI3K-AKT signalling 
Although JAK2-STAT3-SOCS3 signalling is the most well-described and thoroughly investigated 
signalling cascade downstream of LEPRb, it is not the only one. A role for the IRS-PI3K-AKT signalling 
pathway in the regulation of energy homeostasis by leptin was first suggested by a study showing that IRS2-
null mice displayed elevated leptin levels, hyperphagia and decreased energy expenditure [89]. 




Subsequently, it was demonstrated that systemic administration of leptin in rats activates PI3K in the 
hypothalamus and that intracerebroventricular infusion of inhibitors of this enzyme prevented the 
anorexigenic effects of leptin [90]. Leptin-induced PI3K activation is mediated through SH2B1, which 
recruits IRS proteins to JAK2. Activated PI3K catalyses the phosphorylation of phosphatidylinositol-4,5-
bisphosphate to phosphatidylinositol-3,4,5trisphosphate (PIP3), whereas tumour suppressor phosphatase 
and tensin homolog (Pten) initiates the opposite reaction [91]. PIP3 then binds to the Pleckstrin homology 
domain of Akt (also known as protein kinase B, PKB), allowing for the phosphorylation of Akt by its 
activating kinases, phosphoinositide dependent kinase 1 (PDPK1, at threonine 308, and the mammalian 
target of rapamycin complex 2 (mTORC2, at serine 473) [92]. Leptin signalling through this pathway is 
especially important for the regulation of glucose homeostasis, both through direct effects on glucose fluxes 
[93], and by regulating insulin sensitivity [94]. 
1.3.4 SHP2-ERK signalling 
Another signalling cascade through which leptin exerts its effects on energy homeostasis is the mitogen-
activated protein (MAPK)/extracellular signal-regulated kinase (ERK) pathway. The first study to 
demonstrate this showed that leptin administration induces ERK1/2 activation in a mouse embryonic cell 
line [95]. Subsequently, it was shown that food deprivation upregulates levels of activated ERK in the 
hypothalamus, and this effect was reversed after refeeding [96, 97]. LEPRb acts on ERK1 and 2 mainly via 
SHP2, a tyrosine-specific protein phosphatase that contains a Src homology 2 (SH2) domain. The 
phosphatase activity of SHP2 is required for leptin-mediated ERK activation [98]. Whereas LEPRb-
mediated STAT3 activation is mainly exerted through Tyr1138, ERK-mediated leptin action appears to be 
acting specifically via Tyr985 [99]. Interestingly, ERK plays an important role in adipocyte differentiation 
too. ERK1 is required for adipogenesis, both in vitro and in vivo, and ERK1-null mice are protected against 
high fat diet-induced obesity and glucose intolerance [100]. 




1.3.5 AMPK signalling 
Although leptin is known primarily for its role in whole body energy homeostasis, it also regulates energy 
homeostasis on the cellular level, mainly through adenosine monophosphate-activated protein kinase 
(AMPK) signalling. AMPK is an enzyme that activates glucose and fatty acid uptake and oxidation when 
cellular energy stores are low, such as during metabolic stress [101]. AMPK is activated by the upstream 
kinase Peutz–Jegher syndrome tumour suppressor gene product LKB1 and Ca2+/calmodulin-dependent 
protein kinase kinase-b (CaMKKβ) [102]. Leptin has been shown to directly inhibit AMPK activity in the 
hypothalamus of mice, causing reduced food intake and body weight [103]. In the periphery too, AMPK is 
a mediator of leptin action. Systemic leptin administration enhances skeletal muscle AMPK activity and 
upregulates fatty acid oxidation [104]. 
1.3.6 Alternative feedback mechanisms 
Besides SOCS3-mediated feedback inhibition of leptin signalling, several other less well-understood 
mechanisms feed back on the JAK2-STAT3 pathway. SH2B1, a cytoplasmic adaptor protein, positively 
regulates leptin signalling by binding to the SH2 domain of JAK2 [105]. Deletion of SH2B1 induces 
hyperphagia and obesity in rodents [106], and mutations in this gene are strongly associated with human 
obesity [107]. Protein tyrosine phosphatase 1B (PTP1B) negatively regulates leptin signalling through 
dephosphorylation of JAK2 [108]. PTP1B deletion protects mice against diet-induced obesity [109], and 
expression of PTP1B in mice is significantly increased by feeding a high-fat diet, although was shown to 
be mediated via both leptin-dependent and leptin-independent mechanisms [110]. Finally, a positive 
regulator of leptin signalling has been described in the form of SHP2. Deletion of this tyrosine phosphatase 
in the hypothalamus and forebrain induces obesity in mice [111]. 






Figure 1.7 Overview of intracellular leptin signalling. Leptin binds to the extracellular domain of LepRb, activating the 
associated Jak2 tyrosine kinase and promoting the Jak2-mediated phosphorylation of tyrosine residues 985, 1077, and 1138 of 
LepRb. Phosphorylated Tyr985 recruits PTPN11, which initiates the ERK signalling cascade. Phosphorylated Tyr1077 and 
Tyr1138 recruit STAT5 and STAT3, respectively, permitting their trafficking to the nucleus to mediate the control of cognate 
gene expression. In addition, mechanisms that limit LepRb signalling have been defined: Socs3, whose expression is increased 
by leptin, binds to phosphorylated Tyr985 to blunt LepRb signalling. Also, the tyrosine phosphatases, PTP1B and TCPTP, 
dephosphorylate Jak2 and/or LepRb to terminate LepRb signalling. Adapted from Flak and Myers (2016), Created with 
BioRender.com. 




1.4 Central leptin signalling 
The positional cloning of the leptin gene was followed almost immediately by the discovery of the LEPR 
gene. The highest expression of leptin receptors was found in the hypothalamus, specifically within the 
arcuate (ARC), dorsomedial hypothalamic and ventromedial hypothalamic nuclei [112]. These findings 
were in accordance with the decades-old literature highlighting a role for hypothalamic centres in the 
regulation of appetitive behaviour and energy balance. Craniopharyngioma patients, who suffer from a rare 
type of brain tumour derived from pituitary gland embryonic tissue, require surgery that involves partial 
lesioning of the hypothalamus. This procedure was often associated with morbid obesity [113]. 
Experimental evidence from monkeys and cats confirmed that surgical ablation of the hypothalamus 
induced obesity, diabetes mellitus, and disturbed temperature regulation [114]. More specifically, medial 
lesions, in the area including the arcuate nucleus, ventromedial nucleus and paraventricular nucleus, led to 
obesity [115], whereas lateral lesions induced aphagia [116].  
1.4.1 First order signalling 
Primarily, leptin targets two populations of neurons in the arcuate nucleus of the hypothalamus. On the one 
hand, leptin activates an anorexigenic and energy expenditure-inducing population that contains 
proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). On the other 
hand, leptin inhibits an orexigenic and energy expenditure-suppressing population that contains agouti-
related peptide (AgRP) and neuropeptide Y (NPY). POMC is a precursor polypeptide that is cleaved to 
give rise to multiple peptide hormones, including α melanocyte-stimulating hormone (αMSH), 
adrenocorticotropic hormone (ACTH), and β-endorphin [117]. Leptin increases the frequency of action 
potentials in arcuate POMC neurons via depolarization through a nonspecific cation channel and via 
reduced inhibition by local orexigenic NPY/GABA neurons [118]. CART is a neuropeptide protein that 
plays a role not only in energy homeostasis, but also in reward and stress [119]. Following the finding that 
CART mRNA increases with cocaine or amphetamine administration [120], antibody-mediated inhibition 




of CART was found to decrease food intake [121]. Food-deprived animals display significantly 
downregulated CART mRNA expression specifically in the arcuate nucleus. Furthermore, peripheral leptin 
treatment stimulates CART expression in Lepob/ob mice, and central leptin treatment in rats inhibits both 
normal and starvation-induced feeding [122].  
AgRP was identified as an important peptide for body weight regulation following cloning of the gene 
responsible for the phenotype found in the agouti (Ay/a) mouse, characterized by a yellow fur colour and 
an obese phenotype [123]. AgRP therefore owes its name to its homology to the agouti gene [124]. Initial 
reports showed that AgRP mRNA is elevated 5-fold in Lepob/ob mice and inhibited by leptin treatment. 
Fasting induced upregulation of AgRP expression in ad libitum fed Lepdb/db mice compared to wild type 
controls, and this increase was even more significant in fasted Lepdb/db mice, thus demonstrating the link 
between leptin, AgRP and food intake [125]. However, a recent study showed that chronic activation of 
AgRP neurons per se does not cause persistent obesity [126]. 
NPY is the most abundantly expressed neuropeptide in the mammalian central nervous system and plays a 
role in various disorders, including obesity, epilepsy, post-traumatic stress disorder and neurodegenerative 
disorders [127]. Compared to the other neuropeptides described above, NPY was discovered a relatively 
long time ago. In 1982, an unknown peptide was extracted from a porcine brain extract. Due to its structural 
similarities to peptide YY and pancreatic polypeptide it was designated NPY [128]. NPY is highly 
concentrated in the arcuate nucleus and in the dentate gyrus of the hippocampus. Leptin directly inhibits 
NPY expression, and genetic ablation of NPY reduces hyperphagia and obesity in Lepob/ob mice [129, 130]. 
Because leptin regulates energy homeostasis primarily through action in the brain, the access of leptin to 
first-order leptin responsive neurons is critical. Importantly, both neuronal populations (POMC/CART and 
AgRP/NPY) are located in the arcuate nucleus, near a congregation of veins with fenestrated capillaries at 
the median eminence. The median eminence is one of the seven circumventricular organs of the brain, 
which are characterized by rapid neurohumoral exchange [131]. This way the blood brain barrier is 




bypassed, thus permitting neuronal processes access to blood and circulating hormones, including leptin. 
In this regard, leptin has been shown to enter the brain via tanycytes in the median eminence through a 
process that requires ERK-signalling and the passage of leptin through the cerebrospinal fluid [132]. 
Alternatively, leptin can cross the blood brain barrier, via both LEPR-dependent and LEPR-independent 
mechanisms [133, 134]. Specifically, LEPRa appears to be involved in leptin transport, being expressed 
abundantly in the choroid plexus and the endothelial cells of the blood brain barrier [135]. 
1.4.2 The melanocortin system 
The arcuate POMC/CART and AgRP/NPY neurons form the base of the central melanocortin system 
(figure 1.8). This system is involved in a remarkably wide range of physiological functions, including 
pigmentation, adrenocortical steroidogenesis, erectile responses, exocrine gland secretion and energy 
homeostasis [136]. Melanocortin receptors belong to the rhodopsin family of 7-transmembrane G protein-
coupled receptors. Of the five existing melanocortin receptors (MCR), only MC3R and MC4R are 
expressed in the brain. Through these two receptors the melanocortin system exerts its effects on energy 
homeostasis. Pharmacological activation of these receptors suppresses food intake, whereas inhibition has 
the opposite effect [137].  
MC3R knockout mice, although not morbidly obese like Lepob/ob mice, display decreased energy 
expenditure and are more prone to diet-induced obesity [138]. MC3R has furthermore been implicated in 
the circadian control of food intake. Mice lacking MC3R were found to eat more during the light-, but not 
during the dark cycle [139]. In accordance, MC3R is required for the synchronization of metabolism during 
entrainment to a feeding regime that allows food intake only during the light cycle [140].  
MC4R defects account for 6% of all cases of early-onset obesity [141]. The POMC-derived peptide α-
melanocyte-stimulating hormone (α-MSH) directly stimulate MC4R, whereas AgRP directly inhibits 
MC4R. A very recent report showed that binding of α-MSH to MC4R is selectively modulated by calcium, 
whereas AgRP binding is not [142]. Prolonged treatment with an MC4R agonist has been shown to induce 




lasting weight loss in patients with leptin receptor deficiency [143]. Other upstream regulators of the 
melanocortin system include the hormones ghrelin and insulin [144]. 
 
Figure 1.8 A simplified model of hypothalamic leptin signalling. Populations of first-order NPY/AGRP (green) and POMC/CART 
(red) neurons in the arcuate nucleus are regulated by leptin and project to the PVN, specifically to MC4R-expressing second-order 
hypothalamic neuropeptide neurons involved in the regulation of food intake and energy homeostasis. 3V=third ventricle. Created 
with BioRender.com.  




Although the arcuate nucleus of the hypothalamus is regarded to be the main site for afferent input from 
circulating leptin, only about 15% of all LEPRb neurons are found in this area [145]. Moreover, LEPRb 
neurons represent only a minority of arcuate cells [146]. Therefore, other brain areas must be essential for 
leptin action, either via innervation by arcuate nucleus neurons, or via direct action of leptin on LEPRb 
neurons. Indeed, a number of distinct brain regions besides the arcuate nucleus have been implicated in the 
regulation of energy homeostasis by leptin. 
1.4.3 DMH and VMH 
Located between the arcuate nucleus and the dorsomedial hypothalamic nucleus (DMH), the ventromedial 
hypothalamic nucleus (VMH) contains a significant population of LEPRb neurons. These neurons 
characteristically express the transcription factor steroidogenic factor-1 (SF1) and the neuropeptide 
pituitary adenyl cyclase activating protein (PACAP). Ablating LEPRb in SF1/PACAP neurons does not 
alter energy balance under normal dietary conditions, but leads to increased body weight in mice on a high-
fat diet [147]. A similar phenotype is found upon deletion of LEPRb in prodynorphin-expressing cells, 
which include most cells in the ventromedial hypothalamic nucleus, as well as a minority of cells in the 
arcuate and dorsomedial hypothalamic nucleus [148]. The dorsomedial hypothalamic nucleus, or dorsal 
hypothalamic area, contain LEPRb neurons which promote energy expenditure by stimulating energy use 
for generation of heat. Ablation of these cells leads to a decrease in heat output [149].  
1.4.4 PVN 
A region that is densely innervated by the arcuate POMC/CART and AgRP/NPY neurons is the 
paraventricular nucleus of the hypothalamus (PVN). The PVN, which like the ARC lies adjacent to the 
third ventricle, regulates autonomic output, the secretion of corticotropin-releasing hormone (CRH) and 
thyrotropin-releasing hormone (TRH), and via projections to the posterior pituitary where oxytocin and 
vasopressin are produced. Thus, the PVN is an important node in the network controlling autonomic and 
endocrine function [150]. Leptin has been shown to increase sympathetic nerve activity via induction of its 




own receptor on glutamatergic neurons in the PVN [151]. Previously, it has been shown that PVN-specific 
reactivation of MC4R attenuates the hyperphagia found in MC4R-null animals but fails to normalize 
autonomic control [152]. Recently, it has been shown that the PVN mediates a diurnal rhythm of 
metabolism [153].  
Importantly, the PVN is not only innervated by arcuate LEPRb neurons, but also by LEPRb neurons from 
the DMH and VMH. Together, these hypothalamic structures mediate the actions of leptin to regulate PVN 
output [154]. Each set of LEPRb neurons in the ARC, DMH and VMH presumably relays specific 
information to the PVN. The ARC is capable of sensing rapid changes in insulin, ghrelin, and circulating 
nutrients, thereby informing the PVN on acute energy status in the periphery [155]. The VMH expresses 
many glucose-sensing neurons, and LEPRb neurons in this nucleus have been implicated in the regulation 
of glucose homeostasis independent of insulin [156]. The blood-brain barrier prevents the DMH from 
registering fluctuations in peripheral metabolic parameters [157]. Instead, the DMH integrates information 
about body temperature from LEPRb neurons in the preoptic area, along with information on the peripheral 
long-term energy status [158]. Each set of LEPRb neurons thus appears to have a distinct function, and the 
PVN represents an important integration site for the autonomic output of leptin action. 
1.4.5 Leptin and motivation 
Energy homeostasis depends for a large part on food intake. This process is jointly controlled by the 
motivational circuit that modulates initiation of feeding, and the satiety circuit that modulates termination 
of feeding [159]. Dopaminergic neurons in the ventral tegmental area are crucial for motivation. This 
mesolimbic structure contains LEPRb neurons, most of which are dopaminergic, but ablation of these 
neurons does not alter parameters of motivation [160]. However, it has been shown that leptin indirectly 
modulates dopaminergic neurons in the ventral tegmental area by controlling expression of tyrosine 
hydroxylase, the rate-limiting enzyme for dopamine production [161], and by regulating the control of 




dopamine reuptake and extracellular dopamine concentrations in the nucleus accumbens, another structure 
critical for motivation and reward [162]. 
The lateral hypothalamic area has long been known to control appetitive behaviour. Lesioning studies 
demonstrated that ablation of this area leads to diminished motivation and lethal hypophagia [163]. 
Consistently, exposing Lepob/ob mice to leptin only in the lateral hypothalamic area reduces hyperphagia 
and body weight gain, while simultaneously increasing tyrosine hydroxylase expression in the ventral 
tegmental area, thereby demonstrating innervation of the ventral tegmental area by the lateral hypothalamic 
area [161]. Furthermore, the majority of LEPRb neurons in the lateral hypothalamic area express 
neurotensin, a neuropeptide that heavily interacts with the dopaminergic system. Ablation of LEPRb in 
neurotensin-positive neurons of the lateral hypothalamic area leads to increased food intake and body 
weight, while simultaneously displaying decreased mesolimbic dopaminergic function due to increased 
reuptake of dopamine in the nucleus accumbens [164]. In response to leptin, these same neurons have also 
been shown to inhibit adjacent hypocretin/orexin-containing neurons, which play an important role in 
arousal [165]. Thus, the lateral hypothalamic area modulates the effects of leptin on the motivational aspects 
of food intake through multiple mechanisms. 
1.4.6 Leptin in the brainstem 
Finally, a significant population LEPRb-expressing neurons is found in the nucleus of the solitary tract 
(NTS), in the caudal part of the brainstem. This nucleus is activated by afferents from the gastrointestinal 
system via the vagus nerve, which promotes meal termination [166]. Leptin administration into the NTS 
blocks food intake, whereas ablation of LEPRb in the NTS has the opposite effect [167]. Leptin mediates 
the response of the NTS to gut-derived satiety signals, like cholecystokinin, amylin and glucagon-like 
peptide 1. A recent report demonstrated that leptin sensitizes neurons in the nucleus of the solitary tract to 
vagal input by increasing post-synaptic N-methyl-D-aspartate (NMDA) receptor currents [168]. LEPRb-
expressing neurons are also found in other parts of the brainstem, including the dorsal raphe [145] and 




periaqueductal grey [146]. The latter has been implicated in the mobilization of glucose during periods of 
acute demand in the face of diminished energy stores [169]. 
1.5 Leptin resistance 
The vast majority of obesity and type 2 diabetes in humans results not from genetic mutations in the leptin 
gene or its receptor, but from a combination of genetic predisposition, unlimited availability of palatable, 
energy dense and inexpensive calories and the sedentary nature of modern society. Like rodents, humans 
with diet-induced obesity (DIO) are characterized by high circulating leptin concentrations, matching their 
elevated adiposity. However, these elevated leptin levels are unable to normalize body weight. Similarly, 
whereas leptin treatment in rare cases of congenital leptin deficiency rapidly and completely normalizes the 
morbid obesity found in these subjects, exogenous leptin treatment fails to reduce food intake and induce 
weight loss in obese humans and rodents. Together, these findings have led to the concept of leptin 
resistance. Hormone resistance syndromes have been described for various hormones, including thyroid 
hormone, insulin, growth hormone and vasopressin. In most cases these syndromes result from impaired 
receptor signalling due to genetic mutations, circulating antagonists, or uncoupling of the receptor from its 
downstream effectors [170]. Although a number of genetic mutations have been described that render 
people more susceptible to diet-induced obesity, these cases are rare and cannot explain the obesity and 
type 2 diabetes pandemic [171, 172]. Nor is there any evidence pointing towards a role for circulating 
antagonists in DIO rodents or humans. Thus, leptin resistance presumably results from one or more 
disturbances between the leptin receptor and its downstream signalling cascade, on the intracellular or 
intercellular level. This hypothesis is supported by the notion that high-dose exogenous leptin treatment is 
not only unable to rescue the metabolic syndrome found in DIO rodents, but also fails to properly induce 
hypothalamic phosphorylation of STAT3 in rodents [173]. Interestingly, the pSTAT3 response to leptin 
treatment in DIO rodents is impaired most significantly in the ARC [174], suggesting that this region is the 
major site affected by leptin resistance. 




1.5.1 Negative regulators of leptin receptor signalling cannot explain leptin resistance 
The most obvious candidates to explain leptin resistance would be the direct negative regulators of leptin 
receptor signalling. Indeed, numerous studies have attempted to demonstrate inhibition of LEPR signalling 
to be the underlying cause of leptin resistance [175]. SOCS3 is regarded to be the main negative regulator 
of leptin signalling. Decreased SOCS3-mediated feedback, via mutation of the Y985 residue on LEPRb or 
genetic ablation of SOCS3, leads to a decrease in body weight of mice [88]. However, these animals still 
gain significant weight on a high-fat diet [71], thus disproving SOCS3 to explain leptin resistance. PTP1B 
is another well-described negative regulator of leptin receptor signalling, which acts by dephosphorylation 
and deactivation of JAK2. Interestingly, high-fat diet increases arcuate PTP1B expression [110], suggesting 
a role in the promotion of DIO. In accordance with this finding, PTP1B deficient mice have a lean 
phenotype on a normal diet and gain less weight on a high fat diet compared to wild type controls [108]. 
Still, these mice display significant weight gain on a high fat diet. Similarly, T cell protein-tyrosine 
phosphatase (TCPTP) negatively regulates LEPR signalling by dephosphorylating STAT3, and elevated 
leptin levels are associated with upregulated TCPTP expression [176]. Brain-specific combined deletion of 
PTP1B and TCPTP attenuates DIO more effectively than PTP1B alone, although diet-induced weight gain 
cannot be prevented completely. Thus, although negative regulators of LEPR signalling play a role in DIO, 
they do not suffice to explain leptin resistance.  
Various processes related to the hypothalamic response to high-fat diet have been proposed to disturb leptin 
signalling, including decreased access of leptin to hypothalamic LEPR neurons hypothalamic inflammation 
and altered glia cell activity in the ARC 
1.5.2 Blood brain barrier impairments 
Mice that are subjected to a high fat diet rapidly become resistant to peripherally administered leptin, but 
retain a normal response to intracerebroventricular leptin treatment [173], suggesting that the transport of 
leptin into the brain is affected during DIO. Indeed, defective leptin transport across the blood brain barrier 




(BBB) is found early in the onset of DIO in rodents [135]. Interestingly, access of leptin to hypothalamic 
neurons is affected by high fat diet independent of obesity, as animals already exhibit an impaired response 
to peripheral leptin treatment before significant changes in body weight or circulating leptin levels can be 
detected [177]. On the other hand, obesity and obesity-related conditions have been shown to impair leptin 
transport across the BBB. Obesity-prone rats have normal BBB leptin transport, but impaired hypothalamic 
leptin signalling before the onset of DIO [178]. Finally, the level of circulating triglycerides is inversely 
correlated with the rate at which leptin enters the cerebrospinal fluid, showing that triglycerides can induce 
leptin resistance at the BBB [179]. 
1.5.3 Systemic and hypothalamic inflammation 
Diet-induced obesity is associated with a persistent state of low-grade peripheral and central inflammation, 
characterized by the production of proinflammatory cytokines like TNFα and interleukin-6 (IL6), and the 
activation of immune cells like macrophages and CD4+ T cells [180]. Multiple studies showed that systemic 
inflammation is associated with increased levels of circulating leptin and the soluble form of the leptin 
receptor [66, 181]. In the hypothalamus, exposure to a high-fat diet promotes the expression of pro-
inflammatory cytokines and activates intracellular signalling pathways associated with inflammation, 
including the nuclear factor- kB (NF-kB) pathway, c-Jun N-terminal kinases (JNKs) and protein kinase C 
θ-type (PRKCQ) [182, 183]. In this light, it has been hypothesized that hypothalamic inflammation 
attenuates leptin signalling or plays a role in promoting a positive energy balance. Intracerebroventricular 
TNFα treatment increases food intake and body weight gain, and decreases energy expenditure [184]. 
Moreover, immunological inhibition of TNF signalling reduces weight gain on a high-fat diet, and mice 
lacking TNF receptor superfamily member 1A are resistant to DIO[184]. Data from our laboratory show 
that hypothalamic inhibition of NF-kB signalling attenuates high-fat DIO and glucose intolerance [185]. 
On the other hand, various cytokines act centrally to reduce food intake [186], and inhibition of a variety 
of inflammatory markers leads to an increased in susceptibility to DIO [187]. Further complicating, many 




of the manipulations performed to study the effects of hypothalamic inflammation do not target a specific 
cell type. In order to resolve the apparent discrepancy in these studies, it will be essential to study the role 
of individual cytokines in specific cell types. 
1.5.4 Hypothalamic gliosis  
In addition to systemic inflammation, development of DIO is associated with increases in the number and 
activation state of arcuate astrocyte and microglia [188]. As the resident macrophage cells, microglia act as 
primary form of active immune defence in the central nervous system [189]. Astrocytes have various 
functions, including provision of nutrients to neurons, biochemically supporting the endothelial cells that 
make up the BBB and maintenance of the extracellular ion balance [190]. Although microglia and 
astrocytes both accumulate in the ARC of mice on a high fat diet, only the microglia undergo inflammatory 
activation, and depletion of microglia abrogates high fat diet-induced hypothalamic inflammation [191]. 
On the other hand, it has been shown that weight loss following a high fat diet induces reactive astrogliosis 
in the ARC [192]. Thus, both astrocytes and microglia are implicated in leptin resistance, although their 
significance remains somewhat unclear. Arcuate gliosis may play a role in the hypothalamic inflammation 
found in DIO animals or disturb normal function of hypothalamic neurons involved in energy homeostasis. 
Both microglia and astrocytes play an important role in synaptic plasticity, so arcuate gliosis might 
alternatively be a mediator of plasticity during leptin resistance [193]. 
1.6 Leptin and glucose homeostasis 
Glucose is the primary metabolic fuel required for life. Glucose homeostasis is the process of maintaining 
plasma glucose concentrations within a relatively narrow range. In humans, these levels typically range 
between ~60 and 150 mg/dl, with wide variations following meals and exercise [194]. Normoglycemia 
involves various metabolic tissues, including the brain, liver and skeletal muscle, which are tightly regulated 
by metabolic endocrine factors. The endocrine pancreas produces insulin in β-cells to lower blood glucose, 
and glucagon from α-cells to raise blood glucose concentrations via hepatic glycogenolysis [195]. Leptin 




too plays an essential role in the regulation of glucose homeostasis. The loss of leptin action leads to 
hyperglycaemia, hyperinsulinemia and glucose intolerance [196]. The leptin receptor-deficient Lepdb/db 
mouse is named after its diabetic phenotype [197]. Leptin therapy in leptin-deficient rodents and humans 
ameliorates all aspects of dysregulated glucose homeostasis. Initially, these effects were thought to be 
secondary effects following a reduction in body weight. However, it has been firmly established that leptin 
regulates glucose homeostasis independent of its adipostatic effects, by acting on various central and 
peripheral cells. 
1.6.1 Leptin regulates glucose homeostasis independent of its adipostatic function 
Various observations, mostly from studies with Lepob/ob mice, suggest that leptin affects metabolism 
independent of its adipostatic actions. For example, low dose leptin treatment of 1mg/kg/day did not 
improve body weight in Lepob/ob mice, but was still capable of normalizing insulin and blood glucose levels 
[198]. Likewise, acute disruption of leptin signalling in vivo raises blood glucose and plasma insulin levels 
before altering body weight. Moreover, Lepob/ob and Lepdb/db mice become hyperinsulinemic before they 
become obese [199], which suggests that glucose homeostasis is already impaired before body weight 
alterations emerge. Treating Lepob/ob mice with leptin proved to improve blood glucose levels, in 
comparison with Lepob/ob mice that were pair fed the exact amount of food [200]. In addition, humans and 
rodents that suffer from lipodystrophy, meaning their bodies are unable to produce fat and thus have very 
low leptin levels, exhibit hyperglycaemia, hyperinsulinemia and insulin resistance. All of these symptoms 
are corrected by leptin therapy [201, 202]. Thus, leptin can clearly influence glucose homeostasis 
independent from its adipostatic effects. 
1.6.2 Leptin regulates glucose homeostasis centrally 
Data from our laboratory show that intracerebroventricular leptin treatment that leads to negligible 
peripheral leptin levels suffices to restore euglycemia and insulin sensitivity in leptin deficient mice [203], 
consistent with data from insulin deficient [204] and DIO mice [205]. Thus, central signalling alone is 




sufficient for the glucoregulatory actions of leptin. Significant progress has been made over the past years 
to elucidate which brain areas are essential for the leptin-mediated control of glucose homeostasis.  
In diabetic rats, leptin injection into the VMH restored blood glucose levels and hepatic glucose production 
to normal levels, but did not affect glucose uptake in brown adipose tissue or muscle [206]. Selective 
restoration of leptin receptor function in arcuate POMC neurons completely reversed hyperglycaemia and 
improved insulin sensitivity. However, loss of leptin receptors specifically in the POMC neurons of wild 
type mice did not block the glucose lowering actions of leptin. Selective leptin receptor re-expression in 
AgRP neurons of Lepdb/db mice restored blood glucose levels to normal levels [207]. Importantly, AgRP 
neuron-specific loss of leptin receptor blocks the glucoregulatory actions of leptin. Similarly, in Lepob/ob-
MC4R knockout mice and diabetic MC4R-knockout rats, leptin is unable to improve glucose homeostasis 
[208]. Thus, AgRP neurons, but not POMC neurons, and their downstream MC4 receptors are both 
sufficient and required for the glucoregulatory actions of leptin. Furthermore, AgRP neurons are 
GABAergic and co-secrete NPY, but AgRP-selective knockout of either GABA or NPY does not prevent 
the glucoregulatory effect of leptin. Consistently, leptin is still able to lower blood glucose levels in LEPR 
GABA knockout mice that lack insulin [209]. Together, these studies indicate AgRP to be the main 
mediator of glucoregulation by leptin. 
1.6.3 Leptin can regulate glucose homeostasis independent of insulin 
The fact that insulin’s glucoregulatory action is deteriorated in the absence of functional leptin signalling, 
as observed in Lepob/ob, Leprdb/db and Leprs/s mice, all of which exhibit hyperglycaemia and 
hyperinsulinemia, implies that intact leptin action is required for insulin to function. Whether this also 
applies vice versa and insulin is required for leptin to function has long been a matter of debate. To answer 
this question, Neumann et al. conducted a study in mice in which insulin signalling was maximally blocked. 
Mice with streptozotocin (STZ)-induced insulin deficiency that were additionally treated with insulin 
receptor antagonists, as well as mice with global insulin knockout were treated with leptin. In both models, 




Neumann et al. reported that leptin was still efficacious at lowering glucose levels, even though insulin 
knockout mice displayed volatile changes in glucose levels [210]. These data demonstrate that leptin is able 
to restore glucose homeostasis in the total absence of insulin, but minimal insulin is still required to stabilize 
glucose levels indefinitely. The finding that leptin can effectively restore euglycemia in STZ-induced rodent 
models of insulin-deficient T1DM [211] sparked interest in leptin as a therapeutical replacement for insulin 
in the treatment of T1DM in hope to avoid the recurring hypoglycaemic episodes caused by insulin therapy. 
In a clinical trial testing the effect of metreleptin on glycaemic control in human T1DM patients it was 
demonstrated that leptin led to a subtle decrease in body weight [212], potentially due to the reduction in 
leptin levels of approximately 50% that is observed in T1DM patients [213, 214]. Although the authors 
furthermore reported a significant reduction in the daily insulin dose required to maintain glycaemic control, 
they concluded that leptin did not improve any parameters for glycaemic control [212]. We believe, 
however, that comparable to results from rodent models of T1DM ([215], these findings suggest that leptin 
promotes insulin sensitivity in human T1DM patients. However, the canonical WNT pathway appears as a 
potential integration site for these metabolic signals, as discussed in the next section. 
1.7 WNT signalling 
This thesis investigates the link between leptin, glucose homeostasis and the canonical WNT signalling 
pathway. Although known mostly for its role in embryogenesis and tumour formation, a small but 
significant body of evidence suggests that leptin regulates glucose homeostasis via the WNT pathway. A 
2006 genome wide association study (GWAS) identified a link between polymorphisms in the TCF7l2 
gene, a transcription factor of the WNT pathway, and the risk of type 2 diabetes [216]. Out of all common 
genetic mutations implicated in T2DM, TCF7l2 is most significantly associated with disease susceptibility. 
Another GWAS-identified risk gene for T2DM is Cyclin-dependent Kinase 5 Regulatory Subunit-
Associated Protein 1-like 1 (CDKAL1) [217]. Interestingly, CDKAL1 increases protein levels of β-catenin 
and its active unphosphorylated form in the nucleus, thereby promoting Wnt target gene expression, 




suggesting that CDKAL1 activates canonical WNT signalling [218]. Finally, a recent report showed that 
(RSPO3), which has previously been implicated by a GWAS as a risk gene for increased BMI and insulin 
resistance [219], regulates energy homeostasis in association with WNT signalling [220]. Together, these 
studies strongly suggest a role for canonical WNT signalling in the regulation of energy homeostasis. In 
this section, the WNT pathway and its relation to leptin and glucose homeostasis are introduced. 
1.7.1 Overview of WNT signalling 
The WNT pathway was first described in 1976, when it was reported that Drosophila Melanogaster have a 
wingless phenotype when this pathway is mutated [221]. In 1982, the same signalling cascade was found 
to promote tumour formation in mice, and therefore given the term ‘integration-1 (int1)’ [222]. ‘Wingless’ 
and ‘int1’ were later combined and thus the WNT pathway was coined. The WNT signalling pathway is 
evolutionarily highly conserved, and is classically known for its role in embryogenesis and tumorigenesis 
[223]. Its ligands (WNTs) are involved in three different pathways: the canonical WNT pathway, the planar 
cell polarity pathway, and the WNT/Ca2+ pathway. The canonical WNT pathway is activated when a WNT 
ligand binds to the frizzled (Fzd) receptor, which subsequently forms a complex with the co-receptor 
lipoprotein related protein (LRP) 5/6. This causes dishevelled (Dvl) to phosphorylate LRP, which then 
inactivates GSK3β. Next, GSK3β inactivation decreases phosphorylation of the transcriptional co-activator 
β-catenin. Stabilized β-catenin then enters the nucleus where it associates with transcription factors of the 
lymphoid enhancer factor (LEF)/T cell factor (TCF) family, to ultimately regulate the transcription of 
downstream target genes such as cyclin D1 and axin 2 [224] (figure 1.9).  





Figure 1.9 Overview of the canonical WNT pathway. The canonical WNT pathway is activated when a WNT ligand binds to the 
frizzled (Fzd) receptor, which subsequently forms a complex with the co-receptor lipoprotein related protein (LRP) 5/6. This causes 
dishevelled (Dvl) to phosphorylate LRP, which then inactivates GSK3β. Next, GSK3β inactivation decreases phosphorylation of 
the transcriptional co-activator β-catenin. Stabilized β-catenin then enters the nucleus where it associates with transcription factors 
of the lymphoid enhancer factor (LEF)/T cell factor (TCF) family, to ultimately regulate the transcription of downstream target 
genes. Created with BioRender.com. 
1.7.2 WNT’s and TCF’s 
Nowadays, 21 WNT genes and four TCF family members have been described in human and mouse. These 
encode for proteins that act in an autocrine and/or paracrine manner, and often display a high degree of 
redundancy over each other [225]. Furthermore, 15 different WNT receptor and co-receptors have been 
described. The binding of a particular WNT to a particular WNT (co-)receptor determines which 
downstream signalling cascade is activated. This combinatorial code remains to be understood completely, 
although it has been shown that WNT1, WNT3a and WNT8 are usually associated with canonical, β-
catenin-dependent WNT signalling, whereas WNT5a and WNT11 are more commonly found in β-catenin-
independent WNT signalling.  




In humans (and rodents), four closely related TCF genes are found: Lef1, TCF7 (TCF1 in rodents), TCF7l1 
(TCF3), and TCF7l2 (TCF4). Despite their partly overlapping functions, alternative splicing and promotor 
usage can result in dominant-negative isoforms, thereby increasing the functional diversity of the TCF’s 
[226]. A truncated form of LEF1 that lacks the β-catenin-binding domain, for example, is found during the 
development of lymphocytes and in colon cancer [227]. Moreover, the degree of redundancy between the 
TCF’s varies significantly. TCF7 and LEF1 appear to be redundant in their role in morphogenesis of the 
mesoderm and ectoderm during embryogenesis, as well as in limb development [228]. TCF7 also overlaps 
functionally with TCF7l2, as each factor has dual functions as repressor and activator in cancer signalling 
[229]. The wide variety of WNT ligands, (co-)receptors and transcription factors make their signal 
transduction very complex. Another contributing factor to the complexity of WNT signalling is the fact that 
it appears to serve different functions during embryonic development and in later developmental stages 
[225]. More specifically, emerging evidence supports a role for WNT signalling in the adult brain. 
1.7.3 WNT signalling in the adult brain  
One of the first indications that WNT signalling plays an essential role in the adult brain found this 
signalling cascade regulates not only embryonic, but also postembryonic hypothalamic progenitor 
differentiation in both zebrafish and mice, thereby emphasizing the evolutionary conservation of WNT 
action in the brain [230]. Using in situ hybridization for the individual TCF members and for GFP in a 
zebrafish reporter line that expresses canonical WNT activity, it was found that all TCF members are 
expressed in the hypothalamus, especially in the posterior part where postmitotic precursor cells are found 
[231]. Interestingly, the expression of TCF7l2 is confined to a small area right above the future hypophysis. 
Consistent with this finding is a study that reports negative regulation of pituitary development by TCF7l2 
in mouse embryos [232]. Furthermore, zebrafish larvae were found to express LEF1 and TCF7 in the caudal 
zone of the periventricular hypothalamus. No specific expression of TCF7l1a/b or TCF7l2 was found. A 
similar expression pattern was found in adult fish, where TOP:dGFP fluorescence, a canonical WNT 




reporter construct, persisted in cells adjacent to the diencephalic ventricle. Importantly, TOP:dGFP was 
only found in the hypothalamus and optic tectum of adult fish.  
Canonical WNT signalling has been widely implicated in expansion of progenitor poos or neural stem cells, 
suggesting that this pathway is a required factor for neural stem cell maintenance. However, at least 10 
distinct regions have been identified as proliferation zones within the adult zebrafish brain [233]. This 
suggests that the WNT-responsive cells found in the hypothalamus of adult zebrafish serve another purpose. 
The change in function of WNT signalling during development and in adult organisms is far from fully 
understood. In this regard, it is important to note that the key loci for WNT signalling in the adult 
hypothalamus, represent a stem cell population that consists of tanycytes and ependymal cells lining the 
third ventricle and arcuate nucleus neurons [234]. Studies from divergent fields have demonstrated the 
significance of tanycytes and ependymal cells in the neuroendocrine control of feeding and energy balance 
[235]. However, a study by Wang et al. shows that WNT pathway activation decreases the number of 
hypothalamic tanycytes [230]. This excludes WNT signalling from being a necessary requirement for 
tanycyte formation and maintenance, thereby complicating things further. 
1.7.4 WNT pathway and peripheral regulation of glucose homeostasis 
As mentioned previously, genetic studies indicated TCF7l2 to be the highest genetic risk factor for 
developing type 2 diabetes [216, 236]. This generated huge interest in TCF7l2, focusing mostly on the 
insulin-producing pancreatic β-cells, despite evidence that canonical WNT signalling is not active in adult 
β-cells. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis has been 
performed to assess the expression of TCF7l2 upon insulin treatment or high-fat feeding in mice [237]. 
TCF7l2 expression was comparatively lower in the pancreas than the gut, and immunohistochemical 
staining failed to pick up a TCF7l2 signal in the pancreatic islets. Functional studies on TCF7l2 in rodents 
and humans have yielded contradictory findings [238-240]. Particularly hard to explain is the 
incompatibility of data showing that a reduction of TCF7l2 expression in the pancreatic β-cells results in 




blunted glucose-stimulated insulin secretion response [239], whereas evidence from human genetics studies 
shows that the T2D-associated risk alleles actually cause an increased expression of TCF7l2 [241]. On the 
cellular level too, contradicting findings have been made. Several studies concluded that genetic depletion 
of TCF7l2 leads to altered β-cell function [242, 243]. On the other hand, one study reported that TCF7l2 
plays no role in β-cell function, but is rather involved in the hepatic response to metabolic challenge [244]. 
The metabolic role of TCF7l2 in the brain remains poorly studied to date.  
1.7.5 WNT pathway and central regulation of glucose homeostasis 
Data from our laboratory show that DKK-1 mRNA expression is increased in the ARC of Lepob/ob mice. 
Furthermore, ICV DKK-1 treatment in wild type mice leads to severely impaired glucose homeostasis 
[245]. In accordance, humans with type 2 diabetes have markedly higher circulating DKK-1 levels 
compared to healthy controls. Pharmacological inhibition of DKK reduces basal blood glucose levels and 
improves glucose tolerance in mice, and DKK-2 knockout mice have increased hepatic glycogen 
accumulation and decreased hepatic glucose output, coupled with increased WNT activity in the intestines 
[246]. Together, these data implicate an important role for WNT receptor antagonism in the pathogenesis 
of type 2 diabetes. Besides DKK-mediated receptor antagonization, the main endogenous WNT pathway 
inhibitor is GSK3β. Importantly, GSK3β is phosphorylated and inhibited by AKT in L6 myotubes [247], 
skeletal muscle [248] and in HeLa cells [249], thus making it a target of insulin signalling. Indeed, GSK3β 
inhibition is required for insulin stimulation of glycogenesis [250], hence the name glycogen synthase 
kinase. Systemic GSK3β inhibition ameliorates glucose intolerance in Lepob/ob mice [251], suggesting a 
tonic inhibitory effect of GSK3β on glucose homeostasis. While some studies point towards a role for 
GSK3β in skeletal muscle as a mediator of glucose metabolism [252], data from our laboratory show that 
GSK3β action specifically in the hypothalamus is essential for glucose homeostasis. Lepob/ob mice were 
found to have upregulated hypothalamic GSK3β expression, and glucose intolerance in these mice was 
acutely ameliorated by ICV injection of a GSK3β inhibitor. Furthermore, neuron-specific overexpression 




of GSK3β in the hypothalamus exacerbated the effects of a high-fat diet in wild type mice compared to 
mice on a standard diet, measured as increased hyperphagia, obesity and glucose intolerance [245]. In this 
light, it appears that WNT pathway inhibition leads to detrimental effects on energy homeostasis. 
1.7.6 Beneficial effects on metabolic parameters following WNT inhibition 
On the other hand, a number of studies have reported beneficial effects on metabolic health following 
inhibition of WNT signalling. LRP5 plays an important role in osteoblasts, where it regulates maturation, 
matrix mineralization and intermediary metabolism. Mice that lack LRP5 specifically in osteoblasts have 
increased adiposity paired with elevated serum lipid levels, and when challenged with a high-fat diet they 
showed exacerbated hyperglycaemia and glucose intolerance compared to wild type controls, as well as 
reduced serum undercarboxylated osteocalcin. Thus, these findings identify a link between WNT signalling 
and insulin signalling in the osteoblast [253]. Secondly, a role for β-catenin in the regulation of glucose 
homeostasis was demonstrated in a study that used 2'-O-methoxyethyl chimeric antisense oligonucleotides 
(ASOs) to significantly decrease hepatic and adipose expression of β-catenin. ASO-mediated reduction β-
catenin protected mice against high-fat diet-induced hepatic steatosis and hepatic and peripheral insulin 
resistance compared to wild type controls [254]. Finally, a recently synthesized class of trizole-based WNT 
signalling inhibitors appear promising candidates as potential drugs treating dysregulated glucose 
homeostasis. One compound especially, named compound 3a, induced proteasomal β-catenin degradation 
via stabilization of axin, thereby inhibiting WNT signalling. Compound 3a-treatment decreased hepatic 
steatosis in both cultured hepatocytes and high-fat diet-fed mice, and improved glucose tolerance in these 
mice with no significant toxicity [255]. The discrepancies found between studies looking at the metabolic 
effects of WNT pathway inhibition are also found among the various WNT-altering compounds designed 
to treat tumours. While most cancer-targeted WNT compounds inhibit this pathway, the notion that 
universal antagonization of the WNT pathway in cancer would be beneficial has been challenged by the 
finding that increased WNT signalling does no correlate with decreased patient’s survival [256]. It is clear 




that because the WNT pathway is involved in such a wide variety of physiological processes, 
pharmacologically targeting this pathway is very complex. 
1.7.7 Leptin and the WNT pathway 
Studies from our laboratory and others suggest that the WNT pathway plays a role in the leptin-mediated 
control of energy homeostasis (figure 1.10). Polymorphisms in LRP are associated with obesity in humans 
[257]. Lepob/ob mice have reduced phosphorylated LRP6 immunoreactivity in the ARC compared to wild 
type controls, an effect that is normalized by leptin treatment. DKK-1 on the other hand, decreases pLRP6 
activity. Interestingly, an intracerebroventricular injection of DKK-1 prior to leptin treatment blocks the 
glucoregulatory effect of leptin in mice [258]. In further support of a link between leptin and the WNT 
pathway, a study investigating the association between obesity and intervertebral disc degeneration found 
that leptin induces cyclin D1 expression and proliferation of cells in the nucleus pulposus. Interestingly, 
this proliferative effect of leptin was mediated via the JAK2/STAT3- and PI3K/AKT pathway, as well as 
ERK signalling [259]. Previously, it had been shown that leptin mediates the regulation of growth cone 
morphogenesis in developing cortical neurons by inactivating GSK3β [260]. Although the possibility of 
confounding developmental WNT pathway artefacts cannot be excluded here, it is interesting to see that 
leptin activates the WNT pathway in a wide variety of physiological processes. Finally, a study looking at 
the effects of leptin in Xenopus laevis tadpoles found that upon intracerebroventricular injection of 
recombinant leptin, the single most activated pathway was the canonical WNT pathway. Whether leptin 
directly activates WNT signalling at the level of the WNT receptor, or whether this is effect is taking place 
via yet unknown mechanisms remains to be elucidated. 
 
 





Figure 1.10 A model of insulin and leptin crosstalk in the central control of energy and glucose homeostasis. In the mediobasal 
hypothalamus, insulin binds to insulin receptors, leading to activation of IRS. Activated IRS phosphorylates PI3K, ultimately leading 
to phosphorylation of AKT and suppression of GSK-3β, the master inhibitor of insulin action. Binding of leptin to its receptors leads 
to activation of JAK. This causes phosphorylation of the WNT co-receptor LRP and activation of the WNT/β-catenin pathway. 
Subsequently, β-catenin translocates into the nucleus, where it acts as a co-transcription factor of TCF/LEF, and inhibition of GSK-
3β facilitates the activation of insulin signalling. Created with BioRender.com.  




1.8 Investigating leptin in the zebrafish 
In this thesis, the glucoregulatory effects of leptin are investigated from an evolutionary perspective, using 
the zebrafish (Danio rerio) as a model. Non-mammal leptin studies comprise but a tiny fraction (<2%) of 
the total research in the leptin field. However, these studies are needed not only to answer comparative 
questions, but uncovering the evolutionary origins of leptin function will clarify our understanding of how 
this hormone works in the human body. Evolution tends to select against unfavourable traits. Conversely, 
one could argue that what is preserved evolutionarily, must be favourable and important. Evidence of 
evolutionary conservation of the glucoregulatory action of leptin would therefore emphasize its importance 
in the human body. Leptin orthologues have been described in all classes of vertebrate animals, and even 
in evolutionarily more distant species such as the fruit fly (Drosophila melanogaster) [263]. Due to the wide 
variety of ecological niches, different animals require different control of energy homeostasis. For example, 
migratory birds fuel long-distance migration by dramatically changing their metabolic rate [264], snakes 
display extreme metabolic flexibility to process large and infrequent meals [265], and hibernating mammals 
accumulate vast lipid stores to survive long periods of torpor [266]. Therefore, leptin regulates energy 
homeostasis differently across the animal kingdom. However, the intracellular and intercellular signalling 
circuitry described in sections 1.3 and 1.4 are remarkably well-conserved. The regulation of energy 
homeostasis by leptin throughout evolution is discussed in detail in section 7.1 of this thesis. When it comes 
to the glucoregulatory actions of leptin, the zebrafish is an especially interesting model. It has been shown 
that in this animal, leptin regulates glucose homeostasis, but not adipostasis. This suggests that leptin may 
have evolved as a glucoregulatory hormone, and that its adipostatic function is a secondary function that 
has been acquired by mammals somewhere over the course of evolution. 
 
Zebrafish were established as a model for scientific research by George Streisinger in the 1970’s. Over the 
last two decades, the zebrafish has joined the ranks of premier model organisms for biomedical research, 




with a fully annotated genome and a wide range of genetic tools. Strikingly, recent observations in the 
zebrafish suggest that in this vertebrate species leptin’s metabolic role appears to be limited to the regulation 
of glucose homeostasis [261]. Lack of the functional long form of the leptin receptor in zebrafish leads to 
an increase in the number of pancreatic β-cells and elevated levels of insulin mRNA in zebrafish larvae. 
Adipostasis, food intake and fertility remained unchanged. Despite this discrepancy, leptin signalling is 
evolutionarily well-conserved. Homologues for leptin and the leptin receptor can even be found in 
invertebrate species like Drosophila [262]. Although leptins from species of different animal classes have 
low primary sequence homology, the secondary, tertiary, and quaternary structure, as well as key amino 
acids required for leptin’s physiological activity, are evolutionarily highly conserved [263]. Zebrafish 
express two leptin paralogs: leptin-a and leptin-b [264]. Both, like all vertebrate leptin variants, consist of 
four alpha helices, and contain a pair of cysteine residues that form a disulphide bond. Moreover, three 
receptor interaction sites have been mapped, and each of these regions has found to show at least some 
degree of conservation of primary amino acid sequence [265]. These characteristics make the zebrafish an 
excellent but understudied model for the investigation of energy homeostasis. Moreover, the small size, 
high fecundity, externally developing eggs and optical transparency of its larvae allow genetic manipulation 
combined with in vivo investigation of the leptin system.  




1.9 Hypothesis and aims 
Leptin is best known for its role in adipostasis, but it also regulates blood glucose levels. The molecular 
mechanism by which leptin controls glucose homeostasis remains largely unknown. We hypothesize that 
leptin regulates glucose homeostasis via the canonical WNT pathway, independent of adipostatic 
effects. It has been shown that in the zebrafish, leptin regulates glucose homeostasis, but not adipostasis. 
Furthermore, both leptin signalling and canonical WNT signalling are evolutionarily well-conserved. For 
these reasons, we used zebrafish as our model to investigate the glucoregulatory actions of leptin from an 
evolutionary point of view. In order to prove our hypothesis, this thesis aims to: 
1. Establish CRISPR/Cas9-mediated knockout zebrafish lines lacking leptin-a, leptin-b or the leptin 
receptor (Chapter 2). 
2. Establish protocols to investigate glucose homeostasis in the zebrafish (Chapter 3). 
3. Characterize glucose homeostasis in adult leptin-mutated and wild type zebrafish (Chapter 4). 
4. Determine whether leptin activates the canonical WNT pathway in zebrafish (Chapter 5). 
5. Examine whether pharmacological manipulation of canonical WNT signalling alters the ability of 




Chapter 2  
Establishing CRISPR/Cas9-mediated 
leptin- and leptin receptor mutant 
zebrafish lines  





2.1.1 Genetic modification in the zebrafish 
In scientific research on animal models, eliciting a mutant phenotype as a result from genetic knockout is 
considered the gold standard approach for predicting the effects of genes in humans. Due to its genetic 
similarity to humans, small size, high fecundity and low maintenance costs, zebrafish have become one of 
the fastest growing model organisms [266].  In addition, the external fertilization and larval development, 
relatively large size of the female egg and larval transparency make the zebrafish uniquely suitable for the 
functional validation of genes [267]. Until about 10 years ago, functional genomics in zebrafish relied for 
the most part on forward mutagenesis by means of chemical or radioactivity-induced random mutations 
[268]. However, targeted genome-editing tools have been developed in recent years that have 
revolutionized the field of genetic modification. Zinc-finger nucleases (ZFN’s) [269], transcription 
activator-like effector nucleases (TALENs) [270] and clustered regularly interspaced short palindromic 
repeats (CRISPR/Cas9) nucleases [271] have all been proven to be effective tools that allow for targeted 
mutagenesis with unprecedented precision. However, compared to ZFN’s and TALENs, CRISPR/Cas9 is 
technically simpler yet more effective. A systematic comparison of the germline transmission rates of 
ZFNs, TALENs and CRISPR/Cas9 in zebrafish found that the latter is 6 times more effective [272]. Another 
clear advantage of CRISPR/Cas9 over ZFNs and TALENs is that this technique enables multiplexed 
mutagenesis – targeting multiple genes simultaneously [273]. This is especially important given the 
duplicated zebrafish genome. 
  




2.1.2 Concise history of CRISPR in the zebrafish 
CRISPR-Cas was first identified as a microbial adaptive immune system in 1993 [274], but it wasn’t until 
2012 that scientists realized that the Cas9 endonuclease enzyme from Streptococcus pyogenes or 
Streptococcus thermophilus can be guided to a target site, using a guide RNA, to induce a double stranded 
break [271, 275]. This break can then be repaired by either the non-homologous end joining (NHEJ) or 
homology-directed repair (HDR) pathways, both of which are error prone and thus lead to mutations. 
Efficient in vivo genome editing in vertebrates was first reported in the zebrafish [276]. Another landmark 
study in zebrafish demonstrated that CRISPR/Cas9 can be utilized to generate biallelic mutations that result 
in phenotypes that are identical to genetic mutants [277]. Around the same time, the Cas9 endonuclease 
was optimized for zebrafish genome editing using T-antigen nuclear localization signals (nls) at both the 
amino and carboxyl termini, creating the nls-zCas9-nls protein that is now widely used in zebrafish gene 
editing [273]. In combination with easily designed, gene-specific single guide RNA’s (sgRNAs), this new 
Cas9 was shown to efficiently induce biallelic mutations upon injection into one-cell stage zebrafish 
embryos. Moreover, it was demonstrated that up to five genes can be targeted at the same time. In recent 
years, streamlined workflows have been developed to use CRISPR/Cas9 in zebrafish in a high-throughput 
manner, allowing for targeted mutagenesis at unprecedented speed and efficiency [278, 279]. For example, 
zebrafish were used to screen 254 gene mutations to identify 7 new genes involved in hair cell regeneration 
[280]. The CRISPR toolkit in zebrafish is expanding rapidly, and CRISPR-based approaches are currently 
starting to be used for epigenome editing [281], transcriptional modulation [282], lineage tracing [283] and 
live imaging of the genome [284]. 




2.1.3 CRISPR workflow 
The protocol used for generating the knockout zebrafish in this thesis is adapted from a workflow developed 
by Varshney et al. (2015). Gene-specific target sites were selected by consulting multiple online databases. 
For sgRNA synthesis, a cloning-free, oligo-based method was used. Cas9 mRNA was transcribed in vitro 
from a plasmid designed specifically for CRISPR mutagenesis in zebrafish. sgRNAs and Cas9 mRNA were 
microinjected simultaneously into single-cell stage zebrafish embryos of the AB strain. Somatic mutagenic 
activity was determined using a fluorescent PCR approach, as was the identification of germline-
transmitting founder fish. Using this approach, three stable knockout zebrafish lines were developed: ABz-
lepA-/-, ABz-lepB-/- and ABz-lepR-/-. 
 
  




2.2 Selection of leptin and leptin receptor-specific target sites 
2.2.1 General considerations 
The first step towards selecting gene specific target sites for zebrafish leptin-a, leptin-b and the leptin 
receptor, was to consult the CRISPRz database of previously validated sgRNA’s [285]. One study was 
found that knocked out leptin-a, leptin-b and the leptin receptor in zebrafish [261]. However, we decided 
to use a T7 RNA polymerase to synthesize sgRNA’s, and therefore target sequences had to start with GG 
(as opposed to an SP6 RNA polymerase requiring targets to start with GA). This rendered us unable to use 
the same target site as Michel et al. (2016) for leptin-b.  
Gene-specific target sites were selected using the CHOPCHOP web tool [286], taking into account 1. the 
predicted off-target activity, 2. GC content, 3. self-complementarity, 4. exonic vs intronic location, and 5. 
selecting gRNA’s downstream of any in-frame ATG sites to avoid the expression of truncated proteins. 
Laboratory zebrafish are often inbred and therefore they possess relatively high polymorphism rates that 
could affect target-binding specificity. Therefore, potential target sites were also compared in the UCSC 
Genome Browser with data from the NHGRI-1 strain: a zebrafish strain created specifically to account for 
all variations in the founding parents, which have been documented through high-through put sequencing 
[287]. One more consideration is that different Cas9 proteins require different protospacer adjacent motifs 
(PAM) sequences. The pT3TS-nls-zCas9-nls plasmid used in this thesis requires at nGG PAM sequence.  
  





The zebrafish leptin-a gene is located on the 18th chromosome and consists of 2 exons. Exon 1 contains 144 
nucleotides, and exon 2 contains 357 nucleotides. Using Chopchop, 50 potential target sequences were 










Figure 2.1 The zebrafish leptin-a gene with primers and target sequence used for CRISPR mutagenesis. PAM = protospacer 
adjacent motif. Tm = melting temperature. 
  








Target Sequence GGAATCTCTGGATAATGTCCTGG 
Genomic Location chr18:10690042 
Strand Sense 
GC Content 45% 
Self-complementarity 1 
 
Left Primer ATCATCGTCAGAATCAGGGAAC 
Left Primer Coordinates chr18:10689883-10689905 
Left Primer Tm 60.3 °C 
Right Primer TCTGGTCAACATGCTTATTTGG 
Right Primer Coordinates chr18:10690141-10690163 
Right Primer Tm 60 °C 
Amplicon Size 280 





The zebrafish leptin-b gene is located on the 4th chromosome and, like the zebrafish leptin-a gene, consists 
of 2 exons. Exon 1 contains 138 nucleotides, and exon 2 contains 369 nucleotides. Using Chopchop, 63 










Figure 2.2 The zebrafish leptin-b gene with primers and target sequence used for CRISPR mutagenesis. PAM = protospacer 
adjacent motif. Tm = melting temperature. 








Target Sequence GGAACCTCTGGAGCTCCAGGAGG 
Genomic Location chr4:19031954 
Strand Sense 
GC Content 65% 
Self-complementarity 2 
 
Left Primer GGTGCATAAAGAAGAAACAGCC 
Left Primer Coordinates chr4:19032003-19032025 
Left Primer Tm 60.1 °C 
Right Primer GCATGGCTTACACATTTCAGAG 
Right Primer Coordinates chr4:19031861-19031883 
Right Primer Tm 59.8 °C 
Amplicon Size 164 




2.2.4 Leptin receptor 
 The zebrafish leptin receptor gene is located on the 6th chromosome and consists of 20 exons. Using 
Chopchop, 352 potential target sequences were found. The selected target sequence is part of the 9th exon, 






Target Sequence GGAGCGCCAGTAAAGCCGTGTGG 
Genomic Location chr6_KZ115187v1_alt:385269 
Strand Antisense 
GC Content 65% 
Self-complementarity 1 
 
Left Primer ggcttaaatggccctctattct 
Left Primer Coordinates chr6_KZ115187v1_alt:385386-385408 
Left Primer Tm 60.0 °C 
Right Primer TGACCTGCTCATTGATGACTCT 
Right Primer Coordinates chr6_KZ115187v1_alt:385208-385230 
Right Primer Tm 59.9 °C 
Amplicon Size 214 
 
Figure 2.3 The zebrafish leptin receptor gene with primers and target sequence used for CRISPR mutagenesis. PAM = 
protospacer adjacent motif. Tm = melting temperature. 











2.3 In vitro transcription of single guide RNA’s and Cas9 mRNA 
2.3.1 target-specific DNA template synthesis 
Synthesis of sgRNA’s was achieved through a cloning-free, oligo-based method (figure 2.4). This method 
requires a top strand that functions as a target-specific oligo, containing a 17-nt-long T7 promotor 
(TAATACGACTCACTATA), the 18-20-nt-long target sequence, and a 20-nt sequence 
(GTTTTAGAGCTAGAAATAGC) that is complementary to the 80-nt ‘generic’ bottom-strand oligo (5′-
AAAAGCACCGACTCGGTG CCACTTTTTCAAGTTGATAACGGACTAGC CTTATTTTAACTTG 
CTATTTCTAGCTCTAAAAC-3′). The final assembled top-strand oligo sequence for each target was thus 
as follows: TAATACGACTCACTATA ggnnnnnnnnnnnnnnnnnn GTTTTAGAGCTAGAAATAGC. 
Target-specific top strand oligos and the universal bottom-strand ultramer were ordered from Integrated 
DNA Technologies. The oligos were annealed and extended in a thermocycler. Subsequently, oligo 
assembly was confirmed by running 3 μl of each oligo assembly reaction along with a 50bp DNA ladder 
on a 2.5% agarose gel in 1x TAE buffer.  
Figure 2.4 Schematic of DNA template preparation. SgRNAs are synthesized by annealing two oligos. The top strand is target-
specific and the bottom strand is a generic oligo (Ultramer); both oligos are annealed and extended with a DNA polymerase and 
used as template for in vitro transcription. In this schematic, the T7 promoter sequence is depicted in red, the 18- to 20-bp target 
sequence in blue (the NGG PAM site is not included in this sequence) and the remaining sgRNA sequence in green. Based on 
Varshney et al. (2016) 




2.3.2 sgRNA in vitro transcription 
The assembled oligos were transcribed into RNA using a T7 High Yield RNA Synthesis Kit (Thermo 
Fischer), according to the manufacturer’s instructions. After 4 hours, DNAse was added for 20 minutes to 
remove the DNA. The RNA synthesis reaction was then purified using a RNA Clean and Concentrator-5 
Kit (Zymo Research), under RNAse free conditions. Finally, the RNA was eluted with 20 μl of nuclease-
free water. Quantification on a Nanodrop spectrophotometer confirmed that the concentrations were over 
100ng/μl with an A260/280 ratio between 2.0 and 2.3. Successful RNA syntheses were confirmed by running 
a sample of each RNA on a 2% agarose gel in TAE buffer. SgRNA was aliquotted and stored at -80°C. 
2.3.2 Cas9 mRNA transcription 
A pT3TS-nls-zCas9-nls plasmid [273](Addgene plasmid #46757, figure 2.5) was streaked on an agar plate 
that contained 100μg/ml ampicillin. After 12 hours of incubation at 37°C, a liquid culture in LB medium 
with 100μg/ml ampicillin was inoculated by picking a single colony from the agar plate. This culture was 
grown for 12 hours at 37°C on a shaking incubator. Bacterial growth was checked, and the plasmid was 
purified using a Qiagen Miniprep Kit. The circular pT3TS-nls-zCas9-nls plasmid DNA was digested with 
XbaI, and purified using a QIAquick PCR Purification Kit. Linearized Cas 9 DNA was quantified on a 
Nanodrop spectrophotometer, and the final concentration was confirmed to be over 150ng/μl, with a A260/280 
ratio between 1.7 and 1.9. Next, the linear Cas9 DNA was transcribed into RNA using a mMessage 
mMachine T3 Transcription Kit. After 2 hours’ incubation at 37°C, and 15 minutes of incubation with 
Dnase at 37°C, the RNA transcription reaction was purified using a RNA Clean and Concentrator-5 Kit 
(Zymo Research) under Rnase-free conditions. The RNA was eluted in 20 μl nuclease free water. 
Quantification on a Nanodrop spectrophotometer confirmed a concentration of over 500ng/μl with an 
A260/280 ratio between 2.0 and 2.3. Gel electrophoresis confirmed successful RNA transcription, showing a 




band at the expected size of ±1,6kB. Cas9 mRNA was divided into 5μl aliquots with a concentration of 500 
ng/μl and stored at -80°C.  
Figure 2.5 Composition of pT3TS-nls-zCas9-nls plasmid (Addgene plasmid #46757) 




2.4 Microinjection of single guide RNA’s and Cas9 mRNA 
2.4.1 Needle pulling and calibration 
1.0mm OD borosilicate glass capillaries (Harvard Apparatus) were pulled to form pairs of 2 needles using 
pulling program 6 (p=500, heat=450, pull=50, vel=75, time=70) on a Sutter p-97 Flaming-Brown glass 
micropipette puller. Injection solutions were well mixed and 2μl was loaded into the needle with a 
microloader pipette. The needle was placed in the needle holder of an air-pressure MPPI3 system. 10 μl of 
halocarbon oil was pipetted onto a stage micrometer calibration slide. Pressing the injection pedal released 
a droplet of injected solution, which floated on the oil. The drop was measured to ensure it was 1nl. Clean 
forceps were used to trim needle tip and pulse duration was adjusted to change drop size when necessary. 
The pulse duration of the pressure injector was set between 1.5 and 3.5 to minimize needle breakage and 
embryo damage.  
2.4.2 Microinjections 
On the night before scheduled microinjections, zebrafish were set up for breeding. 30 males and 30 females 
of the ABz strain were separated and placed in an iSpawn (Techniplast) embryo collection system. On the 
morning of injections, solutions containing the sgRNA for the gene of interest (35.4ng/μl) and Cas9 mRNA 
(212.2ng/μl) were prepared on ice. Fresh zebrafish eggs at the 1-cell stage were collected and placed in E3 
medium (16.5mM CaCl2, 16.5mM MgSO4, 8.5mM KCl, 250mM NaCl, 0.1% methylene blue dye in sterile 
water). Injections were achieved by lining up embryos on a ridged plate and, under magnification of a Leica 
M80 microscope, guiding the needle tip through the chorion to pierce the yolk sac. Solutions were directly 
injected into the yolk sac at the one cell stage. For each injected group, uninjected controls of the same 
batch were kept to observe normal development and death rates. Embryos were placed into a 28.5°C 
incubator. At 5 hours post fertilization, unfertilized and injection-damaged embryos were removed. 
Subsequently, embryos were placed back into the 28.5°C incubator. At 24 hours post fertilization, counts 




were made of the numbers of normal-looking, deformed and dead embryos, in both the injected and the 
uninjected embryos. Dead and deformed embryos were removed, and E3 medium was refreshed. 
 
 
2.4.3 Method validation through Tyr knockdown 
In order to validate the methods described above, the tyrosinase gene was targeted. Knockdown of tyr is 
associated with reduced pigmentation, which is easily observable at 48hpf [273]. The tyr target sequence 
(GGACTGGAGGACTTCTGGGG) was obtained from the CRISPERz database and a tyr-specific sgRNA 
was synthesized as described in section 2.3. Following microinjection of a tyr-sgRNA and Cas9 mRNA, 
pigmentation rates were assessed at 2dpf to see whether the mutation had taken place. A clear difference 
was found between wild type embryos and embryos that were injected with the tyrosinase sgRNA and Cas9 
mRNA (figure 2.7). In the wild type embryos, many pigment cells were forming. The CRISPR-embryos on 
Figure 2.6 Overview of CRISPR-mediated mutagenesis in zebrafish. (A) Cas9 mRNA (left) and gene-specific sgRNA (right) are 
transcribed in vitro. (B) Zebrafish are bred and fresh eggs are rapidly collected. (C) Microinjection of Cas9 mRNA and sgRNA 
into zebrafish eggs at the one-cell stage. (D) The DNA is cleaved at the site of interest by the sgRNA-guided Cas9 protein. 




the other hand, displayed a severe reduction in pigmentation, leading to an almost albino phenotype. It was 
concluded that the CRISPR/Cas9 pipeline had been set up successfully.  
 
Figure 2.7 Tyrosinase gene knockdown in 48hpf zebrafish. Upper: a 48hpf wild type zebrafish embryo showing clear formation 
of pigment cells. Lower: a 48hpf tyrosine KO zebrafish embryo lacking pigmentation. Scale bar = 100μm 




2.5 Fluorescence PCR-based mutagenesis screening 
Several methods exist for the evaluation of sgRNA activity, the most common of which is amplification of 
the target site through PCR [288]. Here, we demonstrate CRISPR-Cas9-induced mutagenesis in zebrafish 
using three-primer fluorescence PCR. 
2.5.1 Extraction of genomic DNA from zebrafish embryos 
At 48 hours post fertilization, eight embryos from each injection group and eight uninjected embryos were 
euthanized by thermal shock through immersion in an ice slurry. Using 0.2ml 8-strip tubes, one embryo 
was placed in each tube. To burst the chorions, the collected embryos were placed in a -20°C freezer until 
the samples were completely frozen (~30min.). Afterwards, the embryos were thawed again at room 
temperature. For extraction of genomic DNA, 25μl Extraction Solution and 7μl Tissue Preparation Solution 
per embryo were mixed. 32μl of the Extraction Solution/Tissue Preparation Solution mixture was added to 
each well, making sure that every embryo was completely submerged in solution. The embryos were 
incubated at room temperature for 10 minutes, followed by 5 minutes of incubation at 95°C. Subsequently, 
25μl Neutralization Solution B was added to each well. Samples were sealed and vortexed. Finally, the 
extracted DNA was diluted 1:10 with nuclease-free water, and stored at -20°C.  
2.5.2 Fluorescence PCR 
For each target, primer sites were selected as described in section 2.2. To increase PCR-based genotyping 
accuracy, an M13F sequence (5′-TGTAAAACGACGGCCAGT-3′) was added to the 5` side of each 
forward primer, and a pigtail sequence (5′-GTGTCTT-3′) was added to the 5` side of each reverse primer. 
These added sequences have been demonstrated to improve the genotyping efficiency of both human 
samples and of indels generated through CRISPR-Cas9 in zebrafish. PCR primers and a fluorescently 
tagged M13-FAM primer (/56-FAM/-TGTAAAACGACGGCCAGT) were ordered from Integrated DNA 
Technologies. Next, a PCR master mix was prepared from an AmpliTaq Gold DNA Polymerase kit, by 
combining 7.94 ml of 10x PCR Buffer II, 7.94 ml of 25mM MgCl2, 795μl of 100mM dNTP blend (25mM 




each), 635μl of AmpliTaq Gold and 32.69 ml of nuclease-free water. Aliquots of 100μl and 1ml were made 
and stored at -20°C. Next, primer mix was prepared by diluting the forward M13F-tailed primer, the reverse 
pigtailed primer, and the fluorescently tagged M13-FAM primer to a final concentration of 1μM each. 6μl 
of primer mix was added to a 100μl aliquot of PCR master mix. Subsequently, 5μl of the PCR master 
mix/primer mix was added to each well of 0.2ml 8-strip tubes. 1.5μl of diluted DNA was added to the 5μl 
of the PCR master mix/primer mix. Samples were vortexed and spun down. The fluorescence PCR was run 
according the following conditions: 
Table 2.1 Fluorescence PCR conditions 
Cycle number Denature Anneal Extend 
1 94 °C, 12 min   
2-41 94 °C, 30 s 57 °C, 30 s 72 °C, 30 s 
42   72 °C, 10 min 








2.5.3 Determination of somatic activity 
Following the fluorescence PCR, capillary electrophoresis was performed on a 3730xl genetic analyser by 
the Otago Genetic Analysis unit. After the run was completed, data was analysed to determine somatic 
mutagenesis activity using ‘Geneious 11.1.5’ bioinformatics software. In wild type embryos, the DNA 
sequence that is amplified has not undergone any mutations. Thus, the fluorescence PCR plot shows a 
single, large peak (figure 2.8). CRIPSR-injected fish on the other hand have a mosaic expression of the 
mutation, meaning that the target sequence is mutated in some, but not all cells. Furthermore, different cells 
will carry different mutations. Following fluorescence PCR, this leads to fluorescently tagged amplicons of 
different sizes (figure 2.9).  
  
Figure 2.9 Fluorescence PCR plot of uninjected larva. The blue trace represents the amplicon of the gene of interest. The green 
trace represents a dye-labelled size standard used to determine the size of the amplicon. 
Figure 2.8 Fluorescence PCR plot of CRISPR-injected larva. The blue trace represents the amplicon of the gene of interest. The 
green trace represents a dye-labelled size standard used to determine the size of the amplicon. 




Successful somatic mutation will therefore result in a fluorescence PCR plot containing multiple smaller 
peaks. Two examples of the raw data generated with the Genetic Analyser are shown in figures 24 and 25: 
one uninjected wild type embryo, and one leptin-b CRISPR-injected embryo. In both embryos the leptin-b 
target sequence is amplified, with the amplicon size being 192 base pairs. Somatic mutagenic activity was 
found for both leptin-a and leptin-b, as well as for the leptin receptor group (appendix).  
2.6 Selection of founder fish 
2.6.1 General procedure 
The injected CRISPR fish (F0) were raised to adulthood and then screened for germline transmission. To 
do this, pairwise crossings were performed between F0 fish and wild type fish. Embryos were collected and 
incubated at 28.5°C for 2 days. After 2 days, 4 embryos from were collected from each founder, placing 
one embryo per tube in 0.2ml 8-strip tubes. Genomic DNA was extracted as described in section 2.5.1. 
Fluorescence PCR and capillary electrophoresis were performed as described in section 2.5.2. The resulting 
PCR plots show a wild type peak of the expected size, and, if a mutant allele is present, a second peak 
showing an insertion (larger than the wild type peak) or deletion (smaller than the wild type peak) (figure 
2.10). Using ‘Geneious 11.1.5’ bioinformatics software, the size of each insertion or deletion was 
determined by comparing the amplicon size with a GeneScan™ 500 LIZ® Size Standard. To establish 
knockout mutant lines, founder fish were selected that transmitted frameshift mutations (not multiples of 
3). Due to the triplet nature of gene expression by codons, frameshift mutations change the reading frame, 
resulting in a completely different translation from the original sequence. For each line that was established, 
two biallelic mutant founder fish were incrossed. Additional germline screening data can be found in 
appendix 2. 






Figure 2.10 Fluorescence PCR plots of mutant (upper PCR plot) versus wild type F1 zebrafish (lower PCR plot). The blue trace 
represents the amplicon of the gene of interest. The green trace represents a dye-labelled size standard used to determine the size 
of the amplicon. 





To establish the ABz-lepA-/- line, two biallelic mutant founder fish were incrossed. The male carried an 11 
base pair insertion on one allele, and a 7 base pair insertion on the other allele. The female carried an 8 base 
pair insertion on one allele, and a 41 base pair insertion on the other allele (figure 2.11).  
 
Figure 2.11 Fluorescence PCR plots of leptin-a knockout founder fish. The blue trace represents the amplicon of the gene of 
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To establish the ABz-lepB-/- line, two biallelic mutant founder fish were incrossed. The male carried an 8 
base pair deletion on one allele, and a 25 base pair insertion on the other allele. The female carried a 31 
base pair insertion on one allele, and a 7 base pair deletion on the other allele (figure 2.12).  
 
 
Figure 2.12 Fluorescence PCR plots of leptin-b knockout founder fish. The blue trace represents the amplicon of the gene of 
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2.6.4 Leptin receptor 
To establish the ABz-lepR-/- line, two biallelic mutant founder fish were incrossed. The male carried an 8 
base pair deletion on one allele, and a 11 base pair insertion on the other allele. The female carried a 16 
base pair insertion on one allele, and a 25 base pair deletion on the other allele (figure 2.13).  
 
Figure 2.13 Fluorescence PCR plots of leptin receptor knockout founder fish. The blue trace represents the amplicon of the gene 
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2.7.1 Off-target mutagenesis 
Using the CRISPR-Cas9 system, three stable knockout zebrafish lines were developed: ABz-lepA-/-, ABz-
lepB-/- and ABz-lepR-/-. A frequent point of discussion around CRISPR-Cas9 is mutagenesis of an incorrect 
target, as it has been shown to sometimes bind and edit unintended targets [289]. Off-target mutagenesis 
may result in attribution of genetic function to the incorrect gene. Studies looking at off-target mutagenesis 
in zebrafish have shown rates ranging between 1.1% and 4% [290]. Good experimental design can avoid 
this error, and therefore multiple measures have been taken to minimize any off-target activity in the ABz-
lepA-/-, ABz-lepB-/- and ABz-lepR-/- lines. Firstly, during the design of the sgRNAs, every potential target 
sequence was scanned for off-target activity. The CHOPCHOP design tool employs a Bowtie-based 
sequence aligner to predict the specificity of each target site in the genome [291]. Secondly, the pT3TS-
nls-zCas9-nls plasmid used here has been developed to increase specificity compared to the original spCas9 
enzyme and thus reduce off-target activity while retaining high on-target activity. A Cas9-nanos version 
has been developed that preferentially targets the germ cells, but the activity of this endonuclease is 
significantly lower compared to the pT3TS-nls-zCas9-nls endonuclease [292]. Thirdly, sgRNAs and Cas9 
mRNA are introduced via microinjection. This technique results in robust yet transient expression of the 
endonuclease. It has been demonstrated that transient expression is beneficial in keeping off-targets to a 
minimum [290] . In some cell culture systems on the other hand, cells are exposed to high levels of 
constitutive Cas9 expression, and this has been shown to result in accumulation of off-target mutagenesis 
over time [293]. Finally, because the development of stable mutant knockout zebrafish lines involves 
several cross breedings, any off-target mutations are easily outcrossed away. This procedure is a common 
practice for all chemically induced mutant zebrafish, where founder animals are very heavily mutagenized 
[294].  
 




2.7.2 Incrossing germline transmitting founder fish 
In zebrafish, phenotyping is usually done in the F2 generation, where homozygous embryos are generated 
by breeding two heterozygous (F1) lines over the course of 6-7 months [295]. It has been demonstrated 
however, that fish can be screened in the F1 generation already, by inbreeding two biallelic mutant founder 
fish [272]. Moreover, the zebrafish-optimized pT3TS-nls-zCas9-nls improves mutagenic efficiency to a 
level where biallelic mutations are induced at a rate that allows for phenotypic screening in the injected 
embryos already [273]. Thus, to save time and lots of genotyping, the ABz-lepA-/-, ABz-lepB-/- and ABz-
lepR-/- lines generated here were created by incrossing two biallelic founder (F0) fish.  
2.7.3 Controls 
In subsequent chapters, the ABz-lepA-/-, ABz-lepB-/- and ABz-lepR-/- lines generated here are compared to 
wild type fish. A single wild type control line is used for all three transgenic lines. In transgenic mouse 
models, it would be essential to have a control for each line. However, the transgenic zebrafish lines 
described in this chapter are generated against a background that is close to identical to that of the wild type 
controls. The wild type controls were raised from the uninjected embryos described in section 2.4, whereas 
the mutants represent the injected embryos. Therefore, a single wild type line suffices as control for all 
three transgenic lines. 
2.7.4 Confirmation of successful knockout 
Because the capillary electrophoresis-based genotyping procedure, described in section 2.6, reliably 
indicated the size of insertion/deletion for each founder fish, we are confident that we have only selected 
founder fish that carry frameshift mutations, which completely knock out the gene of interest. Moreover, a 
functional validation of these knockouts is provided in section 4.4, where the lack of an effect of leptin in 
the ABz-lepR-/- line confirms a successful knockout of the leptin receptor. However, evidence of the lack of 
mRNA for leptin-a, leptin-b or the leptin receptor, using in situ hybridization or qPCR, would confirm the 
success of the knockouts beyond any doubt. Due to time constraints we have not carried out this procedure. 
Chapter 3 
Measuring glucose  
homeostasis in zebrafish 
  





3.1.1 Glucose homeostasis in the zebrafish 
The systems involved in the regulation of glucose homeostasis in zebrafish and mammals are highly 
conserved. As in humans, in zebrafish glucose homeostasis involves the pancreatic endocrine cells, liver, 
skeletal muscle and brain. Insulin-producing β-cells and glucagon-producing α-cells in the pancreas are 
present as early as 24 hours post fertilization [296]. The liver is the main expression site of leptin in the 
zebrafish, and this organ dynamically regulates gluconeogenesis by both producing and utilizing glucose 
[297]. Skeletal muscle cells contain glucose transporters and take up glucose in an insulin-sensitive manner 
[298]. The role of the brain in regulation of glucose homeostasis in zebrafish has not been studied 
extensively, but it has been shown that the two zebrafish insulin receptor paralogs, insra and insrb, are 
expressed in the developing brain [299], and that the glucose transporter GLUT2 is critical for brain 
development [300]. In the zebrafish, homeostatic levels of blood glucose are comparable to humans and 
mice, ranging between 40 and 300mg/dL with normal physiological levels between 60 and 80 mg/dL [301]. 
The high degree of conservation of glucose homeostatic regulation between zebrafish and mammals makes 
this animal model relevant for studying the physiology of glucose homeostasis.  
3.1.2 Modelling altered glucose homeostasis in zebrafish 
Chronically disrupted glucose homeostasis is the main characteristic of diabetes mellitus [302]. Diabetes 
mellitus is the result of the pancreas not producing enough insulin. A number of studies have tried to mimic 
T1DM and T2DM in the zebrafish. T1DM has been induced chemically in a wide variety of animal models 
via streptozotocin-mediated ablation of the insulin-producing pancreatic β-cells [303]. In the zebrafish too, 
this procedure leads to reduced insulin production, elevated blood sugar levels, impaired wound healing 
and increased non-enzymatic protein glycation [304, 305]. A more elaborate method is the use of 
pancreatic-specific promotors that control the conversion of prodrugs into toxins [306]. However, the 
zebrafish has remarkable regenerative capacity, especially in the endocrine cells of the pancreas [307]. 




Although this makes the zebrafish an exciting model for studying tissue regeneration, it renders it unable 
to realistically mimic human T1DM.  
Zebrafish models for T2DM are scarce. Zebrafish strains have been developed with null mutations in genes 
that have been linked to genetic predisposition towards T2DM in humans, such as pdx1, also known as 
insulin promoter factor 1, ipf1), or tcf7l2 [308, 309]. However, these fish have severe developmental defects 
and reduced viability, and are therefore limited in their applicability for studying T2DM. Zang et al. (2017) 
reported that a diet-induced obesity model of zebrafish displays several characteristics of T2D. Using both 
intraperitoneal and oral glucose tolerance tests, these fish were found to have elevated fasting blood glucose, 
hyperinsulinemia, and impaired glucose tolerance. Interestingly, the well-described antidiabetic drugs 
metformin and glimepiride ameliorated these symptoms. Another method of inducing hyperglycaemia in 
zebrafish has been described by Capiotti et al. (2014). By immersing zebrafish in 1%-2% glucose solutions, 
persistent hyperglycaemia was reported, as well as diabetic retinopathy. Thus, glucose tolerance tests and 
glucose immersion both appear to be promising methods for studying glucose homeostasis is the zebrafish. 
3.1.3 Advantages and challenges in measuring glucose homeostasis in zebrafish 
Although the functional conservation of glucose homeostasis between zebrafish and mammals has been 
clearly demonstrated, there are also obvious differences. This leads to certain advantages and challenges 
when measuring glucose homeostasis in zebrafish. The transparency of its larvae makes the zebrafish an 
unrivalled animal model for the visualization of dynamic processes in vivo. For example, glucose flux can 
be studied in vivo using fluorescent 6-deoxy-2-[(7nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (6-
NBDG) [310]. Because of its ability to readily absorb molecules from the surrounding water, compound 
exposure is straightforward and easy in zebrafish. However, this method does not suffice if a precisely 
defined quantity needs to be delivered to the animal.  
The small size of the zebrafish does hamper certain metabolic investigations. Euglycemic clamping to 
measure insulin action on glucose utilization is not possible in zebrafish. Intraperitoneal injection and blood 




sampling, both of which are required for glucose tolerance tests, are more challenging in zebrafish 
compared to larger species such as mice. Furthermore, because the zebrafish is still a relatively novel animal 
model, the availability of enzyme-linked immunosorbent assays (ELISAs) and antibodies for 
immunohistochemistry is somewhat limited. Likewise, techniques to study food intake and energy 
expenditure in rodents are currently more advanced than in zebrafish. 
  




3.2 Establishing a protocol for intraperitoneal injection 
A convenient way of chemically treating zebrafish is to simply introduce the compound into the tank water, 
where it will be absorbed by the fish[311]. However, glucose tolerance tests require the delivery of a 
precisely defined quantity to each fish, based on body weight. Therefore, a method for intraperitoneal 
injection (IP) needed to be established. The protocol described below was adapted from Kinkel et al. (2010). 
3.2.1 Pre-injection preparations 
For blood glucose studies, fish were fasted for 72 hours instead of the usual 24-hour fast. While a 24-hour 
fast suffices to clean the intestinal bulb, this prolonged fast is required to decrease blood glucose levels to 
baseline prior to injection [312]. D-glucose (0.5gr/ml) was dissolved in Cortland salt solution (124.1mM 
NaCl, 5.1mM KCl, 2.9mM Na2HPO4, 1.9mM MgSO4∙7H2O, 1.4mM CaCl2∙2H2O, 119mM NaHCO3, 4% 
PVP, 1000 USP units Heparin).  Next, to overcome the challenge of injecting the fish outside of their tank 
water, a zebrafish-sized surgical table was made. A 60mm wide disc was cut out of a 3M™ Scotch-Brite™ 
general-purpose sponge. On the flat face, a 10mm deep cut was made. This cut holds the fish for injection. 
The sponge was set into a 60mm Petri dish for containment of liquids used to keep the sponge saturated 
and cool. For weighing, fish were collected, excess water was wicked away and fish were briefly dabbed 
on paper towels. Fish were then transferred to a 500ml glass beaker filled with facility water, placed on a 
tared balance. 
3.2.2 Anaesthesia 
Tricaine (3-amino benzoic acid ethyl ester), or MS-222, is the most frequently used inhalant anaesthetic in 
fish [313]. Tricaine is highly absorbed through the gills and induces general anaesthesia. In the Kinkel et 
al. (2010) protocol on the other hand, anaesthesia is induced by slowly lowering the temperature of the 
water in which the fish is immersed, from 28.5°C to 12°C. The authors of this study reasoned that while 
chemical anaesthesia raises blood glucose levels, cold water anaesthesia does not. In order to decide which 
method of anaesthesia is more suitable for studying glucose homeostasis, both chemical anaesthesia and 




cold water anaesthesia were tested in a pilot experiment. For chemical anaesthesia, tricaine solution 
(164mg/L) was prepared following a standard recipe (ZFIN). For cold water anaesthesia, the protocol from 
Kinkel et al. (2010) was used. Briefly, water in an anaesthesia tank was cooled from 28.5°C to 17°C. 
Zebrafish were placed in the anaesthesia tank, after which the temperature was gradually lowered further 
down to 12°C. Upon reaching the surgical plane of anaesthesia, when the fish are unresponsive to being 
handled, blood samples were taken as described in section 3.3. To compare the blood glucose levels of the 
two groups to the ‘true’ blood glucose level, a third group had to be added in which 3 animals were sampled 
without anaesthesia and sacrificed by thermal shock via immersion in an ice slurry immediately following 
blood sampling. It was found that compared to unanesthetized fish, both chemical and cold water 
anaesthesia significantly elevate blood glucose levels (p=0.0057, one-way ANOVA), to an identical degree 
(mean of 71mg/dL for both cold water and Tricaine anaesthesia; figure 3.1). Because no difference was 
found between the two methods, our preferred method of anaesthesia was chemical anaesthesia using 
tricaine immersion, because this method is more straightforward and less time consuming than cold water 
anaesthesia.  





Figure 3.1 Chemical anaesthesia does not significantly differ from cold water anaesthesia. Boxplots of blood glucose 
measurement following anaesthesia via tricaine (value, n=6) and hypothermia (value, n=6). Three fish were sampled without 
anaesthesia and sacrificed immediately afterwards. Both methods of anaesthesia significantly increased blood glucose levels 
compared to unanesthetized fish (one-way ANOVA; *p=0.0057). 
 
3.2.3 Intraperitoneal injection 
Upon reaching the surgical plane of anaesthesia, fish were gently inserted into the through of the sponge 
with the abdomen up. Working quickly, a 10μl NanoFil micro syringe with a 35G bevelled steel needle was 
inserted into the midline between the pelvic fins. Fish were injected with 0.5mg per gram (of body weight) 
glucose dissolved in Cortland salt solution. Using an 0.5gr/ml glucose solution, the injection volume in μl 
was equal to the body weight of the fish in grams. After injection, the fish were immediately transferred to 
a recovery tank at normal temperature (~28.5°C). To stimulate recovery, water was gently swirled towards 
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In the Kinkel et al. (2010) protocol, injections are achieved using an automated setup consisting of an 
Micro4 micro syringe controller and UMP3 UltraMicroPump (World Precision Instruments). The Otago 
Zebrafish Facility has no access to this equipment. Therefore, we chose to inject the fish manually. To 
ensure that we achieve the desired precision injecting manually, a pilot experiment was carried out in which 
12 fish of different body weights were injected with 0.5mg/g glucose solution (figure 3.2). Thirty minutes 
post injection, blood samples were taken as described in section 3.3. No correlation was found between 
body weight and blood glucose level (r2= 0.0212). Moreover, the variation in blood glucose values 
(192.85.419, meanSEM) was comparable with those found in previous studies [301, 314]. Therefore, it 
was concluded that sufficient precision was achieved using manual injections, and that IP injection is a 
valid procedure to use for intraperitoneal glucose tolerance tests in adult zebrafish.  
 
Figure 3.2 Accuracy of IP injection is not confounded by manual injection. Quantification of blood glucose levels following IP 
injection in zebrafish (n=12) of different body weights (0.22-0.34gr.). Linear regression shows no correlation between body weight 
and blood glucose level (r2=0.0212; p=0.6516). 
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3.3 Establishing a protocol for glucose tolerance tests 
3.3.1 Blood sampling 
Glucose tolerance tests require repeated blood sampling. The small size of the zebrafish complicates this 
common procedure. Several methods for collection of blood from adult zebrafish have been developed, 
including tail ablation [315], decapitation [301], and lateral incision [316]. These techniques are all lethal, 
however, and are therefore only suitable for single sample blood collection. One study reported using 
cardiac puncture as a method for repeated blood sampling [317]. This method requires a high level of 
accuracy and still only allowed for the harvesting of blood samples of approximately 50nl, which is 
insufficient to measure blood glucose. Zang et al. (2013) describe a method for repeated blood collection 
in adult zebrafish where blood is collected form the dorsal aorta using a microcapillary needle. Based on 
this study, we developed the protocol described below. 
Borosilicate glass microcapillaries (Harvard Apparatus) were pulled on a Sutter p-97 Flaming-Brown glass 
micropipette puller to create needles with a 1.0mm outer diameter. Using scissors, the needle tips were cut 
obliquely to create a tip diameter of 100-300μm. Next, needles were heparinized (5mg/ml heparin in saline) 
using an aspirator tube assembly. For blood collection, a heparinized needle was inserted into the nosepiece 
end of the aspirator tube assembly. Adult zebrafish were anesthetized with tricaine as described in section 
3.2.2. Upon reaching the surgical plane of anaesthesia, fish were carefully transferred onto soft tissue paper 
soaked in tricaine solution. Another soaked tissue was used to cover the fish’s head. The needle was then 
carefully inserted at a 30 – 45° angle into the dorsal aorta, along the body axis and ventral to the spine. 
Generally, blood would rise into the needle in a pulsatile manner. If blood did not rise, gentle suction was 
applied through the mouthpiece, and the needle was moved very subtly by hand to encourage blood flow. 
The minimal required sample volume (0.6μl) was collected. The needle was immediately removed, and 
gentle finger pressure with a soaked tissue was applied to the puncture site for ~15 seconds or until bleeding 
stopped. Fish were then transferred to a recovery tank (28.5°C), and water was gently swirled towards the 




gills. The collected blood was expelled from the needle onto a piece of parafilm, and blood glucose was 
measured using a commercial handheld glucometer (Accu-Check Performa, Roche). This glucometer uses 
a dehydrogenase-flavin adenine dinucleotide electrode, requiring a sample volume of 0.6μl. For 
intraperitoneal glucose tolerance tests, blood samples were taken at 0, 30, 90 and 180 minutes. 
 
Figure 3.3 Overview of blood sampling procedure. Procedure for blood collection from adult zebrafish. A volume of 0.6μl of blood 
is collected by inserting a glass microcapillary needle at the blood collection site and gently aspirating to collect blood. The blood 
is expelled from the needle onto a clean piece of parafilm for blood glucose measurement. 
 
3.3.2 Glucose tolerance tests 
Glucose tolerance tests (GTTs) were performed combining the protocols for IP injection (section 3.2.3) and 
blood sampling (section 3.3.1). Fish were injected IP with a 0.5mg/g glucose solution. Blood was collected 
at 0, 30, 90 and 180 minutes post injection. In order to validate IPGTTs a suitable method for studying 
glucose homeostasis in adult zebrafish, a pilot experiment was carried out in which fish (n=8/group) were 
injected IP with either glucose (0.5mg/g) or vehicle (Cortland salt solution) (figure 3.4). Blood glucose 
levels in the glucose-injected fish were significantly higher compared to the control group (P<0.05; 
Student’s t-test; p=0.0050). The slight increase in blood glucose levels found in the control group is likely 
due to stress, replicating IPGTT data in a variety of animal models.  






Figure 3.4 Validation of IPGTT method. Zebrafish (n=8/group) were IP injected with 0.5mg/g glucose or vehicle (Cortland salt 
solution). The glucose-injected group displayed significantly increased blood glucose levels after 30 (value) and 90 (value) minutes. 
Accordingly, the area under the curve is significantly higher in the glucose-injected group compared to vehicle treated fish 
(Student’s t-test; p=0.0050). Data are displayed as meanSEM. 
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3.4 Establishing a protocol for induction of hyperglycaemia 
Glucose tolerance tests are designed to study the effect of a sudden glycaemic challenge. However, diabetes 
mellitus is characterized by chronically elevated blood glucose levels. We therefore wanted to establish a 
zebrafish model for persistent hyperglycaemia. Because zebrafish operate hyperosmotically, they are 
subject to a constant influx of water from their surroundings. This leads them to directly absorb molecules 
from their environment [266]. Therefore, zebrafish can be immersed in a glucose solution to elevate their 
blood glucose levels in a persistent manner. The protocol described here was adapted from Capiotti et al. 
(2014). Fish were placed in standard housing tanks containing a 1% glucose solution (55.5mM). Because 
the tanks were not on the normal recirculation system, solutions were renewed daily after feeding to prevent 
growth of microorganisms. Previous studies used glucose solutions ranging from 55.5-166mM. The 
Capiotti et al. (2014) study immersed fish for up to 14 days, but reported a 30% mortality rate using a 1% 
glucose solution.  
In order to find out how long the fish have to be immersed in the glucose solution to become persistently 
hyperglycaemic, while at the same time minimizing the mortality rate, a pilot experiment was performed in 
which fish (n=5/group) were exposed to a 1% glucose solution for 2-5 days (figure 3.5). To assess whether 
the induced hyperglycaemia was persistent, fish were placed back into tanks containing normal system 
water for three days after being immersed in the glucose solution. Blood glucose levels were measured as 
described in section 3.3.1. It was found that immersion in a 1% glucose solution leads to significantly 
elevated blood glucose levels from three days onwards (P<0.05; repeated-measures ANOVA). However, 
immersing the fish for two or three days did not lead to persistently elevated blood glucose levels, as values 
returned to baseline levels. A four- or five-day immersion appeared to induce persistent hyperglycaemia. It 
was therefore decided to proceed with a 4-day 1% glucose immersion. 
 
 






Figure 3.5 Immersion in a 1% glucose solution induces hyperglycaemia in a duration-dependent manner. Quantification of blood 
glucose levels in zebrafish (n=5/group) after exposure to a 1% glucose solution for different durations (2-5 days). Blood glucose 
levels became significantly elevated after two days of immersion. Persistent hyperglycaemia was induced after 4 days of immersion. 
Data are displayed as meanSEM. 
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Glucose homeostasis in the adult zebrafish can be studied by exposing the fish to an acute hyperglycaemic 
challenge in the form of a glucose tolerance test, or via immersion in a glucose solution to induce persistent 
hyperglycaemia. Here, we successfully established protocols for both.  
3.5.2 Adaptations from previous protocols 
The methods described in this chapter are all newly established protocols at the Otago Zebrafish Facility. 
The IP injection-, blood sampling-, and glucose immersion techniques are all based on previous studies, 
but significant changes have been made in some cases. 
The Kinkel et al. (2010) protocol recommends using cold water anaesthesia over chemical anaesthesia, 
citing a study that reports a smaller rise in blood glucose levels after cold water anaesthesia compared to 
chemical anaesthesia using tricaine [301]. However, the differences reported in this study are not 
significant. Tricaine, or MS-222, is the most frequently used inhalant anaesthetic in fish. Tricaine is highly 
absorbed through the gills and induces general anaesthesia [318]. Some zebrafish studies reported risk of 
overdose in deeper stages of anaesthesia and in procedures of long duration [319, 320]. Intraperitoneal 
injection, however is, when executed correctly, a quick procedure that does not require deep anaesthesia. 
From a pragmatic perspective, it is more efficient to use chemical anaesthesia over cold water anaesthesia, 
as the latter takes approximately three times as long. Other alternatives, like etomidate, propofol or 
lidocaine, are available, too. A systematic review of zebrafish anaesthetics found that using a combination 
of 1.25 μg/mL propofol + 100 μg/mL lidocaine is efficient in inducing anaesthesia in a degree similar to 
tricaine [321]. An advantage of this combination would be that unlike tricaine, propofol and lidocaine do 
not need solution buffering. Furthermore, due to the lack of an automated IP injection setup in the Otago 
Zebrafish Facility, we chose to inject our fish manually rather than with a microsyringe controller. Although 
injection accuracy was of a sufficient level, manual injection does make the procedure technically more 
challenging and time consuming.  




3.5.3 Suitability of techniques  
While the intraperitoneal glucose tolerance test is a commonly used procedure in rodents [302], this is not 
the case for zebrafish. Collecting a single blood sample from an adult zebrafish takes 4-5 minutes. Glucose 
tolerance tests generally require blood samples to be taken at 0, 30, 90 and 180 minutes, meaning that only 
6 zebrafish can be sampled by a single investigator between the first and second round of sampling. In other 
words, IPGTT’s in zebrafish performed by one person can only be done with 6 fish at a time. This number 
is not always sufficient to answer the experimental question. We accounted for this by spreading the fish in 
different groups over multiple GTTs, but this is not ideal. Another factor that limits the applicability of 
IPGTTs in zebrafish is the relative invasiveness. The dorsal aorta, the site of blood sampling, is positioned 
between the spine and the gastrointestinal tract. Damage to these tissues leads to serious injury or death. In 
the pilot study, and in later experiments throughout this thesis, we recorded a mortality rate of ~15%. The 
majority of these cases died at the end of the experiment, not hampering the measurement of blood glucose 
levels. On top of this we were unable to get a proper measurement of blood glucose levels in about 5% of 
all attempts. This was due to the fact that if the microcapillary needle was inserted incorrectly at first 
attempt, no second attempt was made in order to minimize injury to the fish. Altogether, it can be concluded 
that glucose homeostasis can be investigated using IPGTT’s in adult zebrafish, although this animal might 
not be the ideal model for this type of experiment.  
An alternative method of studying altered glucose homeostasis in vivo is to use an adult zebrafish model 
for persistent hyperglycaemia. The protocol we established involves a 4-day immersion in a 1% glucose 
solution. This procedure induced elevated blood glucose levels in a non-invasive manner. Collection of 
blood for measurement of blood glucose levels was performed as in an IPGTT, but because blood samples 
are taken daily, fish have more time to recover between samples compared to an IPGTT. Accordingly, 
mortality rates in both the pilot study and in subsequent experiments in this thesis were <1%. It can therefore 
be concluded that induction of hyperglycaemia via immersion in a glucose solution is a valid method for 




studying glucose homeostasis, and that this method is suitable for adult zebrafish. Together, IPGTTs and 
glucose immersion tests allow us to study both sudden and persistent hyperglycaemic challenges in the 
zebrafish.  
Chapter 4 
Characterization of leptin- and leptin 
receptor mutant zebrafish lines  





4.1.1 Teleost leptin mutant models 
 Three studies investigating leptin- or leptin receptor deficient fish have been published previously, with 
somewhat opposing results. The first leptin-mutated fish model was established in 2006 when an N-ethyl-
N-nitrosourea (ENU)-mediated random mutagenesis approach was used in medaka, also known as Japanese 
rice fish (Oryzias latipes), to generate a cryopreserved library of knockouts for most medaka genes [322]. 
When these fish were characterized in 2014 by the same laboratory group, a 1.6- to 2-fold increase was 
found in body weight of 5 weeks old (post juvenile) fish, but not juvenile fish or 16 weeks old (adult) fish 
[323]. This increased body weight was accompanied by an increase in body length. Quantitative PCR 
analysis showed upregulated levels of NPYa, AgRP and POMC1. Food intake was elevated. Importantly, 
these fish were fed five times a day to have food available ad libitum. Finally, visceral fat depots were 
slightly increased, but no change was found in triacylglycerol levels in liver, muscle or blood plasma. Thus, 
based on these findings the medaka seems to fit at least certain aspects of the adipostat model of leptin.  
The first zebrafish leptin mutant was described by Michel et al. in 2016. Both a leptin receptor deficient 
fish line derived from an ENU library, and CRISPR-generated mutants lacking either leptin-a, leptin-b, or 
the leptin receptor were characterized [261]. Unlike the study on medaka, in zebrafish no effect of genotype 
on body mass or body length was found at any life stage, and food intake and adiposity were unchanged. 
Moreover, while mammalian leptin knockouts often displayed impaired fertility, this was not the case in 
leptin receptor deficient zebrafish. Contrary to the study on medaka, these results therefore disprove a role 
for leptin in the regulation of adipostasis in fish. However, while adipostasis appeared to be unchanged, 
several aspects of glucose homeostasis in zebrafish larvae were found to be altered.  
Firstly, whole body glucose levels were slightly higher in leptin receptor deficient zebrafish larvae 
compared to wild type controls, and the expression of insulin-a, but not insulin-b, was enhanced.  The 
number of pancreatic β-cells was 25% higher at 5 days post fertilization, an effect which was normalized 




by three days of treatment with metformin. Furthermore, the expression of certain enzymes involved in 
hepatic glucose metabolism was altered. In a previous study, the authors showed that nutrient excess 
stimulates β-cell neogenesis in the larval zebrafish. Using the same method, exposure to 5% egg yolk by 
volume for 8 hours at 5 days post fertilization, it was found that nutrient-induced β-cell compensation is 
blocked in leptin receptor deficient larvae. Thus, in the zebrafish larvae leptin receptor deficiency increases 
the number of pancreatic β-cells, but simultaneously blocks nutrient-induced β-cell compensation. In adult 
zebrafish, no difference was found in fasting blood glucose levels between leptin receptor deficient fish and 
wild type controls. However, glucose tolerance in leptin receptor deficient fish was impaired at 30 minutes 
post injection, although overall glucose clearance appeared to be similar to wild type fish. In accordance 
with their results in larvae, adult fish were found to have upregulated expression of insulin-a and of the 
fructose transporter SLC2A5 (Solute Carrier Family 2 Member 5). Finally, 7-month old leptin receptor 
deficient fish had impaired wound healing upon fin clipping compared to wild type fish, a phenomenon that 
is typically found in type 2 diabetic patients. In conclusion, this study clearly demonstrates a role for leptin 
in glucose homeostasis and casts doubt over the adipostatic function of leptin in fish. 
A third study on fish with a mutated leptin system has recently been published [324]. Confusingly, the 
results from this study contradict the findings from the Michel et al. (2016) study. Using the TALEN system, 
a leptin-a knockout zebrafish line was created. Subsequent characterization showed that, unlike the leptin 
mutants in the Michel et al. (2016) study, these fish had increased body weight and body length at 9 months 
of age compared to wild type controls. The authors then test the effects of leptin-a knockout on a wide range 
of behavioural tests, and report hyperactivity with increased exploratory behaviour, decreased aggression 
as measured with a mirror biting test, decreased predator avoidance, decreased social interaction and 
shoaling behaviour, dysregulated circadian rhythm, and reduced colour preference. In order to explain these 
behavioural abnormalities, the authors perform ELISA’s in brain and muscle measuring the levels of 28 
neurotransmitters and biochemical markers. Surprisingly vast differences were reported. For example, a 
12-fold reduction in both serotonin and norepinephrine levels was found in leptin-a knockout zebrafish. 




The authors conclude that leptin in the zebrafish is essential for the regulation of body weight, and for the 
modulation of a wide range of behaviours.  
The previous studies on fish models of mutated leptin systems described here appear to contradict each 
other in certain aspects. Thus, the role of leptin in the regulation of adipostasis and glucose homeostasis in 
the zebrafish remains questionable. Using the CRISPR Cas9-mediated leptin-a, leptin-b and leptin receptor 
knockout zebrafish, described in chapter 2, and the techniques for measuring glucose homeostasis in 
zebrafish, described in chapter 3, we set out to characterize glucose homeostasis in leptin-mutated zebrafish.   




4.2 Fish husbandry 
4.2.1 Housing 
For all experiments, unless stated otherwise, zebrafish of the ABz strain (derived from an AB line originally 
obtained from the Zebrafish International Resource Center, ZIRC) were used. The AB strain is the single 
most frequently used strain to study energy homeostasis and metabolism in zebrafish [322, 325]. Fish were 
housed in 3.5 L tanks on a Palletized Centralized Life Support System (Tecniplast). The water in this 
recirculating system was pumped through mechanical filtration, charcoal filtration, and UV-treatment, with 
10% of the water being replaced every hour. The water was kept at 24–30˚C, with pH 7.6–8.0 and a 
conductivity of 300–600 μS. Water quality parameters were automatically measured and adjusted. The 
facility environment maintained a 14-hour light and 10-hour dark circadian cycle.  
To rule out the effects of background genetics and tank densities, fish were initially raised at a density of 
30 larvae per 3.8L tank. After 1 month post fertilization, density was reduced to 20 fish per 3.8L tank. Upon 
reaching sexual maturity at 4 months post fertilization the density was further reduced to 12 fish per 3.8L 
tank, with a 1:1 ratio between males and females. For experiments requiring bigger n-numbers, 8L tanks 
were used instead of 3.8L tanks, and fish numbers were doubled. 
 
  





Fish were fed twice a day of Zebrafish Management Ltd. (ZM) dry pellets consisting of  58% protein, 14.5% 
fat, 11.5% ash, 7.0% moisture, 30,000 I.U./kg vitamin A, 2,500 I.U./kg vitamin D3, 400 mg/kg vitamin E, 
2,000 mg/kg vitamin C, 30 mg/g 3 highly unsaturated fatty acids. ZM pellets come in different sizes with 
the diameter dependent on zebrafish age. ZM000 was given up until 14dpf, ZM100 was given between 15 
and 35dpf, ZM200 was given between 36 and 90dpf, and ZM300/400 was given after 90dpf. On top of this, 
a live feed was given once a day. Fry were fed rotifer until 50 dpf and then given Artemia throughout 
adulthood. Artemia Nauplii (Brine Shrimp Direct) were grown at 1.2 g/L for two days (until 24 hours post 
hatching, instar II-III), in two alternating cultures. Each day the Artemia was harvested and, after decanting 
the cysts and straining the water, the hatched Artemia biomass was weighed. The yield was then 
resuspended to 25 mg/mL and the appropriate volume was dispensed to the fish. 
  




4.3 Leptin-mutated zebrafish have altered glucose tolerance 
4.3.1 Leptin does not regulate body weight or body length in the zebrafish under standard 
feeding conditions 
We started characterizing the ABz-lepA-/-, ABz-lepB-/- and ABz-lepR-/- zebrafish lines by firstly measuring 
the body weight and body length of fish that were housed under normal conditions, described in section 
4.2, at 4, 6 and 12 months post fertilization. In total, 24 fish per genotype were tested, which were divided 
over 2 tanks per genotype. No differences were found at any stage between any two tanks containing fish 
of the same genotype (data not shown). Fish were collected from their home tank, excess water was wicked 
away and fish were briefly dabbed on paper towels. Fish were then transferred to a 500ml glass beaker 
filled with facility water, placed on a tared balance. For measurement of body length, fish were anesthetized 
with tricaine as described in section 3.2.2, and placed along a ruler on a tricaine-saturated paper tissue. 
Standard length was defined as the measurement taken from the tip of the lower jaw to the posterior end of 
the hypural bone (the last vertebra).  
No differences were found at 4, 6, or 12 months of age between wild type fish and leptin-a KO, leptin-b 
KO or leptin receptor KO zebrafish, neither in body weight nor in body length (figure 4.1, figure 4.2). 
Interestingly, the variation in body weight was found to be significantly higher in female zebrafish (P<0.05; 
Student’s t-tests). This is likely due to the fact that females are continuously producing and releasing eggs, 
which can make up to 25% of the total body weight [326]. In conclusion, leptin does not regulate body 
weight or body length in the zebrafish under standard feeding conditions.  
 
 





Figure 4.1 Leptin has no effect on male body weight or body length in the zebrafish. ABz-lepA-/-, ABz-lepB-/-, ABz-lepR-/- zebrafish 
and wild type controls (n=24) were raised at identical tank densities. Body weight was measured at 4 months post fertilization (A), 
6 months post fertilization (C) and 12 months post fertilization (E). Standard length was measured simultaneously (B,D,F). No 
significant differences were found between any groups at any stage, as measured using one-way ANOVAs. lepA= ABz-lepA-/-; 















































































































































































































Figure 4.2 Leptin has no effect on female body weight or body length in the zebrafish. ABz-lepA-/-, ABz-lepB-/-, ABz-lepR-/- zebrafish 
and wild type controls (n=24) were raised at identical tank densities. Body weight was measured at 4 months post fertilization (A), 
6 months post fertilization (C) and 12 months post fertilization (E). Standard length was measured simultaneously (B,D,F). No 
significant differences were found between any groups at any stage, as measured using one-way ANOVAs. lepA= ABz-lepA-/-; 
lepB= ABz-lepB-/-; lepR= ABz-lepR-/-; WT=wild type control; NS = not significantly different; data displayed as boxplots with 

















































































































































































































4.3.2 Leptin regulates glucose homeostasis in the zebrafish 
To investigate whether leptin mutations alter glucose homeostasis in the zebrafish, intraperitoneal glucose 
tolerance tests (IPGTT’s) were performed as described in section 3.3.2. We chose to only do IPGTT’s in 
male zebrafish, because the fluctuating body weight in females, described in section 4.3.1, complicates the 
delivery of a precisely defined quantity of glucose to the fish.  
It was found that fasting blood glucose levels were not significantly different in any of the mutant fish 
compared to wild type fish. Glucose tolerance on the other hand was significantly impaired in what appears 
to be an incremental effect of leptin on glucose tolerance, with leptin-b having the least impact, and the 
leptin receptor having the biggest effect (figure 4.3; P<0.05; one-way ANOVA).  
 
Figure 4.3 Glucose tolerance is impaired in leptin mutant zebrafish. ABz-lepA-/-, ABz-lepB-/-, ABz-lepR-/- zebrafish and wild type 
controls (n=11) were challenged with a 0.5mg/g glucose solution, administered via IP injection. Blood samples were taken at 0, 
30, 90 and 180 minutes. Leptin receptor deficient zebrafish have significantly impaired glucose tolerance 
(323942149mg/dl*minutes) compared to wild type controls (245062355mg/dl*minutes), as measured per one-way ANOVA 
(*p<0.05). Main: blood glucose values over time; Insert: area under the curve of glucose tolerance test depicted in main figure. 
Data displayed as meanSEM. 
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4.4 Leptin injection ameliorates glucose immersion-induced 
hyperglycaemia 
To investigate whether leptin can normalize blood glucose levels when zebrafish are in a hyperglycaemic 
state, we immersed 9 month old male and female zebrafish in a 1% glucose solution for 4 days as described 
in section 3.4. Blood samples were taken daily, as described in section 3.3.1. Pilot experiments described 
in section 3.4 showed that upon immersion in a 1% glucose solution, blood glucose levels become 
significantly elevated after two days. We therefore decided to inject the fish on the third day, to see whether 
leptin ameliorates glucose immersion-induced hyperglycaemia. One hour before blood sampling, fish were 
injected intraperitoneally with recombinant mouse leptin (2mg/kg), or with vehicle solution (Cortland salt 
solution). Recombinant leptin treatment has been shown to have effects on glucose homeostasis in trout 
(Oncorhynchus mykiss) [327] and goldfish (Carassius auratus) [328], but has not been tested in zebrafish 
before. 
It was found that recombinant leptin treatment temporarily prevents glucose-immersion induced elevation 
of blood glucose levels (figure 4.4, figure 4.5). Blood glucose levels on day 3 were not significantly higher 
than blood glucose levels on day 2. On day 4, one day after the leptin treatment, blood glucose levels were 
significantly higher again (P<0.05; Student’s t-test). This finding was consistent for ABz-lepA-/- fish, ABz-
lepB-/- fish and wild type controls, but not for ABz-lepR-/- fish. The absence of an effect in ABz-lepR-/- fish 
is not surprising, given that these fish do not have a functional leptin receptor to which the recombinant 
leptin has to bind in order to induce downstream effects. This absence of an effect serves as a functional 
validation of the CRISPR-mediated knockout of the leptin receptor. Furthermore, no differences were found 
between male (figure 4.4) and female fish (figure 4.5), not for any of the mutants and neither for wild type 
fish. 
 








Figure 4.4 Leptin treatment ameliorates glucose immersion-induced hyperglycaemia in male zebrafish. ABz-lepA-/-(A), ABz-lepB-/-
(B), ABz-lepR-/- zebrafish (C) and wild type controls (D) (n=5) were immersed in a 1% glucose solution for 4 days. Blood glucose 
levels were measured daily. Blood glucose levels were significantly elevated in all groups after 2 days of immersion in 1% glucose 
(p<0.05, repeated measures ANOVA). On the third day, one hour before blood sampling, fish were injected intraperitoneally with 
recombinant mouse leptin (2mg/kg) or vehicle. Leptin treatment ameliorated hyperglycaemia in leptin-a KO- (106.66.8 vs 
128.85.4), leptin-b KO- (98.25.8 vs 120.24.4) and wild type fish (94.23.7 vs 111.88.5), but not in leptin receptor KO fish 
(130.84.6 vs 135.012.9)(*p<0.05, student’s t-test). Data displayed as meanSEM. 
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Figure 4.5 Leptin treatment ameliorates glucose immersion-induced hyperglycaemia in female zebrafish. ABz-lepA-/-(A), ABz-lepB-
/-(B), ABz-lepR-/- zebrafish (C) and wild type controls (D) (n=5) were immersed in a 1% glucose solution for 4 days. Blood glucose 
levels were measured daily. Blood glucose levels were significantly elevated in all groups after 2 days of immersion in 1% glucose 
(p<0.05, repeated measures ANOVA). On the third day, one hour before blood sampling, fish were injected intraperitoneally with 
recombinant mouse leptin (2mg/kg) or vehicle. Leptin treatment ameliorated hyperglycaemia in leptin-a KO- (103.46.6 vs 
130.26.1), leptin-b KO- (95.23.5 vs 121.24.8) and wild type fish (95.45.4 vs 111.05.1), but not in leptin receptor KO fish 
(129.68.0 vs 132.66.4) (*p<0.05, student’s t-test). Data displayed as meanSEM. 
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4.5 Overfeeding increases body size and elicits an effect of leptin-a and 
the leptin receptor on body weight 
We describe above that under standard feeding conditions, there is no effect of leptin mutations on body 
weight. This finding does not rule out any effect of leptin on body weight regulation in the zebrafish though. 
It could be that leptin-mutated fish are unaffected under standard feeding conditions, but these mutations 
potentially make them more prone to diet-induced obesity. It has previously been shown that zebrafish 
become obese upon exposure to an overfeeding regime [314]. Diet-induced obesity in zebrafish shares 
common pathophysiological pathways with mammalian obesity [329]. In order to investigate the effects of 
leptin mutations on energy homeostasis in times of nutrient excess, we exposed six-month old leptin-mutant 
fish and wild type controls (n=12, divided over 2 tanks per group) to a 6-week long overfeeding regime. 
This regime consisted of 6 daily feeds alternating between 20 mg/fish of ZM-400© fish pellets and artemia 
(2 mg dry weight/day/fish). Alternatively, controls were fed twice a day. Feeding times were 9:00, 11:30, 
14:00, 16:30, 19:00 and 21:30h under the overfeeding regime, and 11:30 and 16:30 in the standard fed 
group. Feeding was done manually, because automatic food dispensers were not available and because 
leftover food had to be removed by siphoning to prevent an effect of water quality on body weight. Body 
weight was measured weekly. Standard length was measure every three weeks. An IP glucose tolerance 
test (0.5mg/g body weight) was performed to assess changes in glucose homeostasis at the end of the 6-
week period.  
The overfeeding regime was found to cause significantly elevated body weight from two weeks onwards 
(figure 4.6; P<0.001; repeated measures ANOVA). The fish that were assigned to a standard diet gained 
weight slightly as well (0.2850.005gr at week 0 vs 0.3170.004gr at week 6), but this is in the range of 
normal somatic growth throughout their life (i.e. their growth trajectory does not plateau out). 
Unexpectedly, overfeeding elicited an effect of leptin on body weight regulation in the zebrafish. Both 
leptin receptor deficient fish (0.3980.010gr) and leptin-a deficient fish (0.3820.009gr), but not leptin-b 




deficient fish (0.3480.006gr), had significantly higher body weight when compared to wild type fish under 
the same overfeeding regime (0.3470.006; repeated measures ANOVA). However, this increase in body 
weight was accompanied by a significant increase in body length (figure 4.7; P<0.05; one-way ANOVA). 
Standard length was measured at the start, in the middle and at the end of the experiment. Only in those 
fish that had significantly increased body weight under overfeeding conditions, ABz-lepA-/- fish and ABz-
lepR-/- fish, an increase in standard length was found (28.4170.229mm at week 0 vs 30.5450.312mm at 
week 6 in ABz-lepA-/- fish, 28.7500.250mm at week 0 vs 31.7270.359mm at week 6 for ABz-lepR-/- fish). 
Thus, it appears that in times of nutrient excess, leptin regulates somatic growth rather than body weight. 
 
 
Figure 4.6 Overfeeding elicits an effect of leptin on body weight regulation in the zebrafish. ABz-lepA-/-, ABz-lepB-/-, ABz-lepR-/- 
zebrafish and wild type controls (n=12) were assigned to a 6-week overfeeding regime or standard diet. Body weights were 
measured weekly. Overfed fish (0.3170.008gr) had significantly increased bodyweight compared to standard fed fish 
(0.3040.008gr) from 2 weeks onwards (repeated measures ANOVA). Overfeeding elicited an effect of leptin on body weight 
regulation, as leptin receptor deficient fish (0.3980.010gr) and leptin-a deficient fish (0.3820.009), but not leptin-b deficient fish 
(0.3480.006gr), had significantly increased body weight compared to overfed wild type fish (0.3470.006gr), as measured per 
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Figure 4.7 Standard length is increased in leptin receptor deficient fish and leptin-a deficient fish during overfeeding. ABz-lepA-/-
(A), ABz-lepB-/-(B), ABz-lepR-/- (R) zebrafish and wild type controls (WT) (n=12) were assigned to a 6-week overfeeding regime or 
standard diet. Standard length was measured at week 0 (left), 3 (middle), and 6 (right). Standard length was significantly increased 
in overfed leptin-a deficient fish (28.4170.229mm vs 30.5450.312mm; *P<0.05, one-way ANOVA) and overfed leptin receptor 
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Figure 4.8 Examples of leptin receptor deficient and wild type zebrafish at the start and end of the overfeeding regime. 
 
4.6 Overfeeding impairs glucose tolerance 
4.6.1 Glucose tolerance after overfeeding 
Diet-induced obesity has been widely shown to result in dysregulated glucose homeostasis in mammals 
[302]. To investigate whether this applies to zebrafish as well, intraperitoneal glucose tolerance tests were 
carried out (as described in section 3.3.2) at the end of the six-week feeding paradigm, described in section 
4.5. We then compared the glucose tolerance of leptin mutants and wild type control fish that had been 
overfed to the glucose tolerance of fish that were housed under standard feeding conditions (n=12). It was 
found that overfeeding raises basal blood glucose levels, independent of genotype (figure 4.9; P<0.001; 
two-way ANOVA). In the standard fed group, leptin receptor deficient fish had significantly impaired 
glucose clearance (P<0.05; one-way ANOVA). Overfed fish on the other hand, all groups had maximally 
impaired glucose tolerance. This effect was independent of genotype, as statistical significance between the 
leptin receptor deficient fish and other group was lost. Thus, overfeeding itself impairs glucose tolerance. 








Figure 4.9 Overfeeding impairs glucose homeostasis in the zebrafish. After 6 weeks of overfeeding or standard diet, ABz-lepA-/-, 
ABz-lepB-/-, ABz-lepR-/- zebrafish and wild type controls (n=11) were challenged with a 0.5mg/g glucose solution, administered via 
IP injection. Blood samples were taken at 0, 30, 90 and 180 minutes. (A) Overfeeding resulted in significantly elevated basal blood 
glucose levels (****P<0.0001, two-way ANOVA). Between the standard fed fish (B), leptin receptor deficient fish had significantly 
impaired glucose clearance (326572791mg/dl*minutes) compared to wild type fish (241472189mg/dl*minutes, *P<0.05, one-
way ANOVA). (C) Overfeeding resulted in significantly impaired glucose tolerance, independent of genotype. (D) Area under the 
curve of (B) and (C), overfeeding impairs glucose tolerance (#P<0.0001, two-way ANOVA). Data displayed as meanSEM. 
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4.6.2 Metformin treatment 
To further validate the zebrafish as a model for studying glucose homeostasis, we exposed overfed zebrafish 
to metformin, a medication for T2DM with speculated effects on hepatic glucose homeostasis and insulin 
sensitivity [330]. Six-month old male zebrafish were overfed as described in section 4.5. After 5 weeks of 
overfeeding, fish were treated with metformin for one week. Metformin was dissolved in system water to 
a final concentration of 20 µM. The metformin solution was freshly prepared and changed daily. Finally, 
an IPGTT was carried out as described in section 3.3.2, to assess the effect of metformin treatment on 
glucose homeostasis. Metformin treatment ameliorated glucose tolerance, bringing the blood glucose levels 
down to levels that were not significantly different to those found in wild type fish on a standard diet (figure 
4.10).   In hindsight, an n-number of 11 animals appears just insufficient to adequately power the statistical 
analysis needed to demonstrate significant differences between the metformin-treated overfed group and 
the overfed group. Based this experiment, a power analysis with μA-μB=7000mg/dl*minutes, 
σ=620mg/dl*minutes, α=0.05 and β=0.1 requires an n-number of 13. This adjustment is recommended for 
future experiments. 
 
Figure 4.10 Metformin improves glucose 
tolerance in the zebrafish. After 5 weeks 
of overfeeding or standard diet, and one 
week of metformin (20 µM) treatment, 
wild type zebrafish (n=11) were 
challenged with a 0.5mg/g glucose 
solution, administered via IP injection. 
Blood samples were taken at 0, 30, 90 
and 180 minutes. Overfed fish had 
significantly impaired glucose tolerance 
(349503211mg/dl*minutes) compared 
to standard fed fish 
(241472192mg/dl*minutes; 
*P=0.0155, one-way ANOVA with 
multiple comparisons), but not compared 
to metformin-treated overfed fish 
(290332169mg/dl*minutes). Main: 
blood glucose values over time; Insert: 
area under the curve of glucose tolerance 
test depicted in main figure. Data 
displayed as meanSEM. 
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4.7.1 Teleost leptin knockout models 
Previous studies on teleost leptin knockout models have yielded contradicting results, with some studies 
reporting an effect of leptin on adipostasis [323, 324], and others claiming to disprove a role for leptin as 
an adipostat [261]. We found no effect of mutations in leptin-a, leptin-b or the leptin receptor on body 
weight regulation or body length under standard feeding conditions, not in males nor in females. However, 
we also found that overfeeding elicits an effect of leptin on the regulation of body weight and body length. 
The different effects of different feeding regimes might explain the discrepancies found in previous studies. 
Due to its novelty as an animal model for research looking into energy homeostasis, standardized feeding 
protocols to induce metabolic syndrome in (zebra)fish are limited. It has furthermore been shown that 
different commercial diets lead to significantly different growth rates [331, 332], thereby potentially 
confounding metabolic studies.  
Another essential factor influencing growth and body composition in fish is tank density. It has been shown 
that both low- and high-density husbandry influence postembryonic development, somatic growth, fat 
accumulation and reproduction [333]. We took this into account by keeping tank densities equal for all 
experiments. The same approach is used by Michel et al. (2016), but is not reported by Chisada et al. (2013) 
and Audira et al. (2018). It is therefore not unlikely that the latter two studies have been confounded by 
tank density effects. Although zebrafish and medaka are both teleosts, they are evolutionary separated by 
around 300 million years [334]. In comparison, humans and mice are estimated to only have diverged about 
90 million years ago [335]. Leptin might therefore have different functions in zebrafish and medaka. 
However, a study on leptin knockout medaka with appropriate tank density control should resolve this 
question.  




4.7.2 Recombinant leptin 
Because the zebrafish is a relatively ‘young’ model in the field of energy homeostasis, certain tools have 
not been optimized for use in this animal model. For example, a zebrafish-specific leptin (a or b) enzyme 
linked immunosorbent assay (ELISA) kit is currently unavailable. Likewise, recombinant zebrafish leptin 
cannot be obtained commercially at the moment. To investigate the effects of leptin in the zebrafish, we 
injected fish with recombinant mouse leptin. It was found that mouse leptin potently normalizes 
hyperglycaemia in zebrafish, in both an acute and a persistent hyperglycaemic challenge. The fact that 
mouse leptin was active in zebrafish suggests that leptin function is highly preserved across species. This 
finding is in line with other studies that previously demonstrated anorexigenic effects of recombinant leptin 
in trout (Oncorhynchus mykiss) [327], goldfish (Carassius auratus) [328] and a number of other species 
(see table 2). It has furthermore been shown that recombinant pufferfish (Takifugu rubripes) leptin can 
activate the BAF/3 cells stable transfected with the long form human leptin receptor [336]. Although 
pufferfish leptin was less potent than human leptin, a human leptin antagonist completely blocked the action 
of pufferfish leptin. A recent study on mandarin fish (Synchiropus splendidus) showed that injections of 
recombinant mandarin fish leptin-a and leptin-b have slightly different effects on food intake [337], 
demonstrating the differential roles of the two paralogs. Our data show that mouse leptin can be used to 
study the glucoregulatory effects of leptin in the zebrafish, but further investigations into the specific roles 
of leptin-a and leptin-b would greatly benefit from the availability of homologous zebrafish leptin. 
  





Table 4.1 Overview of the effects of heterologous leptin in different species 
Species Leptin Source Mode Effects Reference 
Coho Salmon Human osmotic pump none [338] 
Fence Lizard Mouse Pellet ↑ metabolic rate 
↓ food intake 
[339] 
Green Sunfish Mouse IP ↑ fat metabolism [340] 
Goldfish Mouse ICV, IP ↓ food intake [341] 
Chicken Human ICV ↓ food intake [342] 
Xenopus Xenopus ICV ↓ food intake 
↑ limb development 
[343] 
Goldfish Human ICV, IP ≈ food intake 
↓ body weight 
[328] 
Rainbow Trout Rainbow Trout IP ↓ food intake [344] 
Rainbow Trout Human ICV ↓ food intake 
↑ glucose sensing 
[327] 
Grass Carp Grass Carp IP ↓ food intake [345] 
Rainbow Trout Rainbow Trout IP ↓ growth [346] 
Xenopus Xenopus ICV ↑ mitosis [347] 
Mandarin Fish Mandarin Fish IP leptin-a:  ≈ food intake 
 ↓hepatic gluconeogenesis 
leptin-b: ↓ food intake 
↓hepatic gluconeogenesis 
[337] 
Zebrafish Mouse IP ↓ blood glucose this thesis 
  




4.7.3 Overfeeding vs high fat diet 
Diet-induced obesity can be acquired by changing either the quantity or the quality of available food. We 
chose overfeeding rather than high fat feeding to induce obesity in zebrafish, because the literature is more 
consentient compared to the use of high fat diet in studies for zebrafish. However, we acknowledge that 
overfeeding-induced obesity does not necessarily equal high fat-induced obesity. Landgraf et al. (2017) 
compared how short-term overfeeding with standard diet or high fat diet affected metabolic health [348]. 
Both methods lead to significantly increased body weight and adipose tissue. In addition, unlike the 
standard diet-overfed fish, high fat diet-overfed fish had ectopic lipid accumulation in the liver, adipocyte 
hypertrophy, and upregulation of systemic inflammation markers. According to this study, short-term 
overfeeding thus leads to metabolically healthy or metabolically unhealthy obesity. Although the elevated 
basal glucose levels and impaired glucose tolerance in our overfed fish indicate that these fish displayed 
metabolic dysregulation, we did not have the time to investigate whether these fish have systemic 
inflammation or hepatic steatosis. Future studies are warranted to resolve this.  
In conclusion, we showed that in the zebrafish leptin does not regulate body weight or body length under 
standard feeding conditions. Leptin does regulate glucose homeostasis, however, and leptin treatment 
ameliorates hyperglycaemia. An overfeeding regime revealed that in times of nutrient excess leptin 
regulates both body weight and body length, and glucose tolerance is impaired. Metformin treatment 




Leptin activates  
the canonical WNT pathway 
  





Although the glucoregulatory actions of leptin have been well described [349], the mechanism through 
which leptin exerts these actions remains largely unknown. Studies from our laboratory and others have 
identified the canonical WNT pathway to be a potential mediator of the effect of leptin on glucose 
homeostasis [258, 350, 351].  
5.1.1 Overview of the canonical WNT pathway 
The canonical WNT pathway is activated when a WNT ligand binds to the frizzled (Fzd) receptor, which 
subsequently forms a complex with the co-receptor lipoprotein related protein 5/6 (LRP5/6). This causes 
dishevelled (Dvl) to phosphorylate LRP, which then inactivates GSK3β. Next, GSK3β inactivation 
decreases phosphorylation and proteasomal degradation of the transcriptional co-activator β-catenin. 
Stabilized β-catenin then enters the nucleus where it associates with transcription factors of the lymphoid 
enhancer factor (LEF)/T cell factor (TCF) family, to ultimately regulate the transcription of downstream 
target genes such as cyclin D1 and axin 2 [224]. Nowadays, 21 WNT genes and four TCF family members 
have been described in humans. These encode for proteins that act in an autocrine and/or paracrine manner, 
and often display a high degree of redundancy over each other [225]. In mammals, four closely related TCF 
genes are found: Lef1, TCF7 (TCF1 in rodents), TCF7l1 (TCF3), and TCF7l2 (TCF4). One of these genes, 
TCF7l1, is duplicated in zebrafish [352]. Despite their partly overlapping functions, alternative splicing and 
promotor usage can result in dominant-negative isoforms, thereby increasing the functional diversity of the 
TCF’s [226]. 
5.1.2 A TCF7l2 polymorphism: linking WNT signalling and energy homeostasis 
The WNT pathway is classically known for its role in embryogenesis and tumorigenesis, but a genome-
wide association study in 2006 implicated an important role for canonical WNT signalling in energy 
homeostasis as well [216]. This study identified the strongest genetic determinant of type 2 diabetes risk in 
humans: a microsatellite, DG10S478, located within the 4th intron region of the TCF7L2 gene. This gene 




encodes for a transcription factor that interacts with β-catenin as a downstream effector of the canonical 
WNT signalling pathway. This finding generated huge interest in the role of WNT signalling in energy 
homeostasis, which has resulted in both considerable achievements and disputes. Interestingly, the majority 
of these studies focus on the insulin-producing pancreatic β-cells, despite evidence that canonical WNT 
signalling is not active in adult β-cells [242].  
Functional studies on TCF7l2 in rodents and humans have yielded contradictory findings. For example, 
data showing that a reduction of TCF7l2 expression in the pancreatic β-cells results in blunted glucose-
stimulated insulin secretion response [239, 240] is rather incompatible with evidence from human genetics 
studies showing that the T2D-associated risk alleles actually cause an increased expression of TCF7l2 [241, 
353]. On the cellular level too, contradicting findings have been made. Several studies concluded that 
genetic depletion of TCF7l2 leads to altered β-cell function [242, 243]. On the other hand, one study 
reported that TCF7l2 plays no role in β-cell function, but is rather involved in the hepatic response to 
metabolic challenge [244].  
A WNT-mutant zebrafish line, bearing a functional null allele for TCF7l2, was isolated from a zebrafish 
library mutagenized with N-ethyl-N-nitrosourea (ENU) with the purpose of studying intestinal 
development [354]. Facchinello et al. (2017) used this fish line to study the role of Tcf7l2 in glucose 
homeostasis and in the development, regeneration and vascularization of the pancreatic islet [309]. First, 
the authors characterized the metabolic phenotype of TCF7l2 heterozygous mutants by assessing blood 
glucose levels of adult fish in three dietary regimes: 4 days of fasting, 4 days of immersion in a 1% glucose 
solution, or 30 minutes postprandial. In the third case, but not the first two, significantly elevated blood 
glucose levels were found in the TCF7l2 mutants. β-cell numbers were similar in TCF7l2 mutants compared 
to controls at early stages of development, but a significant decrease in insulin-positive β-cells was observed 
at 16dpf in TCF7l2 mutants. Furthermore, it was shown that TCF7l2 mutants have decreased caudal fin 
regeneration, mimicking the impaired wound healing found in diabetic rodents and humans. Few studies 




have investigated the metabolic function of TCF7l2, and WNT signalling in general, outside of the 
pancreas. The field currently does not seem to appreciate that TCF7l2 is expressed in a wide variety of 
tissues, including adipose tissue, skeletal muscle, liver and brain.  
5.1.3 WNT signalling and leptin 
A way through which canonical WNT signalling could potentially regulate energy homeostasis, 
independent of developmental effects, is by interacting with leptin. One study investigated the effects of 
leptin on cell proliferation and gene expression in the preoptic area and hypothalamus of the tadpole 
Xenopus brain, and found that leptin induced mitosis in the neurogenic zones of the tadpole brain [347]. In 
order to find out through which pathway leptin elicited these actions, DNA microarray analysis was 
performed following intracerebroventricular injection of recombinant leptin. It was found that leptin 
induced 2322 genes and inhibited 1493 genes. Interestingly, pathway enrichment analysis indicated that the 
WNT pathway was among the most strongly activated signalling cascades, thus suggesting that leptin can 
activate the WNT pathway in the brain. In accordance with this, data from our lab show that in the 
Djungarian hamster (Phodopus sungorus), leptin administration causes activation of LRP6 within 15 
minutes [351].  It is unknown whether leptin can signal via this pathway in teleosts. In this chapter, we 
investigated whether leptin activates the WNT pathway in the zebrafish brain.   




5.2 Immunohistochemical exploration of WNT markers in zebrafish 
larvae 
Due to a lack of available literature on the various components of the canonical WNT pathway in the 
zebrafish, we started our investigation by using immunohistochemistry to assess the presence in zebrafish 
larvae of the two main factors in this pathway: β-catenin and GSK3β. WNT receptor activation leads to the 
stabilization of cytosolic β-catenin. Stabilized β-catenin then enters the nucleus to activate target genes 
together with LEF/TCF transcription factors.  The main biological effect of the canonical WNT pathway is 
to regulate β-catenin stabilization by GSK3β. 
5.2.1 Β-catenin 
Wild type zebrafish larvae were euthanized at 2, 3, or 4 dpf through hypothermal shock by immersing them 
in an ice bath. Subsequently, larvae were fixed overnight in 4%PFA at 4°C. The next morning, larvae were 
washed 3x in 0.1M PO4-buffer for 5 minutes, and then washed in dH2O for 5 minutes. Then, the larvae 
were permeabilized in pre-chilled acetone for 30 minutes at -20°C. After another washing step with PO4-
buffer and dH2O, larvae were treated with PBS/BSA/TritonX100 + 5% normal goat serum (NGS) for 30 
minutes Subsequently, the larvae were soaked in β-catenin (D1048, Cell Signalling) Rabbit monoclonal 
antibody (mAB, 1:100), diluted in PBS/BSA/TritonX100 + 2%NGS for 5 hours at room temperature. Larvae 
were washed 4x20 minutes in PBS/BSA/TritonX100, after which they were soaked in Cy5 goat-anti-rabbit 
antibody (1:200), diluted in PBS/BSA/TritonX100 +2%NGS overnight at 4°C. The next morning, larvae 
were washed 4x30 minutes in PBS/BSA/TritonX100, transferred into 1xPBS, and stored in 80% glycerol. 
Images were taken on a Zeiss LSM 510 Inverted Confocal Microscope. B-catenin expression was found 
throughout the whole tissue in a membrane-bound way, at all tested developmental stages (figure 5.1). In 
order to investigate whether β-catenin is also present in the hypothalamus, 20μm sections of 4 dpf larvae 
were prepared on a cryostat (CM1950 Leica), after which immunohistochemistry was performed as 
described above. The presence of β-catenin in the hypothalamus was clearly detectable (figure 5.2).  





Figure 5.1 Immunohistochemical exploration of β-catenin expression in zebrafish larvae at 2- 3- and 4 days post fertilization. 
Representative images of wild type ABz zebrafish larvae stained for β-catenin and visualized using a Cy5 secondary antibody. 
Images displayed as Z stacks of ~40 focal planes. Larvae were analysed at 2 (A,B), 3 (C,D) and 4 (E,F) days post fertilization. 










Figure 5.2 Immunohistochemical exploration of β-catenin expression in the larval zebrafish brain. 20μm sagittal section of 4dpf 
wild type ABz zebrafish larva stained for β-catenin and visualized using a Cy5 secondary antibody. (A) Overview. Scale bar = 









Wild type zebrafish larvae were euthanized at 2, 3, or 4 dpf through hypothermal shock by immersing them 
in an ice bath. Subsequently, larvae were fixed overnight in 4%PFA at 4°C. The next morning, specimens 
were immersed in 30% sucrose for 48h to cryoprotect the tissues. For antigen retrieval, cryoprotected larvae 
were incubated in 150 mM Tris-HCl at pH 9.0 for 5 min, followed by heating at 70°C for 15 min [355]. 
After heating, the embryos were re-cryoprotected in 30% sucrose at 4°C overnight. The next morning, 
larvae were washed 3x in 0.1M PO4-buffer for 5 minutes, and then washed in dH2O for 5 minutes 
Subsequently, the larvae were permeabilized in pre-chilled acetone for 30 minutes at -20°C. After another 
washing step with PO4-buffer and dH2O, larvae were treated with PBS/BSA/TritonX100 + 5% normal goat 
serum (NGS) for 30 minutes Subsequently, the larvae were soaked in GSK3β (27C10, Cell Signalling) 
Rabbit monoclonal antibody (mAB, 1:500), diluted in PBS/BSA/TritonX100 + 2%NGS for 8 hours at room 
temperature. Then, the larvae were washed 4x20 minutes in PBS/BSA/TritonX100, after which they were 
soaked in Cy5 goat-anti-rabbit antibody (1:200), diluted in PBS/BSA/TritonX100 +2%NGS overnight at 
4°C. The next morning, larvae were washed 4x30 minutes in PBS/BSA/TritonX100, transferred into 1xPBS, 
and stored in 80% glycerol. 
Images were taken on a Zeiss LSM 510 Inverted Confocal Microscope. GSK3β expression was found to 
change throughout development (figure 5.3). At 2dpf GSK3β was highly expressed in and around the spine, 
and in the yolk sack. At 3dpf and 4dpf, GSK3β expression appeared to be more limited to the heart and 
brain. In comparison with β-catenin, GSK3β expression was patchier and less uniform. This is likely due 
to the fact that β-catenin is not only involved in WNT gene transcription, but also in regulation and 









Figure 5.3 Immunohistochemical exploration of GSK3β expression in zebrafish larvae at 2- 3- and 4 days post fertilization. 
Representative images of wild type ABz zebrafish larvae stained for GSK3β and visualized using a Cy5 secondary antibody. Images 
displayed as Z stacks of ~40 focal planes. Larvae were analysed at 2 (A,B), 3 (C,D) and 4 (E,F) days post fertilization. Images on 








5.3 Validation of Tg(7xTCFXla.Siam:nlsmCherry)ia5 zebrafish larvae 
One of the main advantages of using zebrafish as a research model is the optical transparency of its larvae. 
This feature renders them ideal for in vivo imaging of physiological processes at a microscopic level. For 
in vivo WNT signalling, two transgenic constructs have been developed: Tg(TOP:GFP)w25 [357] and 
Tg(7xTCFXla.Siam:nlsm)ia5 [358]. We tested the Tg(TOP:GFP)w25 zebrafish line (data not shown) and 
found that, although useful for applications like in situ hybridization, it is unsuitable for live imaging 
because GFP expression is low due to the use of a destabilized version of GFP.  
The Tg(7xTCFXla.Siam:nlsmCherry)ia5 line was developed by Moro et al. (2012), and expresses mCherry 
upon translocation of β-catenin and TCF to the nucleus. It was constructed using three gateway destination 
vectors in a Tol2 transposon backbone. The entry vector contains a cassette with seven multimerized 
TCF/LEF binding sites upstream to a 0.13 kilobyte minimal promoter derived from the Xenopus gene 
siamois [359]. This vector was then combined with an mCherry-carrying middle vector and a simian virus 
40 polyadenylation (S40V-polyA) signal-carrying vector to signal the end of the transcriptional unit. This 
transgenic zebrafish line has been used in many studies investigating embryonic development [360, 361], 
but not yet to explore the functional connection between leptin signalling and WNT signalling.  
5.3.1 Activation and inhibition 
First, we established that 5dpf is the best stage to image non-developmental canonical WNT signalling. 
Subsequently, we set out to validate the Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae as intrinsically WNT-
responsive. In order to do so, we pharmacologically activated or inhibited the canonical WNT pathway. 
Furthermore, because we found that zebrafish larvae quickly develop melanocytes which hamper the 
reliability of the fluorescent signal, we incorporated N-phenylthiourea (PTU) treatment in all our imaging 
experiments from here onwards. At the standard concentration of 0.003% (200 μM), PTU inhibits 
melanogenesis and reportedly has minimal other effects on zebrafish embryogenesis [362].  




To activate the WNT pathway, 5dpf Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae were exposed to 10μM 
lithium chloride (LiCl), dissolved in E3 medium, for 2 hours. LiCl activates the canonical WNT pathway 
by inhibiting GSK3β, thereby maintaining an active destruction complex and thus preventing the cytosolic 
accumulation of β-catenin [363]. To inhibit the WNT pathway, 5dpf Tg(7xTCFXla.Siam:nlsmCherry)ia5 
larvae were exposed to 10μM PNU74654 (2-phenoxy-, 2-[(5-methyl-2-furanyl)methylene]hydrazide; 
PNU), dissolved in E3 medium in 0.1% DMSO, for 2 hours. PNU inhibits the canonical WNT pathway by 
blocking the interaction between β-catenin and TCF/LEF to prevent translocation into the nucleus. Control 
larvae were treated with E3 medium [364]. 
Images were taken using a Leica M205 FA epifluorescence microscope, and analysed using ImageJ. 
Determining activation or inhibition of a fluorescent reporter gene requires measurement of overall 
fluorescence (as opposed to counting dendritic spines for example). An initial analysis was carried out to 
assess the number of saturated pixels in the images. In some larvae, saturated pixels were found in the heart 
and protruding mouth, but not the hypothalamus (figure 5.4). We therefore concluded that our experimental 
setup was suitable for measuring WNT pathway activation in the hypothalamus of 5dpf 
Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae. 





Untreated larvae displayed low-level WNT pathway activation, most notably in the heart and protruding 
mouth. LiCl-treated larvae showed robust WNT pathway activation (figure 5.5; P<0.0001; one-way 
ANOVA), with widespread fluorescence throughout the larvae, including in the otic vesicle, yolk sack and 
brain. PNU-treated larvae on the other hand showed a decrease in fluorescence to almost unnoticeable levels 
(P<0.05; one-way ANOVA), confirming that inhibition of the WNT pathway prevents activation of the 
transgenic mCherry construct. The low-level fluorescence that remained after PNU treatment can be 
attributed to autofluorescence of the specimen. Thus, it can be concluded that 
Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae are a valid model for studying WNT pathway dynamics in vivo.  
 
Figure 5.4 Pixel saturation in Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae. Representative image of a 5dpf Tg(7xTCFXla.Siam: 
nlsmCherry)ia5 larva treated with LiCl. Saturated pixels, shown in red, are found in the heart and protruding mouth but not in 
the hypothalamus or brain in general. 





Figure 5.5 Pharmacological validation of Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae. 5dpf Tg(7xTCFXla.Siam: nlsmCherry)ia5 
larvae were treated with E3 medium (A, B), 10 μM LiCl (C, D), or 10 μM PNU74654 (E, F). Images on the left are brighfield 
images of fluorescent specimens on the right, for anatomical reference. Scale bar = 500 μM. G) Quantification of fluorescence 
found in A-F. PNU74654 (n=12) significantly decreased fluorescence compared to vehicle-treated larvae (n=22) (12.31 1.121 
vs 19.220.914; *P<0.05). LiCl (n=16)(30.952.139) significantly increased fluorescence (****P<0.0001), one-way ANOVA with 
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5.4 Leptin activates the canonical WNT pathway 
To investigate whether leptin directly activates the canonical WNT pathway we exposed 5dpf 
Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae to recombinant mouse leptin. A stock solution of 100μM leptin 
in fish saline (134 mM NaCl, 2.9 mM KCl, 2.1 mM CaCl2, 1.2 mM MgCl2, 10 mM HEPES, and 10 mM 
glucose, pH 7.8) was prepared. Larvae were exposed to 100nM leptin for 2 hours before imaging. Images 
were taken using a Leica M205 FA epifluorescence microscope, and analysed using ImageJ. Hypothalamic 
WNT pathway activation was quantified by manually drawing a region of interest around the hypothalamus, 
followed by measurement of average fluorescent intensity in the region of interest.  
Compared to vehicle-treated larvae, leptin-treated larvae exhibited robust WNT pathway activation (figure 
5.6; P<0.0001; Student’s t-test). Interestingly, while LiCl activated the WNT pathway throughout the 
larvae, leptin appears to activate the WNT pathway specifically in the brain.  





Figure 5.6 WNT pathway activation by leptin in Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae. 5dpf Tg(7xTCFXla.Siam:nlsm 
Cherry)ia5 larvae were treated with 100nM recombinant mouse leptin (C, D) or vehicle (A, B). (A) and (C) represent brighfield 
images of larvae shown in (B) and (D). E) Magnification of hypothalamus and heart in (D). F) Quantification of fluorescence found 
in (B) vs (D). Leptin treatment (n=18) significantly increased fluorescence compared to vehicle treatment (n=22) (34.122.709 vs 
19.220.914; ****P<0.0001, Student’s T-test). Scale bar = 500μM. Data displayed as meanSEM. 
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5.5 Knockout of the leptin receptor prevents WNT pathway activation by 
leptin 
To further corroborate the finding that leptin activates the WNT pathway, the CRISPR/Cas9 system was 
used to knock out the leptin receptor in Tg(7xTCFXla.Siam:nlsmCherry)ia5 zebrafish. Freshly fertilized 
zebrafish eggs in the one cell stage were microinjected with 1.4nl of a leptin receptor sgRNA (35.4ng/µl) 
and Cas9 mRNA (212.2ng/µl). Uninjected embryos from the same clutch were saved. Embryos were placed 
into a 28.5°C incubator. At 5hpf, unfertilized and injection-damaged embryos were removed. Subsequently, 
embryos were placed back into the 28.5°C incubator. At 1dpf, counts were made of the numbers of normal-
looking, deformed and dead embryos, in both the injected and the uninjected embryos. Dead and deformed 
embryos were removed, and E3 medium was refreshed. At 5dpf, the now leptin receptor deficient WNT 
reporter fish were treated with either LiCl or recombinant mouse leptin again. Knocking out the leptin 
receptor was found to prevent the effect of leptin on WNT pathway activation, but not the effect of LiCl on 
WNT pathway activation (figure 5.7; P<0.0001; Student’s t-test).  
 





Figure 5.7 Leptin receptor knockout prevents WNT pathway activation by leptin in Tg(7xTCFXla.Siam:nlsmCherry)ia5 F0 larvae. 
CRISPR-mediated leptin receptor knockout Tg(7xTCFXla.Siam:nlsmCherry)ia5 (F0, 5dpf) larvae were treated with 100nM 
recombinant mouse leptin (A, B) or 10μM LiCl (C, D). (A) and (C) represent brighfield images of larvae shown in (B) and (D). E) 
Quantification of fluorescence found in (B) vs (D). Knockout of the leptin receptor inhibited WNT pathway activation by leptin 
(n=17; 22.231.196) but not by LiCl (n=15; 40.22.207); ****P<0.0001, Student’s t-test. Scale bar = 500μM. Data displayed as 
meanSEM. 
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5.6 Leptin activates the WNT pathway in the adult zebrafish brain 
So far in this chapter, we have used transgenic zebrafish at the larval stage to show that leptin activates the 
WNT pathway in vivo. In the previous chapters however, glucose homeostasis has been measured in adults, 
and not in larvae. There might be a potential difference in glucose levels between zebrafish at the larval and 
adult stage. However, it is technically very challenging to measure glucose levels in individual zebrafish 
larvae. To confirm the validity of our findings in this chapter, we also tested whether leptin activates the 
WNT pathway in adult Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 zebrafish. To confirm that leptin activates the 
canonical WNT pathway in the brain, we injected adult male Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 fish 
with recombinant mouse leptin (2mg/kg), or vehicle (Cortland salt solution), and then assessed the WNT 
activity expression level and pattern in 30 μm-thick coronal brain sections. As a positive control, we 
incubated fish in 10μM LiCl, dissolved in system water, for 2 hours. Baseline WNT activity was found to 
be present at very low levels throughout the brain (figure 5.8A). In the hypothalamus, 4% of all cells 
expressed WNT pathway activity (figure 5.8G). Leptin treatment was found to robustly activate the WNT 
pathway in the brain of adult zebrafish. Surprisingly, the expression pattern was not limited to the 
hypothalamic areas classically known to express leptin receptors in mammals, but instead found throughout 
the brain (figure 5.8C), with no difference in expression level between the optic tectum and the 
hypothalamus (figure 5.8E). In the hypothalamus, 12% of all cells expressed WNT pathway activity. Lastly, 
we found that LiCl treatment also steadily activates the WNT pathway (figure 5.8E). In the hypothalamus, 
19% off all cells expressed WNT pathway activity (figure 5.8I). 





Figure 5.8 Activation of the WNT pathway in the brain of adult Tg(7xTCFXla.Siam:nlsmCherry)ia5fish. (A) Representative image 
of vehicle-treated control. Left: mCherry fluorescence, representing WNT pathway activation; Middle: DAPI staining, representing 
total cell number; Right: Merge of mCherry and DAPI images. Scale bar = 500 μm. (B) Magnification of mediobasal hypothalamic 
area in (A, marked by white box). Scale bar = 100 500 μm. (C) Representative image of leptin-treated zebrafish. (D) Magnification 
of (C). (E) Representative image of LiCl-treated zebrafish. (F) Magnification of (E). (G) Percentage of cells displaying WNT 
pathway activity in vehicle-treated controls. (H) Percentage of cells displaying WNT pathway activity in leptin-treated zebrafish. 
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5.7.1 Measuring WNT signalling in vivo 
In this chapter we used a transgenic zebrafish line, Tg(7xTCFXla.Siam:nlsmCherry)ia5, which expresses 
mCherry upon activation of the canonical WNT pathway.  The optical transparency of its larvae makes the 
zebrafish uniquely suitable for in vivo imaging of biological processes without the need for invasive 
procedures. Following pharmacological validation of the Tg(7xTCFXla.Siam:nlsmCherry)ia5 reporter line, 
we demonstrated that leptin activates the WNT pathway in vivo, and that knockout of the leptin receptor 
blocks the WNT pathway-activating effect of leptin. To our knowledge, this is the first evidence of in vivo 
WNT pathway activation by leptin in the zebrafish. The fact that mouse leptin activates the canonical WNT 
pathway in the zebrafish is another indication of how well-preserved this signalling system is from an 
evolutionary perspective. Although methodologically straightforward, several considerations need to be 
taken into account before any firm conclusions can be drawn. Firstly, because the WNT pathway is heavily 
involved in embryonic development [223], baseline WNT pathway activity is a potential confounding 
factor. Furthermore, the question of whether the WNT pathway is activated or not requires overall 
measurement of fluorescent intensity, as opposed to counting a definite number (e.g. dendritic spines or 
cellular processes). However, fluorescent intensity is not a linear signal, so it is impossible to reliably 
conclude to which degree certain manipulations (e.g. LiCl treatment) activate or inhibit the WNT pathway. 
To overcome these limitations, we analysed baseline activity at different developmental stages and found 
that at 5dpf baseline activity is reduced significantly. We also assessed whether the microscope parameters 
we used resulted in saturated pixels. This was found to be the case in the heart but not in the hypothalamus, 
our main site of interest. Therefore, we proceeded by comparing the overall fluorescent intensity in the 
hypothalamus of the different groups. Given the long half-life of mCherry, ~24 hours, it is possible that the 
detection of a fluorescent signal reflects WNT signalling that has already ceased in the tissue. However, the 
original study first that established the Tg(7xTCFXla.Siam:nlsmCherry)ia5 line used in situ hybridization 




with antisense mCherry riboprobes to demonstrate that the expression pattern stayed within the 
fluorescently labelled domains [358]. Thus, we are confident that our results reliably depict the differential 
effects of leptin and previously described WNT (ant)agonists. 
5.7.2 Hypothalamic WNT signalling in the zebrafish 
We found that leptin activates the canonical WNT pathway, and that the hypothalamus was one of the areas 
that was activated the most. These data point towards a role for WNT signalling, specifically in the 
hypothalamus, in the regulation of energy homeostasis. One of the first studies on WNT signalling in the 
adult brain found that this pathway regulates not only embryonic, but also postembryonic hypothalamic 
progenitor differentiation in both zebrafish and mice, thereby emphasizing the evolutionary conservation 
of WNT action in the brain [230]. Wang et al. investigated the precise expression pattern of WNT-
responsive and TCF-expressing cells in the embryonic, larval and adult zebrafish hypothalamus. Using in 
situ hybridization for the individual TCF members, they found that all TCF members are located in the 
hypothalamus, especially in the posterior part where post mitotic precursor cells are present. Interestingly, 
the expression of TCF7l2 (the TCF member associated with diabetes risk) is confined to a small area right 
above the future hypophysis. It was furthermore found that zebrafish larvae express LEF1 and TCF7 in the 
caudal zone of the periventricular hypothalamus. No specific expression of TCF7l1a/b or TCF7l2 was 
found. A similar expression pattern was found in adult fish, where TOP:dGFP fluorescence, the first 
canonical WNT reporter construct, persisted in cells adjacent to the diencephalic ventricle. Importantly, 
TOP:dGFP was only found in the hypothalamus and optic tectum of adult fish. Canonical WNT signalling 
has been widely implicated in expansion of progenitor pools or neural stem cells, suggesting that this 
pathway is a required factor for neural stem cell maintenance [365]. However, at least 10 distinct regions 
have been identified as proliferation zones within the adult zebrafish brain [233]. This suggests that the 
WNT-responsive cells found in the hypothalamus of adult zebrafish serve another purpose. 




5.7.3 Off-target effects of lithium chloride 
LiCl has a wide range of physiological effects. Clinicians have been using LiCl to treat manic depression 
and bipolar disorder, but unwanted side effects are often reported. These include granulocytosis and 
lymphopenia, as well as kidney damage [371]. The mechanisms through which LiCl act are not well 
understood, but inhibition of GSK3β is widely considered to be its main effect [368, 372]. This effect itself 
would be able to explain the wide range of effects of LiCl, as GSK3β is an integral part of a multitude of 
signalling cascades [373]. Thus, while we acknowledge that LiCl has potential off-target effects in our 
experiments, we regard it to be a suitable drug to pharmacologically activate the canonical WNT pathway 
in the experiments described in this chapter. 
 
Chapter 6 
Leptin regulates glucose homeostasis 
through the canonical WNT pathway 
 
  





6.1.1 WNT signalling-mediated regulation of glucose homeostasis by leptin 
The idea that the canonical WNT pathway represent a novel integration site for the leptin signal is supported 
by several studies from our lab and others. The first indication of a role for WNT signalling in glucose 
homeostasis came from a study that used two different cell culture systems to show that the WNT pathway 
directly responds to glucose [366]. Most WNT signalling genes are strongly expressed in the mediobasal 
hypothalamus [258]. This region contains the arcuate nucleus, which is regarded to be the main center for 
the neuroendocrine control of energy homeostasis [367]. Leptin-deficient Lepob/ob mice were shown to have 
impaired WNT signalling in the arcuate nucleus, as the levels of WNT7a, WNT4, axin2 and cyclin D1 were 
significantly lower in these mice compared to wild type control mice [258]. Importantly, the decreased 
expression of WNT ligands was specifically due to the lack of leptin, because leptin replacement completely 
normalized gene expression levels. The glucose-lowering effects op leptin have been extensively described, 
including in this thesis (section 4.5). Our lab has shown that pharmacological inhibition of the WNT 
pathway using Dkk1, which acts by isolating the LRP6 co-receptor thereby preventing activation of the 
downstream WNT signalling cascade, prevents the ability of leptin to improve glucose homeostasis in a 
glucose tolerance test [245]. In accordance with this, human data show that plasma Dkk1 levels are 
significantly upregulated in type 2 diabetic patients compared with healthy controls [368].  
6.1.2 GSK3β: a convergence site of WNT- and insulin signalling 
The possibility of WNT-mediated regulation of glucose homeostasis by leptin is further evidenced by 
studies showing that leptin inactivates GSK3β in vitro, both in developing cortical neurons [259] and in 
NPY neurons in the arcuate nucleus of adult mice [245]. GSK3β is not only a central part of the canonical 
WNT signalling pathway, but also a target of PI3K/Akt signalling [247]. The PI3K/Akt pathway is an 
intracellular signalling cascade that is essential for cellular quiescence, proliferation and longevity, and 




forms the main mediator of insulin signalling. Thus, GSK3β is a site of convergence between canonical 
WNT signalling and insulin signalling.  
Systemic GSK3β inhibition has been shown to improve whole body glucose tolerance, pointing towards a 
tonic inhibitory effect of GSK3β on glucose homeostasis [250]. We previously studied the role of 
hypothalamic GSK3β in the regulation of glucose homeostasis and found that not only was hypothalamic 
GSK3β expression increased in Lepob/ob mice, glucose tolerance in these mice could be rapidly improved 
through ICV injection of a GSK3β inhibitor [245]. Conversely, we then overexpressed GSK3β specifically 
in the neurons of the arcuate nucleus of wild type mice. This manipulation had little effect in mice on a 
normal diet, but induced exacerbated hyperphagia, obesity and impairment of glucose tolerance in mice on 
a high fat diet. It can thus be concluded that GSK3β is essential for the brain-mediated control of glucose 
homeostasis. Interestingly, phosphorylated Akt has been demonstrated to inactivate GSK3β in L6 myotubes 
[247] and skeletal muscle [248], and in HeLa cells [249]. This suggests the possibility feedback loop in the 
PI3K/Akt pathway that connects to the canonical WNT signalling pathway. In this loop, the pAkt-mediated 
inhibition of GSK3β reduces phosphorylation of inhibitory phosphorylation sites on IRS-1, which 
subsequently activates the PI3K signalling cascade. However, it is important to note that while the 
glucoregulatory actions of GSK3β appear to be mediated centrally, pAkt-mediated inhibition of GSK3β 
has so far only been shown peripherally.  
6.1.3 Pharmacological manipulation of the canonical WNT pathway  
Aberrant regulation of the WNT pathway has been implicated in a wide variety of diseases, including 
cancer, type 2 diabetes, fibrosis and neurodegeneration [369]. Over the past decades, numerous studies have 
identified potentially therapeutic agents that activate or inhibit different components of the WNT signalling 
cascade. However, only a limited number of these agents have recently entered clinical trials, and none 
have been approved yet [370]. In this chapter, we use one WNT pathway-activating compound, LiCl, and 
two WNT pathway antagonists to pharmacologically manipulate the WNT pathway. LiCl activates the 




WNT pathway by inhibiting GSK3β, thereby preventing the proteasomal degradation of β-catenin [371]. 
Pyrvinium pamoate inhibits CK1α, which is part of the destruction complex that targets β-catenin [372]. 
PNU74654 (2-phenoxy-, 2-[(5-methyl-2-furanyl)methylene]hydrazide) acts further downstream and 
antagonizes canonical WNT signalling by interfering with the formation of the β-catenin-TCF/LEF 
complex that translocates into the nucleus to regulate target gene expression [364]. Using these compounds, 
we set out to explore whether activation or inhibition of the WNT pathway alters the ability of leptin to 
regulate glucose homeostasis. 
 
  
Figure 6.1 Overview of pharmacological manipulation of the canonical WNT pathway. LiCl activates the WNT 
pathway by inhibiting GSK3β. Pyrvinium and PNU74654 inhibit WNT signalling by interfering with CKIα and the 
TCF/β-catenin complex respectively. Wnt = wingless/integration1; LiCl = lithium chloride; CK1α = casein kinase 1 
alpha; GSK3β = glycogen synthase kinase 3 beta; TCF = transcription factor. 




6.2 Pharmacological WNT manipulation in wild type zebrafish 
In order to investigate the effects of pharmacological manipulation of the WNT signalling pathway on the 
glucoregulatory actions of leptin, we exposed adult zebrafish to well-described compounds that either 
activate (LiCl) or inhibit (PNU74654 and pyrvinium pamoate) the canonical WNT pathway, and then 
assessed the ability of leptin to regulate blood glucose levels in both an acute (glucose tolerance test) and 
persistent glycaemic challenge (1% glucose immersion). Both tests have been described previously, in 
sections 3.3 and 3.4 respectively.  
6.2.1 Acute glycaemic challenge 
For the acute glycaemic challenge, 8-month old wild type male zebrafish (n=6) were fasted for 72 hours. 
Three hours before being challenged with a 0.5mg/g glucose solution, fish were individually placed in a 
tank containing either 10μM LiCl, 10μM PNU74654 or 10μM pyrvinium pamoate, all dissolved in normal 
tank water with 0.1% DMSO, or in tank water with 0.1% DMSO only. One hour before glucose injection, 
fish were injected intraperitoneally with 0.6gr/L of recombinant mouse leptin dissolved in Cortland salt 
solution, or with vehicle only. Following glucose injection, blood samples were taken at 30, 90 and 180 
minutes post injection. We previously found that leptin ameliorates hyperglycaemia during immersion in a 
1% glucose solution. Similarly, leptin improves glucose tolerance during an acute hyperglycaemic 
challenge. This finding is in accordance with studies on leptin’s glucoregulatory actions in a wide range of 
animal models. Activating the WNT pathway through LiCl treatment improved glucose tolerance compared 
to untreated control fish, to a similar degree as leptin (figure 6.2; area under the curve P<0.0001; one-way 
ANOVA). Both PNU74654 treatment and pyrvinium treatment significantly impaired glucose tolerance 
(area under the curve P<0.05, one-way ANOVA). Combining PNU74654 treatment or pyrvinium treatment 
with leptin treatment resulted in an area under the curve that is not significantly different from that of control 
fish. Importantly, these data show that inhibition of the WNT pathway leads to a partial reduction in the 
ability of leptin to lower blood glucose levels. 





Figure 6.2 Glucose tolerance in wild type zebrafish following WNT manipulation and leptin treatment. 8-month old wild type male 
zebrafish (n=6) were exposed to either 10μM LiCl (A, B), 10μM PNU74654 (C, D) or 10μM pyrvinium pamoate (E, F), for three 
hours before glucose injection. One hour before glucose injection, fish were injected intraperitoneally with 0.6gr/L of recombinant 
mouse leptin dissolved in Cortland salt solution, or with vehicle only. Following 0.5mg/g glucose injection, blood samples were 
taken at 30, 90 and 180 minutes post injection. A, B) LiCl, leptin, and a combination of LiCl and leptin all significantly improved 
glucose tolerance compared to untreated controls (A-B=P<0.0001, one-way ANOVA). C, D) PNU74654 significantly impaired 
glucose tolerance compared to leptin-treated fish and untreated controls, whereas combined treatment with PNU and leptin did 
not result in significantly altered glucose tolerance (P<0.05, one-way ANOVA). E, F) Pyrvinium pamoate significantly impaired 
glucose tolerance compared to leptin-treated fish and untreated controls, whereas combined treatment with pyrvinium and leptin 
did not result in significantly altered glucose tolerance (P<0.05, one-way ANOVA). Data displayed as meanSEM. 
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6.2.2 Persistent glycaemic challenge 
For the persistent glycaemic challenge, 10-month old wild type male zebrafish (n=6) were placed in a 1% 
glucose solution for 4 days. We previously established that basal blood glucose levels become persistently 
hyperglycaemic after 3 days of immersion in a 1% glucose solution. Blood glucose values were measured 
daily. On the third day, 3 hours before blood glucose measurement, fish were treated individually with 
10μM LiCl, 10μM PNU74654 or 10μM pyrvinium pamoate, dissolved in a new 1% glucose solution with 
0.1% DMSO. One hours before blood sampling, fish were injected intraperitoneally with 0.6gr/L of 
recombinant mouse leptin dissolved in Cortland salt solution, or with vehicle only. Following blood glucose 
measurement on day 3, fish were returned to a fresh 1% glucose solution.  
We found that leptin temporarily prevents glucose immersion-induced elevation of blood glucose levels 
(figure 6.3), consistent with previous findings in section 4.4. Stimulating the WNT pathway with LiCl 
ameliorated hyperglycaemia to a similar degree as leptin. Blocking the WNT pathway using PNU74654 or 
pyrvinium pamoate did not significantly impair basal blood glucose levels any more than vehicle treatment 
did. Treatment with PNU74654 or pyrvinium pamoate in combination with intraperitoneal leptin injection 
suggested that pharmacological inhibition of the WNT pathway reduces the ability of leptin to regulate 
glucose homeostasis, although statistical significance was not reached (P=0.059 for PNU+leptin and 
P=0.058 for pyrvinium+leptin). 





Figure 6.3 Glucose immersion-induced hyperglycaemia in wild type zebrafish following WNT manipulation and leptin treatment. 
10-month old wild type male zebrafish (n=6) were immersed in a 1% glucose solution for 4 days. On the third day, fish were 
exposed to either 10μM LiCl (A), 10μM PNU74654 (B) or 10μM pyrvinium pamoate (C), for three hours before daily blood 
sampling. One hour before blood sampling, fish were injected intraperitoneally with 0.6gr/L of recombinant mouse leptin dissolved 
in Cortland salt solution, or with vehicle only. D) Comparison of blood glucose levels pre-treatment (day 2) and post treatment 
(day 3). Blood glucose levels were significantly higher in vehicle-treated control fish, PNU-treated fish, pyrvinium-treated fish, but 
not in leptin-treated fish, LiCl-treated fish, or ‘leptin+LiCl’-treated fish. ‘Leptin+PNU’-treated fish and ‘leptin+pyrvinium’-
treated fish closely approached, but did not reach, statistical significance (P<0.05; Student’s t-test). Data displayed as meanSEM.  
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6.3 Pharmacological WNT activation in leptin-mutant zebrafish 
Following our finding that pharmacological activation of the WNT pathway improves glucose homeostasis, 
we decided to further investigate how leptin relates functionally to WNT signalling by assessing the effects 
of pharmacological WNT manipulation on the glucoregulatory actions of leptin in leptin-mutant zebrafish. 
Again, we used both an acute and a persistent glycaemic challenge to study glucose homeostasis.  
6.3.1 Acute glycaemic challenge 
For the acute glycaemic challenge 6-7 month-old male ABz-lepA-/-, ABz-lepB-/- and ABz-lepR-/- zebrafish 
(n=6) were used. LiCl treatment, recombinant leptin injection and intraperitoneal glucose tolerance tests 
were performed as described in section 6.2.1. Firstly, it was found that in ABz-lepA-/- and ABz-lepB-/- fish, 
but not in ABz-lepR-/- fish, leptin improved glucose tolerance compared to untreated controls (figure 6.4; 
P<0.0001; one-way ANOVA). Treating ABz-lepA-/- and ABz-lepB-/- fish with lithium before injecting 
glucose lead to a similar improvement of glucose tolerance (P<0.0001; one-way ANOVA). Whereas leptin 
was unable to improve glucose tolerance, for obvious reasons, in leptin receptor deficient fish, it was found 
that lithium treatment on the other hand significantly improved glucose tolerance (P<0.0001; one-way 
ANOVA). Likewise, a combination of lithium treatment and leptin injection improved glucose tolerance 
compared to untreated and leptin-treated fish (P<0.0001; one-way ANOVA).  





Figure 6.4 Glucose tolerance in leptin-mutant zebrafish following WNT manipulation and leptin treatment. 6-7 month old ABz-
lepA-/-, ABz-lepB-/- and ABz-lepR-/- zebrafish (n=6) were exposed to either 10μM LiCl or a control solution, for three hours before 
glucose injection. One hour before glucose injection, fish were injected intraperitoneally with 0.6gr/L of recombinant mouse leptin 
dissolved in Cortland salt solution, or with vehicle only. Following a 0.5mg/g glucose injection, blood samples were taken at 30, 
90 and 180 minutes post injection. A, B) In ABz-lepA-/-fish, both leptin treatment and LiCl treatment, as well as leptin treatment 
and LiCl treatment combined, significantly improved glucose tolerance compared to untreated controls (***P<0.0001, one-way 
ANOVA. C,D) In ABz-lepB-/-fish too, both leptin treatment and LiCl treatment, as well as leptin treatment and LiCl treatment 
combined (210551930mg/dl*minutes), significantly improved glucose tolerance compared to untreated controls (***P<0.0001, 
one-way ANOVA. E, F) In ABz-lepR-/-fish on the other hand, LiCl treatment, and ‘leptin+LiCl’ treatment, but not leptin treatment, 
significantly improved glucose tolerance compared to untreated controls (***P<0.0001, one-way ANOVA. Data displayed as 
meanSEM. 
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6.3.2 Persistent glycaemic challenge 
For the persistent glycaemic challenge, 7-8 month-old male ABz-lepA-/-, ABz-lepB-/- and ABz-lepR-/- 
zebrafish (n=6) were placed in a 1% glucose solution for 4 days. LiCl treatment, recombinant leptin 
injection and glucose immersion were performed as described in section 6.2.2. We previously established 
that leptin ameliorates glucose immersion-induced hyperglycaemia in wild type fish, as well as in male 
ABz-lepA-/-and ABz-lepB-/-, but not in ABz-lepR-/- zebrafish. Here, we show that pharmacological activation 
of the WNT pathway with lithium also, at least partially, prevents elevation of blood glucose levels due to 
glucose immersion, even in leptin receptor deficient zebrafish (figure 6.5). Interestingly, lithium treatment 
induced a more lasting effect on blood glucose levels than leptin. In previous experiments (section 4.4) we 
found that although leptin treatment significantly ameliorated hyperglycaemia on the day of treatment, this 
effect was rather short-lived because one day later the blood glucose levels of leptin-treated fish no longer 
differed from vehicle-treated control fish. Lithium treatment on the other hand lead to significantly 
decreased blood glucose levels, not only on the day of treatment, but one day later as well (P<0.05; repeated 
measures ANOVA). Because our pilot data (section 3.4) suggest that zebrafish should only be kept in 1% 
glucose for a maximum of 4 days, we did not extend the experiment beyond this timeframe.  





Figure 6.5 Glucose immersion-induced hyperglycaemia in leptin-mutant zebrafish following pharmacological WNT activation and 
leptin treatment. 7-8-month old wild type male zebrafish (n=6) were immersed in a 1% glucose solution for 4 days. On the third 
day, fish were exposed to either 10μM LiCl or vehicle, for three hours before daily blood sampling. One hour before blood sampling, 
fish were injected intraperitoneally with 0.6gr/L of recombinant mouse leptin dissolved in Cortland salt solution, or with vehicle 
only. A, B) Blood glucose values did not rise significantly in ABz-lepA-/-fish treated with LiCl only or with leptin+LiCl, unlike 
vehicle-treated controls (*P<0.05, Student’s t-test). Blood glucose levels remained significantly lower in ‘LiCl’ and ‘leptin+LiCl’ 
groups post treatment (*P<0.05, repeated measures ANOVA). C, D) Blood glucose values did not rise significantly in ABz-lepB-/-
fish treated with LiCl only or with leptin+LiCl, unlike vehicle-treated controls (*P<0.05, Student’s t-test). Blood glucose levels 
remained significantly lower in ‘LiCl’ and ‘leptin+LiCl’ groups post treatment (*P<0.05, repeated measures ANOVA). E, F) Blood 
glucose values did not rise significantly in ABz-lepR-/-fish treated with LiCl only or with leptin+LiCl, unlike vehicle-treated controls 
(*P<0.05, Student’s t-test). Blood glucose levels remained significantly lower in ‘LiCl’ and ‘leptin+LiCl’ groups post treatment 
(*P<0.05, repeated measures ANOVA). Data displayed as meanSEM.  
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In this chapter, we pharmacologically manipulated the canonical WNT pathway in both wild type zebrafish 
and leptin- or leptin receptor deficient zebrafish to investigate whether leptin regulates glucose homeostasis 
through this pathway. Inhibition of the canonical WNT pathway was found to impair glucose homeostasis. 
Importantly, blocking the WNT pathway prevented the ability of leptin to lower blood glucose levels. 
Activation of the WNT pathway on the other hand, improved glucose tolerance and ameliorated 
hyperglycaemia, even in leptin receptor deficient zebrafish. These data show that leptin can regulate glucose 
homeostasis via the canonical WNT pathway, but WNT signalling can control glucose homeostasis 
independent of leptin as well.  
6.6.1 WNT pathway-mediated control of glucose homeostasis 
The ability of WNT signalling to regulate blood glucose levels is often ascribed to GSK3β being a site of 
convergence between canonical WNT signalling and insulin signalling [374]. We inhibited the WNT 
pathway both upstream (using pyrvinium pamoate) and downstream (using PNU74654) of GSK3β, yet both 
manipulations impaired glucose tolerance and blocked the glucoregulatory effect of leptin. Oncological 
studies suggest that insulin and the WNT ligands regulate GSK3β via different mechanisms, thus leading 
to distinct downstream cellular events. For example, in a number of cancer cell lines a 2-hour treatment 
with insulin leads to increased Ser9 GSK3β phosphorylation and decreased GSK3β enzymatic activity, but 
free cytoplasmic β-catenin levels remained unchanged [375]. WNT ligands and lithium on the other hand 
induced accumulation of free cytoplasmic β-catenin but had no effect on GSK3β phosphorylation. The 
mechanism of how lithium is cleared from the body is not well understood, but it could be that compared 
to leptin, lithium is bioactive for a longer time. It has been shown that lithium is cleared from the body 
primarily through glomerular filtration, but due to its small size it is partly reabsorbed together with sodium 
through the proximal tubule in the nephron [373]. Other studies have found that activation of WNT target 
genes can be induced by IGF-1 and insulin [376]. Interestingly, one of these studies implicated a role for 




Erk signalling in the mediation of β-catenin stabilization [377]. Since leptin has been widely shown to 
signal through the Erk signalling pathway [378], it would be interesting to test whether the WNT-mediated 
glucoregulatory effects of leptin are dependent of Erk signalling. It is important to note though that these 
studies primarily looked at cancer cell lines. Whether the same mechanisms apply to central signalling in 
the hypothalamus remains to be elucidated. 
Although we used various WNT signalling-altering agents with the intent of functionally dissecting the 
interaction between leptin and WNT signalling, these and many other compounds have originally been 
studied as potential therapeutics to treat disorders caused by aberrant WNT signalling. Because the WNT 
pathway is a highly fundamental and evolutionary conserved pathway, it plays an important role in a wide 
range of physiological processes, especially during embryonic development but also in virtually every 
organ system in adults [379]. Thus, despite enormous potential, safely targeting the WNT pathway has 
proven to be extremely challenging. For a discussion on the potential of targeting the WNT pathway to 








The aim of this thesis was to demonstrate that leptin regulates glucose homeostasis via the canonical WNT 
pathway in the zebrafish. From an evolutionary perspective, zebrafish are much older than humans or 
mammalian animal models like mice and rats. Thus, by attempting to demonstrate this mechanism in 
zebrafish, we furthermore aimed to uncover the evolutionary origins of leptin’s physiological function. 
Therefore, it is important to place our findings in the context of the literature not only on mammalian and 
teleost leptin, but also on other animal species. In this chapter, it is first described how leptin regulates 
energy homeostasis throughout evolution. The data generated in this thesis is then discussed from an 
evolutionary point of view, initially examining the general role of leptin in the zebrafish, and subsequently 
focusing on how leptin and the canonical WNT pathway interact. 
7.1 Regulation of energy homeostasis by leptin throughout evolution 
The seminal paper reporting the positional cloning of the leptin gene contains a southern blot that strongly 
suggests that the leptin gene is evolutionary conserved (figure 7.1). However, it took more than a decade 
before the first non-mammalian leptin was cloned positionally. This was due to the low conservation in 
primary amino acid sequence between mammal and non-mammal leptin. Based on the principle of gene 
synteny, conservation of order, non-mammalian leptin was finally positionally cloned in 2005 in the 
Japanese Pufferfish (Takifugu rubripes). Today, leptin orthologues have been described in all classes of 
vertebrate animals, and even in evolutionary more distant species such as the fruit fly (Drosophila 
melanogaster). Non-mammal leptin studies still comprise only a tiny fraction (<2%) of the total research 
in this field. However, these studies are needed not only to answer comparative questions, but uncovering 
the evolutionary origins of leptin function will clarify our understanding of how this hormone works in the 
human body. 





7.1.1 Leptin in invertebrates 
A homeostatic circuit controlling energy homeostasis has been described in invertebrate species like 
Drosophila. In this insect, a functional analogue of the vertebrate adipose tissue, called the fat body, conveys 
the long-term energy status. Firstly, upon activation of the insulin-producing cells in the brain, Drosophila 
insulin-like peptides (DILPs) are secreted to regulate energy balance and promote systemic growth. 
Secondly, Unpaired 2 (Upd2), a protein that is structurally similar to vertebrate type 1 cytokines and 
activates the JAK/STAT pathway [380], is secreted by the fat body and activates a population of 
GABAergic neurons that project onto the insulin-producing cells in the brain, which results in DILPs 
Figure 7.1 Suggestion of evolutionary leptin conservation. The original southern blot from the seminal 
Zhang et al. (1994) paper that described the positional cloning of the leptin gene, showing cross-
species hybridization of ‘ob’. Genomic DNA from each of the species shown was blotted after EcoRI 
digestion and probed with ‘ob’ cDNA. Hybridization signals were detectable in every vertebrate 
sample, including in fish. Copied from Zhang et al. (1994) 




secretion. Disruption of Upd2 signalling in the fat body leads to altered energy homeostasis and reduced 
growth. Upd2 was thus identified as the Drosophila homolog of leptin. Convincingly, human leptin 
treatment rescues the phenotype found in Upd2 mutant flies [262]. A recent study following up on this 
finding reported that genetic knockdown of Upd2 mimics a starved-like state, again through innervation of 
DILP cells in the brain [381].  
Besides a leptin homologue, a leptin receptor homologue has been identified in the fruit fly as well. The 
Domeless (Dome) protein was shown to be essential for germline and follicle cell development via Upd 
and JAK/STAT signalling [382]. Furthermore, Upd has been shown to be enriched in the mushroom bodies, 
which form the memory center in Drosophila. In fact, its action on Dome in this brain area regulates memory 
[383]. Thus, fruit flies have a complete homologous leptin system, including leptin, a leptin receptor, 
JAK/STAT signalling and a feedback loop between the brain and the periphery. Molecular modelling shows 
that the Upd2 protein consists of four α-helices and 9 out of 20 amino acids contributing to leptin-LEPR 
interaction are conserved in Upd2. Structural alignment between Dome and LEPR reveals that the 7 
vertebrate motifs are all conserved to some degree in the fruit fly, including the amino acids essential for 
disulphide bond formation and the tyrosine residues [265]. Finally, in a local alignment search analysis, the 
same study showed that the Dome protein has homologs in 48 other invertebrate species.  
7.1.2 Leptin in fish  
Putative leptin sequences have been identified in the following bony fish species: 
Table 7.2 Overview of leptin paralogs in teleost fish. 
Name Latin name Paralogs Reference 
Japanese pufferfish Takifugu rubripes 1 [384] 
Striped bass Morone saxatilis 1 [385] 
Common carp Cyprinus carpio 4 [386] 
Rainbow trout Oncorhynchus mykiss 4 [344] 
Zebrafish Danio rerio 2 [264] 




Goldfish Carassius auratus 3 [387] 
Atlantic salmon Salmo salar 4 [388] 
Orange-spotted grouper Epinephelus coioides 2 [389] 
European eel Anguila 2 [390] 
Japanese eel Anguila japonica 2 [390] 
Japanese medaka Oryzias latipes 2 [391] 
Yellow catfish Pelteobagrus fulvidraco 1 [392] 
Nile tilapia Oreochromis niloticus 2 [393] 
Jian carp Cyprinus carpio var. Jian 4 [394] 
Arctic charr Salvelinus alpinus 1 [395] 
Grass carp Ctenopharyngodon idella 1 [345] 
Chub mackerel Scomber japonicus 2 [396] 
Mandarin fish Siniperca chuatsi 2 [397] 
White-clouds mountain minnow Tanichthys albonubes 2 [398] 
 
Conservation of amino acid identity compared to humans is low, varying between 13 and 25%. Even within 
the teleost lineage, there is often a low degree of primary sequence similarity (<50%). The majority of fish 
species investigated so far express more than one leptin protein. This is the result of a teleost-specific third 
whole genome duplication event [399]. Within the salmonid and cyprinid lineages, a fourth whole genome 
duplication event results in up to four leptin paralogs. Unlike Drosophila and mammals, where leptin is 
produced predominantly in adipose tissue, teleost fish have the highest expression levels of leptin in the 
liver. Conversely, the majority of tested fish species have low or non-detectable leptin expression levels in 
adipose tissue. Other tissues shown to express leptin mRNA in fish include the brain, gonads, muscle, heart 
and kidney [400]. However, a great degree of variability is found between species. In certain fish species, 
including the zebrafish, the distribution of expression between leptin paralogs differs. For example, leptin-
a.I and leptin-a.II are expressed predominantly in the liver of salmonids, whereas leptin-b.I and leptin-b.II 




are more prominent in the gonads and the heart [401]. Whether different leptin paralogs have different 
physiological functions is discussed in section 7.2.5.1. 
The original data described in this thesis, as well as previous studies [261, 309], show that leptin in fish 
regulates glucose homeostasis and not adipostasis. A comparison of leptin function between the three main 
animal models in biomedical research (mice/rat, zebrafish and fruit fly), shows that these animals have in 
common that leptin is essential for the regulation of glucose homeostasis (figure 7.2). Thus, from an 
evolutionary perspective leptin appears to have originated as a glucoregulatory hormone. This hypothesis 
is further supported by the limited number of studies on leptin in amphibians, reptiles and birds.  
 
Figure 7.2 Leptin function throughout evolution. Studies examining the control of energy and glucose homeostasis throughout 
animal kingdom indicate that leptin initially evolved as a glucoregulatory hormone, whereas its body weight regulatory function 
was acquired throughout evolution. Created with BioRender.com. 
 




7.1.3 Leptin in amphibians 
Amphibians are ectothermic, oviparous tetrapod vertebrates that are born in water. In the class of 
amphibians approximately 8000 species have been identified, 90% of which are in the order of Anura 
(frogs). The African clawed frog, Xenopus laevis, is a popular animal model in the field of developmental 
biology. Xenopus express a single leptin paralog, and a single leptin receptor [343]. Leptin and leptin 
receptor expression was explored using RT-qPCR. Leptin expression was highest in the brain, the heart, 
stomach, intestine, kidney and ovary. Leptin receptor expression was most highly expressed in the pituitary. 
Despite low amino acid sequence similarity between Xenopus and mammalian leptin (~35%), the frog 
protein has a highly conserved tertiary structure, and is able to activate the mouse leptin receptor in vitro. 
Interestingly, leptin treatment has acute anorexigenic effects on food intake, but only in frogs past the 
midprometamorphic stage. Before this stage, leptin is involved in growth and development of the hind 
limbs, thus showing that the role of leptin in Xenopus changes drastically over the course of development 
[343]. The role of leptin in growth and development was confirmed in studies showing that leptin stimulates 
Xenopus lung development [402], and induces mitosis in premetamorphic tadpoles, most likely via the 
canonical WNT pathway [347]. Amphibian leptin paralogs have furthermore been described in tiger 
salamander (Ambystoma tigrinum) [403] and spadefoot toad (Spea hammondii) [404]. Importantly, 
amphibian leptin has been shown to induce STAT3 and STAT5 signalling in several hypothalamic areas 
via conserved tyrosine residues in the cytoplasmic domain of LEPR [405], strongly suggesting that the 
intracellular signalling pathways and neural substrates that mediate leptin action are evolutionarily 
conserved. 
7.1.4 Leptin in reptiles 
Reptiles are poikilothermic, oviparous tetrapod vertebrates, characterized by a skin covered in scales. Little 
is known about leptin in the reptile class of animals. The first report on reptilian leptin described that 
injection of murine leptin in fence lizards (Sceloporus unulatus) decreases food intake and increased 




metabolic rate and body temperature compared to vehicle-treated lizards [339]. Unlike fish (zebrafish) and 
amphibians (Xenopus), there is no particularly popular research model amongst reptiles. The presence of 
leptin has been confirmed in various reptile species, including the Italian wall lizard (Podarcis sicula) [406], 
the hawksbill turtle (Eretmochelys imbriacata) [407] and green anole lizard (Anolis carolinensis) [263]. A 
recent study looked at the sensitivity to leptin of the immune system and the reproductive system in the 
green anole lizard. It was found that leptin treatment improved immune function, but not reproductive 
function, in calorie-restricted lizards [408], suggesting that limited energetic resources are allocated 
unevenly to different energy-requiring systems. No effects of leptin on adipostasis or glucose homeostasis 
were reported. Many reptiles undergo drastic seasonal changes in body weight associated with brumation 
and reproduction, which presumably requires a sophisticated lipostatic system. This makes these animals 
very interesting for the study of leptin. To date however, body weight regulation in reptiles remains a poorly 
studied area in the field of energy homeostasis. 
7.1.5 Leptin in birds 
Birds are endothermic, oviparous vertebrates, characterized by feathers, toothless beaked jaws and a strong 
yet lightweight skeleton. Of all vertebrate classes, leptin was the most difficult to identify in birds. 
Relatively soon after the molecular cloning of the mammalian leptin gene, a leptin gene in chickens was 
reported [409]. However, this turned out the be an artefact of wrongly designed primers [410]. It then took 
another 15 years before the elusive bird leptin was finely found in the rock dove (Columba livia) and 
Peregrine falcon (Falco peregrinus), within genomic regions that were difficult to characterize due to 
unusually high GC content and repetitive sequences [411, 412]. Developments in whole genome sequencing 
has recently allowed for the identification of leptin in a wide range of bird species. Using RNAseq, leptin 
in chicken was found to be highly expressed in the brain, more specifically in the hypothalamus, pituitary 
and cerebrum [413]. Moderate expression levels were found in the pancreas and testis. Importantly, 
expression levels in the adipose tissue and liver, typically high in other vertebrates, were relatively low. 
The distribution of LEPR expression was found to follow a highly similar pattern. This strong correlation 




between leptin and LEPR expression has led to the hypothesis that avian leptin acts not as an endocrine 
factor, but rather in a paracrine or autocrine manner. In line with this, bird blood was found unable to 
activate a sensitive chicken leptin receptor assay, even in species with high levels of adiposity like the 
Adelie penguin (Pygoscelis adeliae) [414]. On the other hand, one study documented nuclear translocation 
of GFP-labelled STAT3 in a similar chicken LEPR assay following incubation with chicken serum or crow 
blood [415]. However, the lack of major adipostatic genes like resistin and TNFα (in chickens), and ghrelin 
(in falcons), suggests that energy homeostasis works fundamentally different in birds compared to other 
vertebrates. Despite this, tertiary structure and intracellular signalling of avian leptin is evolutionarily 
conserved [411]. Many bird species undergo extreme changes in energy homeostasis on a yearly basis as 
part of their breeding and feeding cycle. For example, emperor penguins (Aptenodytes forsteri) lose more 
than half of their body mass during a 4-month fast during the breeding season [416], and the red knot 
(Calidris canutus piersmai) switches from utilizing protein stores to adipose stores during its 9000-
kilometer long migration flights [417]. Elucidating the mechanisms that enable these extreme adaptations 
may provide fascinating new insights into the regulation of energy homeostasis, but the involvement of 
leptin is likely to be limited. 
7.1.6 Synthesis 
Despite low primary sequence homology, the secondary and tertiary structure, and key amino acids required 
for leptin’s physiological activity, are evolutionarily conserved. All vertebrate leptins consist of two exons 
separated by a short intron. This sequence is translated into a protein containing four alpha helices, and 
contain a pair of cysteine residues that form a disulphide bridge between α-helices C and D. Moreover, 
three receptor interaction sites have been mapped, and each of these regions has found to show at least some 
degree of conservation of primary amino acid sequence (figure 7.3, figure 7.4). Regarding the leptin 
receptor, protein folding is preserved throughout evolution by conservation of seven linear motifs. 
Moreover, 16 conserved sites for posttranslational modification within the receptor have been reported. 
Thus, it can be concluded that the leptin system is evolutionarily well-conserved.    





Figure 7.3 Alignment of teleost leptin A (LepA) with the leptin homologs from other vertebrate classes. Accession numbers: tilapia 
LepA, AHL37667.1; zebrafish LepA, NP_001025357.2; salmon LepA, ACZ02412.1; fugu, NP_001027897.1; Xenopus, 
NP_001089183.1; falcon, NP_001298279.1; mouse, NP_032519.1; human, NP_000221.1. Shaded areas represent the conserved 
cysteine residues required for the formation of the disulphide bridge. The four alpha-helices are indicated by dashed lines within 
the parentheses. (Adapted from Deck et al., 2017) 
 





Figure 7.4 Alignment of teleost leptin B (LepB) with the leptin homologs from other vertebrate classes. Tilapia leptin A (LepA), 
has been included for comparison. Accession numbers: tilapia LepA, AHL37667.1; tilapia LepB, AHL37668.1; salmon LepB, 
NP_001266063.1; zebrafish LepB, NP_001025357.2; Xenopus, NP_001089183.1; falcon, NP_001298279.1; mouse, 
NP_032519.1; human, NP_000221.1. Shaded areas represent the conserved cysteine residues required for the formation of the 








7.2 Zebrafish as a model for the investigation of energy homeostasis 
Leptin is known mostly for its role in mammalian adipostasis. Humans with a genetic mutation that leads 
to leptin deficiency display a severely disrupted balance between energy intake and expenditure, leading to 
extreme obesity. Treating these people with leptin injections completely normalizes their food intake and 
energy balance [418]. Moreover, humans with obesity and/or type 2 diabetes are characterized by leptin 
resistance [419]. 
In a landmark study performed by Michel et al. it was shown that under normal feeding conditions, leptin 
only regulates glucose homeostasis but not adipostasis in zebrafish. We sought to investigate this further 
by exploring potential catabolic actions of leptin under overfeeding conditions. It has been shown that 
zebrafish become obese when they are exposed to an overfeeding regime, and they display metabolic 
alterations similar to DIO mammals, like hypertriglyceridemia, hepatic steatosis, and systemic 
inflammation [329]. Performing GTTs, under normal feeding conditions, we could confirm the results by 
Michel et al. Knockout of the leptin receptor impaired glucose tolerance but had no effect on body weight 
regulation in the zebrafish, as neither knockout of leptin-a or leptin-b did in fish fed normally. Intriguingly, 
overfeeding elicited an effect of leptin on body weight and standard length. Under these conditions ABz-
lepR-/- fish and ABz-lepA-/- fish had elevated body weight compared with ABz-lepB-/- fish and wild type 
zebrafish.  
The induction of obesity through diet in rodents is usually done by exposing them to a high fat diet, by 
changing the quality, rather than the quantity of the diet. An essential difference between rodents and 
zebrafish is that the former has permanently unrestricted access to food (i.e. ad libitum), whereas the latter 
is only exposed to food for a set number (usually three) of times per day. Rodent-style ad libitum feeding 
would not be feasible in the zebrafish, because these animals refuse to eat food pellets that have been in 
their tank water for longer than about 10 minutes. Commercial fish farms have solved this problem by using 
automated food dispensers [420]. However, despite a few exceptions [314] this feeding technique remains 




surprisingly unpopular within the zebrafish community. One manufacturer (Tecniplast) has developed an 
automatic feeding system for zebrafish that is capable of feeding both dry and liquid diets, adjusting the 
quantity for each tank. A state-of-the-art system like this would significantly improve the standardization 
of feeding experiments currently lacking for zebrafish. 
7.2.1 Obesity-inducing diets in zebrafish 
We induced obesity through diet in zebrafish by overfeeding fish according to previously established 
protocols [314, 329]. Other studies have recently started to investigate the effects of a high-fat diet in 
zebrafish. One study used a seven weeks-long dietary regime with a high fat diet consisting of normal food 
pellets enriched with 20% lard oil. This diet led to increased body weight, impaired glucose tolerance, and 
an osteoporosis-like phenotype in scales with increased tartrate-resistant acid phosphatase activity in 
osteoclasts [421]. Another study used the same 20% lard oil dietary enrichment for 11 weeks, albeit on a 
different type of zebrafish chow. High fat diet impaired cognition, as measured by active avoidance test, 
and RNAseq and qrtPCR revealed changes in gene expression similar to those found in mammals on a high 
fat diet. For example, genes related to anti-oxidative stress, blood-brain barrier function and degradation of 
amyloid β were found to be downregulated, whereas apoptosis-related gene expression was increased [422]. 
A third study supplemented a standard diet of flakes (instead of pellets used in the other studies) with 26% 
vegetable oil to establish a high fat diet. This diet was fed to adult zebrafish for 491 days. Consistently, 
high fat diet induced significant weight gain compared to a normal control diet. Additionally, various 
changes in the cardiac system were found. Trabecular thickness of the myocardium was increased, and the 
ventricle changed from a triangular into a more globular shape in high fat diet-fed fish [423]. Finally, 
another study created a high fat diet by enriching fish food pellets with 10% cocoa butter. 25-day exposure 
to this diet induced dysbiosis of the microbiome and intestinal inflammation compared to control diet-fed 
fish [424].  




 Together, these studies demonstrate that a high fat diet in zebrafish leads to impairments in cognitive, 
cardiac, intestinal and bone health. It has been well established that similar impairments are found in high 
fat diet-fed rodents [302], as well as in obese humans [4]. These studies further validate the zebrafish as a 
useful model to investigate energy homeostasis. However, the lack of a standardized high fat diet remains 
a point of attention that needs to be addressed by future studies.  
7.2.2 Metabolically healthy versus unhealthy obesity in zebrafish 
Some controversy exists over the question whether overfeeding, without changing the quality of the diet, 
leads to metabolic impairment. We found that overfeeding zebrafish with a combination of pellets and 
Artemia nauplii elevated body weight, and impaired glucose tolerance. The changes in body size do not 
necessarily reflect metabolic impairment, as somatic growth per se is likely to be beneficial instead of 
detrimental in fish. The landmark study that established the zebrafish as a model of diet-induce obesity 
showed that overfeeding zebrafish with Artemia nauplii not only increased body weight and body length, 
but also leads to hypertriglyceridemia, hepatic steatosis, and alterations in intracellular signalling cascades 
involved in lipid metabolism. Moreover, these symptoms were ameliorated by caloric restriction [329]. A 
follow up study from the same lab subsequently showed that overfeeding zebrafish with food pellets also 
impaired glucose tolerance, and gene-set enrichment analysis identified similarities between overfed 
zebrafish and type 2 diabetic humans in gene sets related to immune response, nervous system, and 
vascularization [314]. Thus, these studies suggest that overfeeding per se does impair metabolic health. On 
the other hand, one study compared the effects of short-term overfeeding with a normal or a high-fat diet 
as a model for the development of metabolically health versus unhealthy obesity [348]. Using a combination 
of Artemia nauplii and egg yolk powder to mimic a high-fat diet, it was found that, in contrast to normal 
diet-overfed fish, high-fat diet-overfed fish presented hyperglycaemia, hepatic steatosis and increased 
expression of inflammatory markers. No effect of diet quality was found on body weight or body length. 
The wide variety of different high-fat enrichments to already different standard diets makes it very hard to 




interpret these discrepancies. Moreover, because this study did not include a group of normal-fed fish, no 
firm conclusions can be drawn about the effect of overfeeding with a standard diet. Peculiarly, the normal 
diet-overfeeding regime in this study was identical to the Oka paper (5mg dry weight/day/fish of Artemia 
nauplii, for 8 weeks), yet one reported impaired metabolic health where the other does not. A systemic, 
longitudinal comparison of the various methods to induce obesity through diet is warranted to understand 
whether overfeeding per se impair metabolic health. 
7.2.3 Density effects 
While raising these fish, we took great care to prevent any tank density effects on body weight, which have 
been shown to affect postembryonic development, somatic growth and fat accumulation [333]. Previous 
studies on teleost leptin knockout models have yielded contradicting results, with one study convincingly 
disproving a role for leptin as an adipostat in the zebrafish [261], whereas others reported an effect of leptin 
on adipostasis in zebrafish [324] or medaka [323]. In the Michel et al. study, fish were kept at the same 
density across experimental groups for half a year, scoring weight and standard length at various time 
points. Feeding the fish a normal diet, no effect of leptin on body weight or body length was found at any 
time point. The other two studies, however, do not report such an approach. The Chisada et al. study 
reported a 1.6- to twofold increase in post-juvenile body weight in leptin receptor knockout fish, although 
juvenile and adult body weight were unchanged. In regards to adiposity, a small increase in visceral fat was 
found, but the authors were unable to detect changes in liver, muscle, or plasma triacylglycerol level. 
Likewise, the Audira et al. study reports that zebrafish carrying a mutated leptin-a gene display elevated 
adiposity, as well as a wide range of (seemingly unrelated) behavioural changes, including colour 
preference dysregulation and decreased aggression. Because neither of these latter two studies reports on 
tank densities, it cannot be excluded that the effects of leptin on body weight reported in these studies have 
been confounded by tank density effects. In accordance with the Michel et al. study, our own data show 




that at identical tank density and under normal feeding conditions, manipulation of the leptin system has no 
effect on body weight or body length.  
7.2.4 Glucose homeostasis and diabetes 
Long before fish were established as a model of diet-induced obesity, they were already used to model 
diabetes. In the early 90’s gobies (Gillichthys mirablis) underwent surgical removal of the pancreatic 
endocrine islet to induce an insulin-dependent diabetic phenotype [425]. Because of their remarkable 
regenerative capacities, ablation of the pancreatic β-cells is rather challenging in zebrafish [306]. However, 
the zebrafish model offers a unique advantage over rodent models when it comes to investigating glucose 
homeostasis: hyperglycaemia can be induced not only acutely, through IP injection of a glucose bolus for 
subsequent glucose tolerance testing, but also persistently. Because of its ability to readily absorb molecules 
from the surrounding water, compound exposure is relatively straightforward in the zebrafish. We took 
advantage of this by immersing fish in a 1% glucose solution to induce a persistent hyperglycaemic 
challenge. This procedure has previously been shown to readily induce hyperglycaemia over time, leading 
to retinopathy and increased glycosylated haemoglobin [426]. In line with these previous observations, 
glucose levels were significantly elevated after two days of immersion and continued to rise steadily at a 
rate of about 15-20mg/dl/day. In addition to this model of persistent hyperglycaemia, we also established a 
protocol for ipGTTs in zebrafish to induce an acute hyperglycaemic challenge.  
7.2.5 Paralog- and sex differences 
7.2.5.1 Leptin-a vs leptin-b 
The difference in body weight between leptin-a knockout zebrafish and leptin-b knockout zebrafish 
following an overfeeding regime suggests that these paralogues play different roles. The existence of 
multiple leptin paralogues offers a fascinating example of the consequences of genome duplication. After 
teleosts and tetrapods diverged evolutionarily, the bony fish underwent a third whole genome duplication 
event [427]. As a result, tetrapods and their closest living relatives express only one leptin gene. The only 




known exception is the Anolis lizard (Anolis carolinensis), whose genome contains two leptin genes, one 
of which is not expressed [263]. Bony fish on the other hand, typically express two leptin paralogs, which 
are referred to as leptin-a and leptin-b. The presence of a second leptin paralog in the majority of teleost 
species suggests that each paralog has a distinct function. However, the specific roles of these paralogs 
remain largely unknown.  
We found that leptin-a, but not leptin-b, plays a role in the regulation of body weight and body size when 
fish are overfed. Furthermore, ABz-lepA-/- fish displayed consistently higher blood glucose levels following 
both an acute and a persistent hyperglycaemic challenge when compared to ABz-lepB-/- fish. In accordance, 
it has been shown that knockout of leptin-a, but not leptin-b, leads to an increase in the number of pancreatic 
β-cells in zebrafish larvae [261]. Tissue distribution studies show that in teleost fish, usually one leptin 
paralog is expressed at higher message copies and with a more narrow distribution compared to the other 
paralog [264, 428]. Furthermore, in silico binding simulation of zebrafish leptin-a and leptin-b predicts 
significantly lower binding energy to the leptin receptor for leptin-b [429]. Thus, it appears that leptin-a 
functionally resembles mammalian leptin, whereas leptin-b appears to have a different function. One 
explanation would be that leptin-b acts not as an endocrine factor, but rather in an autocrine or paracrine 
manner. A similar hypothesis has been proposed for avian leptin [430]. In accordance, transcriptomic 
analyses show that leptin-b is highly induced during tissue regeneration in the heart and fins of zebrafish. 
This is enabled by a short DNA sequence element upstream of the leptin-b gene, which regulates injury-
dependent expression from minimal promotors [431]. Likewise, a study investigating Müller glial cell-
mediated regeneration in the zebrafish retina found that leptin-b expression is increased up to tenfold 
following lesion of the retina [432]. Interestingly, mammalian leptin has been implicated in Müller glial 
cell-mediated regeneration of the retina too, through synergy with IL6 family cytokines [433]. Thus, it 
appears that after the teleost leptin gene was duplicated, the two paralogs diverged functionally and each 
took one some functions of the original leptin. Leptin-a primarily exerts the metabolic effects described in 
mammalian leptin, whereas leptin-b is involved more in tissue regeneration.   




7.2.5.2 Males vs females 
We found that in the artificially-induced hyperglycaemia experiments, male and female fish were affected 
identically. This is surprising because in humans and other mammals, fundamental anatomical and 
physiological differences between males and females lead to a partially differential regulation of energy 
homeostasis. For example, women have more adipose mass with corresponding higher leptin levels, and 
higher levels of circulating free fatty acids compared to men, whereas men have more skeletal muscle mass. 
The prevalent hypothesis is that these differences arose because only females have to bear the energetic 
burden of pregnancy and lactation [434]. Whereas humans and other mammals are viviparous, fish are 
oviparous. Although laying eggs is energetically still more costly than producing sperm, it is significantly 
less energetically demanding than pregnancy and lactation. This makes the zebrafish an interesting animal 
model to explore the sex differences in energy homeostasis. In our glucose immersion experiments, we 
found that both the rate at which hyperglycaemia was induced, and the potency of leptin to reduce 
hyperglycaemia was identical in male and females. These data suggest that in the zebrafish, leptin acts 
sexually monomorphic. Conversely, the brains of female rats are more sensitive to the catabolic actions of 
ICV injected leptin than those of age- and weight-matched males [435].  
  




7.3 The role of leptin in energy homeostasis of zebrafish 
We set out to investigate how leptin regulates glucose homeostasis in the zebrafish, and confirmed previous 
work showing that under normal feeding conditions leptin regulates glucose homeostasis. Unexpectedly, 
we found that overfeeding zebrafish reveals an effect of leptin on the regulation of body weight and body 
length. Thus, we demonstrate here that the function of leptin changes depending on nutrient availability. 
7.3.1 Normal feeding conditions: leptin regulates glucose homeostasis 
After confirming that manipulation of the leptin system does not alter body weight or body length under 
normal feeding conditions, we tested whether leptin can ameliorate a persistent state of artificially induced 
hyperglycaemia. Leptin administration on the third day of a four-day 1% glucose immersion consistently 
reduced glucose levels in wild type, ABz-lepA-/- and ABz-lepB-/-, but not in ABz-lepR-/- fish, confirming that 
the glucose-lowering properties of leptin are mediated by the receptor. This is further substantiated by the 
fact that glucose levels in the 1% glucose-vehicle treated fish were higher after 3 days of immersion in ABz-
lepR-/- fish compared not only to wild type fish but also to ABz-lepA-/- and ABz-lepB-/- fish. The elevated 
glucose levels in ABz-lepR-/- fish compared with ABz-lepA-/- and ABz-lepB-/- fish suggests that KO of only 
one of the two leptin paralogs is not sufficient to induce hyperglycaemia, but loss of effect of both variants 
at leptin receptor level is required to reveal the full phenotype. Consistently, our ipGTT data show a 
stepwise impairment in glucose tolerance, with values in ABz-lepB-/- fish almost identical to wild type 
controls, ABz-lepA-/- fish having consistently higher (though not significantly) blood glucose levels than 
ABz-lepB-/- fish and wild type controls, and ABz-lepR-/- fish having significantly impaired glucose tolerance. 
In hindsight, it would have been useful to create a double knockout of both leptin-a and leptin-b. We 
hypothesize that the phenotype in this double knockout would be equal that of ABz-lepR-/- fish. 
7.3.2 Nutrient excess: leptin regulates body weight and body length 
We exposed fish to a six-week long overfeeding regime to assess the effect of diet-induced obesity on 
glucose homeostasis. Consistent with previous studies [314], overfeeding per se led to glucose intolerance 




in fish independent of genotype. This suggests that this treatment maximally impairs the glucoregulatory 
system as loss of leptin function in addition to overfeeding does not increase glucose intolerance further. 
Fascinatingly, overfeeding elicited an effect of leptin on the regulation of body weight and body length. At 
the end of the six-week overfeeding period, ABz-lepA-/- and ABz-lepR-/- fish had significantly increased 
body weight compared to ABz-lepB-/- fish and wild type controls. This increase in body weight was 
accompanied by an increase in body length. These data point towards a role for leptin in the regulation of 
somatic growth during times of nutrient excess. Importantly, only one paralog, leptin- a, appears to be 
involved.  
In accordance, one recent study could show that overfeeding in zebrafish larvae leads to leptin resistance 
and reduced hypothalamic pomca levels, subsequently leading to activation of the melanocortin system, 
elevation of growth hormone levels, and enhanced somatic growth [436]. The authors argue that leptin 
resistance may represent an ancient mechanism to ‘seize the opportunity’ and promote somatic growth 
when food resources are abundant. This mechanism is like to have been lost during the evolutionary 
transition from water to land. Most aquatic species continue to grow somatically throughout life, whereas 
growth in terrestrial animals usually reaches a plateau due to gravity limitations. Because somatic growth 
limits movement much less in the water than on land, an adipostatic role of leptin may not be as critical as 
in terrestrial species. This is in line with the recent discovery of the gravitostat in mammals [437]. This 
system has been shown to regulate fat mass in obese mice independently of leptin, whereas leptin-mediated 
regulation of fat mass seems to be limited to healthy lean mice [438]. 
  




7.3.3 Implications for the evolution of the leptin system 
The initial and still prevalent view on the physiological purpose of leptin, as recounted in the majority of 
textbooks and reviews [439] is essentially as follows:  
 
 
Figure 7.5 Classic model of leptin and the regulation of energy balance. “Leptin is the afferent signal in a negative feedback loop 
that maintains homeostatic control of adipose mass. It circulates in the blood and acts on the brain to regulate food intake. When 
fat mass falls, plasma leptin concentrations fall too, stimulating appetite and suppressing energy expenditure until fat mass is 
restored. When fat mass increases, leptin levels increase, suppressing appetite until weight is lost. This system maintains 
homeostatic control of adipose tissue mass. Leptin acts on a receptor localized in the hypothalamus, and elsewhere in brain, to 
regulate energy balance and other systems. Leptin thus conveys nutritional information to specific neural populations in the brain, 
which in turn regulate most, and perhaps all, other physiological systems. This homeostatic system enables mammalian organisms 
to maintain optimal levels of stored energy (fat) under a wide range of environmental conditions”. Copied from Friedman (2010). 
 
According to this adipostatic model, the main function of leptin is to promote leanness, hence its name from 
the Greek ‘λεπτός’ (= leptos, meaning ‘thin’). Fish do not fit the adipostat model of leptin. The anorexigenic 
actions of leptin have been described in fish [344], amphibians [343], reptiles [339], birds [342] and 
mammals [198]. However, leptin in mammals is expressed mainly in the adipose tissue and circulates in 




proportion to the amount of adipose tissue. In fish on the other hand, leptin is expressed primarily in the 
liver, and not the adipose tissue [264, 384]. Moreover, leptin levels in fish do not circulate proportionally 
to fat stores. Instead, rather than decreasing upon depletion of adipose stores, plasma leptin levels 
consistently increase with fasting [440, 441]. According to the adipostat model, knockout of leptin or its 
receptor should result in obesity. This is indeed the case for mammals, but our data demonstrate that it is 
not the case for zebrafish. Instead, we found that the glucoregulatory actions of leptin have been conserved 
throughout evolution. Therefore, we propose that leptin originated as a glucoregulatory hormone, and that 
the adipostatic function of leptin found in mammals has been acquired somewhere over the course of 
evolution. Whether leptin in zebrafish serves as a glucostat remains to be elucidated (figure 7.6). Especially, 
it is not known whether circulating leptin levels correspond to the amount of glycogen stored in the liver. 
Figure 7.6 A hypothetical glucostat model for leptin action in the zebrafish. Leptin is produced mainly in the liver. When hepatic 
glycogen stores drop, plasma leptin concentrations drop as well, thereby promoting appetite and decreasing energy expenditure 
until glucose homeostasis is restored. Leptin acts on the leptin receptor, located primarily in the hypothalamus, to regulate energy 
balance and other systems. Thus, leptin conveys nutritional information to specific neural subpopulations in the brain, which in 
turn regulate a wide range of physiological systems. This homeostatic system enables the zebrafish to maintain optimal levels of 
stored energy (glycogen) under a wide range of environmental conditions. Figure generated in Biorender. 




Despite a lack of evidence for an adipostatic role of leptin, we also found that leptin is involved in the 
regulation of body weight and body length, but only in times of nutrients excess. This offers fascinating 
insights in the evolution of the leptin system. From an evolutionary perspective, it seems that promoting 
energy storage in response to food intake would actually oppose the function of leptin, which acts to limit 
food intake and the storage of energy. In other words, an effective leptin system would reduce survival 
during times of limited food availability. In this case, leptin would most likely be selected against 
throughout evolution. Leptin resistance offers an answer to this evolutionary dilemma. A thrifty genotype 
would arise if the leptin system can be temporarily disabled, as in leptin resistance. In accordance, 
heterozygous Lepob/+ mice have higher survival rates following starvation compared to wild type controls 
[196, 442]. We found that ABz-lepA-/- fish and ABz-lepR-/- fish gain more weight and have increased body 
length in times of nutrient excess. Thus, our data fit the hypothesis that leptin resistance evolved in order 
to limit the ability of leptin to inhibit food intake during periods of abundant nutrient availability.  
7.4 WNT pathway-mediated glucoregulation by leptin 
The canonical WNT pathway has been shown to be activated by glucose in a macrophage cell line [366]. 
In mice, we previously demonstrated that WNT signalling in the hypothalamus is impaired during obesity 
and reinstated by leptin treatment [258]. In this thesis, we took advantage of the optical transparency of 
zebrafish larvae to provide the first in vivo evidence of canonical WNT pathway activation by leptin. Using 
LiCl as a positive control, we found that leptin-induced TCF activation was especially prominent in the 
hypothalamic region in the brain of zebrafish larvae. Intriguingly, CRISPR-mediated knockout of the leptin 
receptor totally abolished this activation, suggesting that leptin activation of the WNT pathway is solely 
mediated by the leptin receptor. Leptin receptor expression in the zebrafish is found not only in the 
hypothalamus, but also in a variety of peripheral organs, including the eye, gut, liver, pancreas, and heart 
[443]. Another region that showed high intensity of TCF fluorescence after WNT activation by LiCl was 
the heart. However, leptin did not significantly induce TCF fluorescence in the heart. 




7.4.1 Leptin-mediated WNT pathway activation in adults 
Leptin induces mitosis via the canonical WNT pathway in the brain of developing Xenopus tadpoles [347]. 
To demonstrate that the activation of canonical WNT signalling by leptin is not limited to embryogenesis, 
we treated adult Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 fish with leptin or LiCl. Expression of an older, less 
sensitive WNT reporter construct (TOP:GFP), was limited to the optic tectum and the hypothalamus of 
adult zebrafish [231]. We found that activation of the WNT pathway with LiCl leads to widespread 
expression of the fluorescent construct throughout the brain. Leptin receptor expression in the adult 
zebrafish has been reported in the hindbrain and several hypothalamic regions, including the lateral tuberal 
nucleus (the fish homologue of the arcuate nucleus) [443]. Surprisingly, we observed leptin-induced WNT 
pathway activation throughout the brain, including in areas that have not been described to express the 
leptin receptor, like the optic tectum for example. One explanation would be that the brain-wide staining 
represents endothelial cells of the vascular network, as it has been shown that these cells can display 
canonical WNT pathway activity [358]. Whether these cells express the leptin receptor, or whether leptin 
activates the WNT pathway in these cells via a second-order mechanism remains to be elucidated by 
colocalization experiments.  
7.4.2 WNT-mediated glucoregulation 
We could demonstrate that pharmacological inhibition of the WNT pathway blocks the ability of leptin to 
lower blood glucose levels both during acute and persistent hyperglycaemia, suggesting that leptin regulates 
glucose homeostasis predominantly via the WNT pathway. An antidiabetic action upon activation of the 
WNT pathway has been confirmed for LiCl treatment, which has been shown to attenuate non-fasting blood 
glucose levels in diabetic Lepob/ob BTBR T+ Itpr3tf/J (BTBR) mice [444]. In accordance, we can show that 
LiCl treatment improves glucose tolerance and normalizes blood glucose levels during a persistent 
hyperglycaemic challenge in zebrafish. Activation of the WNT pathway with LiCl improved glucose 
homeostasis, even in leptin- or leptin receptor deficient fish, suggesting that LiCl acts independently of 




leptin and that leptin acts upstream of the canonical WNT signalling cascade. Together, these data provide 
solid evidence that the WNT pathway is a leptin signal transduction pathway and that leptin regulates 
glucose homeostasis through this pathway. 
We could previously show that leptin induces phosphorylation of LRP6 in the arcuate nucleus of the 
Djungarian hamster [351]. It is therefore likely that leptin activates the canonical WNT pathway at the level 
of the WNT receptor and LRP5/6 co-receptor. Interestingly, LRP6+/- mice have upregulated leptin receptor 
gene expression and lower body fat content, despite plasma leptin levels not being significantly different 
compared to wild type mice [445]. Furthermore, these mice exhibited reduced endogenous hepatic glucose 
output, due to diminished glucose-6-phophatase (G6pase). Another study showed that TCF7l2 gene 
expression is reduced Lepdb/db and high fat diet-induced obese mice [446]. These data are in accordance 
with previous work showing that canonical WNT signalling is involved in the regulation of hepatic 
metabolism [447, 448]. In conclusion, the liver appears to be a key player in WNT pathway-mediated 
control of energy homeostasis.  
  




7.5 Implications for human health 
Genome wide association studies indicated the WNT transcription factor TCF7l2 to be the highest genetic 
risk factor for developing T2DM [216, 236]. Curiously, subsequent studies investigating the link between 
WNT signalling and T2DM focused largely on the insulin-producing pancreatic β-cells, despite evidence 
that canonical WNT signalling is not active in adult β-cells of mice [242] and zebrafish [309]. Our data 
suggest that the association between TCF7l2 and T2DM is mediated through the leptin system. 
This raises the question of whether the canonical WNT pathway can be targeted to treat T2DM. Because 
this pathway is involved in a wide variety of physiological processes, including embryogenesis, cell 
proliferation and differentiation, apoptosis and maintenance of pluripotency of stem cells, dysregulation is 
associated with a multitude of diseases. These include, but are not limited to, cancer [256], neurological 
diseases [449], osteoporosis [450], fibrosis [451], rheumatoid arthritis [452] and T2DM [453]. This both 
incentivizes and complicates the search for effective and safe therapeutic agents specifically targeting the 
WNT pathway.  
Therapeutically targeting the WNT pathway has enormous potential, and many compounds have been 
developed to this end. Pyrvinium pamoate for example, which has also been used successfully as an 
anthelmintic effective for pinworms [454], has been shown to have some antitumor activity in a cancer cell 
culture system [372]. However, targeting a pathway as fundamental as the WNT pathway comes with a 
number of issues. Because this pathway is essential for embryogenesis, targeting it can have devastating 
effects on the developing foetus, as evidenced by the severely shortening of limbs in children whose 
mothers were treated with the WNT pathway antagonist Thalidomide [455]. Vismodegib, an antagonist of 
the developmentally equally important Hedgehog signalling pathway, has been approved for the treatment 
of certain tumours, but is associated with a wide range of adverse side effects, including alopecia, dysgeusia, 
weight loss and muscle spasms [456]. To date, no compounds targeting the WNT pathway have been 
clinically approved, but if this will ever become the case, similar side effects can be anticipated. 




Another challenge is the fact that the choice of activating or inhibiting the WNT pathway to improve health 
is not straightforward. Inhibition of the WNT pathway is generally thought to improve oncological 
malignancies [457], even though there is no correlation between upregulated WNT signalling and patient 
survival [256]. In regards to the glucoregulatory actions of WNT signalling, our data suggest that increasing 
WNT signalling with lithium can improve glucose tolerance and ameliorate hyperglycaemia. Interestingly, 
lithium is one of the most widely prescribed therapies to treat bipolar disorder [458]. Here too, however, 
various adverse side effects are often found, the most common of which is kidney problems [459]. It is 
clear that targeting the WNT pathway for therapeutic purposes is extremely complicated. Various 
compounds have entered clinical trials, and promising data has been obtained in several tumour models 
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1. Additional CRISPR/Cas9 mutagenesis information 
1.1 Confirmation of successful Cas9 mRNA in vitro transcription 
 
Figure 11 Confirmation of successful Cas9 mRNA in vitro transcription. Upper: Agarose gel showing successful Cas9 digestion. 
Middle: Agarose gel showing successful Cas9 mRNA transcription. Lower: Nanodrop quantification of Cas9 mRNA. 




1.2 Confirmation of successful in vitro transcription of leptin-a and leptin-b sgRNA’s 
  
Figure 12 Confirmation of successful Cas9 mRNA in vitro transcription. Upper: Agarose gel showing successful assembly of 
DNA templates for leptin-a and leptin-b target strands. Middle: Agarose gel showing successful leptin-a and leptin-b sgRNA 
transcription. Lower: Nanodrop quantification of leptin-a and leptin-b sgRNA. 
 




1.3 Confirmation of successful in vitro transcription of leptin receptor sgRNA 
 
Figure 13 Confirmation of successful Cas9 mRNA in vitro transcription. Upper: Agarose gel showing successful assembly of DNA 
templates for leptin receptor target strand. Middle: Agarose gel showing successful leptin receptor sgRNA transcription. Lower: 
Nanodrop quantification of leptin receptor sgRNA. 




2. PCR plots of founder fish – raw data 
2.1 Leptin-a male 
 
2.2 Leptin-a female 
 




2.3 Leptin-b male 
 
 
2.4 Leptin-b female 
 





2.5 Leptin receptor male  
 
 
2.6 Leptin receptor female 
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Leptin is a body weight regulatory hormone, but it is arguably even more potent at regulating blood glucose 
levels. The molecular mechanism by which leptin controls glucose homeostasis remains largely unknown. 
To further our understanding, we use a transgenic zebrafish model and conditional deletion of beta catenin 
in the mediobasal hypothalamus of adult mice to show that Wnt signalling mediates glucoregulatory effects 
of leptin. In zebrafish, under normal feeding conditions, leptin regulates glucose homeostasis but not 
adipostasis. In times of nutrient excess, we found that leptin also regulates body weight and size in this 
species. Using a Wnt signalling reporter fish, we show that leptin directly activates the canonical Wnt 
pathway in vivo. Pharmacological inhibition of this pathway prevented the leptin-induced improvement in 
glucose tolerance. In adult mice, conditional deletion of the key Wnt effector molecule, β-catenin, in the 
mediobasal hypothalamus of male mice confirmed the essential role of the Wnt pathway in mediating leptin 
action and neuroendocrine regulation of glucose homeostasis. Adult-onset β-catenin deletion in the 
mediobasal hypothalamus led to glucose intolerance, high fat diet-induced exacerbation of body weight 
gain and caloric intake as well as resistance to exogenous leptin. 
Keywords: leptin, Wnt, glucose homeostasis, zebrafish, TCF7l2, beta catenin 










The hormone leptin is known for its role in regulating food intake, autonomic outflow, and endocrine 
function to maintain energy balance. Although leptin is the primary adipostatic factor in mammals, it has 
been well established that leptin can affect glucose homeostasis, independent of its adipostatic actions [1-
5]. This is supported by the following key observations. First, leptin is more potent at regulating glucose 
levels in blood than it is at suppressing appetite [6]. Second, acute disruption of leptin action in vivo raises 
blood glucose and plasma insulin levels before effects on body weight become apparent, and treatment with 
leptin in leptin-deficient Lepob/ob mice corrects glucose levels before body mass [7]. Third, Lepob/ob and 
leptin receptor-deficient Leprdb/db mice become hyperinsulinemic before they become obese [8]. Fourth, 
humans who suffer from lipodystrophy, and rodent models of this disease, characterized by very low body 
fat and leptin levels, exhibit hyperglycaemia, hyperinsulinemia and insulin resistance. All of these 
symptoms are corrected by leptin therapy [9, 10], which received  approval by the FDA for this treatment 
purpose [11].  
Leptin signalling is evolutionarily well-conserved. Homologues for leptin and the leptin receptor are present 
even in invertebrate species like Drosophila melanogaster [12]. Although leptin from species of different 
animal classes have low primary sequence homology, the secondary, tertiary, and quaternary structure, as 
well as key amino acids required for leptin’s physiological activity, are evolutionarily conserved [13]. 
Zebrafish (Danio rerio) express two leptin paralogs: leptin-a and leptin-b [14]. Both, like all vertebrate 
leptin paralogs, consist of four alpha helices, and contain a pair of cysteine residues that form a disulphide 
bridge. Three receptor interaction sites have been mapped, and each of these has at least some degree of 
amino acid sequence conservation [15].  
Despite the conservation between species, it has been reported that leptin does not mediate adipostasis in 
zebrafish, but instead has an essential role in regulation of glucose homeostasis. Loss of the zebrafish leptin 
receptor leads to an increase in the number of pancreatic β-cells and elevated levels of insulin mRNA in 




larvae. However, adipostasis, food intake and fertility remain unchanged [16]. These data suggest that the 
glucoregulatory actions of leptin may, in fact, be the evolutionarily earlier function, with adipostasis added 
in higher vertebrates. 
The most extensively studied leptin signalling pathway is the janus kinase 2 – signal transducer and 
activator of transcription 3 (JAK2-STAT3) pathway, which mediates most of the metabolic effects of leptin. 
While clear evidence suggests regulation of body weight and food intake by leptin is mediated by the JAK2-
STAT3 pathway [17-20], evidence for the involvement of this pathway in the glucoregulatory actions of 
leptin is scarce [21, 22]. It seems more likely that alternative pathways are mediating this effect. Indeed, 
leptin has been shown to directly regulate insulin sensitivity via the insulin receptor substrate - 
phosphoinositide 3-kinase – protein kinase B (IRS-PI3K-AKT) pathway [23].  
Genome-wide association studies (GWAS’s) identified that polymorphisms in several genes of the 
canonical Wnt pathway increase the risk of type 2 diabetes (T2DM) [24-26]. Specifically, polymorphisms 
in the transcription factor 7-like 2 (TCF7l2) gene, which encodes a transcription factor of the canonical 
Wnt pathway, convey the single largest genetic risk for T2DM [27]. The canonical Wnt pathway, known 
mostly for its role in embryogenesis and tumour formation, is activated when a Wnt ligand binds to the 
frizzled (Fzd) receptor, which subsequently forms a complex with the co-receptor lipoprotein related 
protein (LRP) 5/6. This causes dishevelled (Dvl) to phosphorylate LRP, which then inactivates glycogen 
synthase kinase 3β (GSK3β). GSK3β inactivation decreases phosphorylation of the transcriptional co-
activator β-catenin. Stabilized β-catenin then enters the nucleus where it associates with transcription 
factors of the lymphoid enhancer factor (LEF)/T cell factor (TCF) family, to ultimately regulate the 
transcription of downstream target genes [28]. Although canonical Wnt signalling has been studied 
extensively in the contexts of embryonic development and tumorigenesis, much less is known about its role 
in energy homeostasis [29]. Our laboratory showed that canonical Wnt signalling, specifically in the 
hypothalamus, is impaired during obesity and reinstated by leptin treatment [30]. Furthermore, we showed 




that GSK3β action specifically in the hypothalamus appears essential for glucose homeostasis. Lepob/ob mice 
were found to have elevated levels of active hypothalamic GSK3β, and glucose intolerance in these mice 
was acutely ameliorated by intracerebroventricular injection of a GSK3β inhibitor [31]. In the present study, 
we hypothesize that leptin regulates glucose homeostasis via the canonical Wnt pathway.  
To test this hypothesis, we created CRISPR-mediated leptin- and leptin receptor-deficient zebrafish to 
confirm, as reported previously [16], under normal feeding conditions leptin regulates glucose homeostasis 
but not adipostasis, although we found that in times of nutrient excess leptin also regulates body size. Using 
a transgenic Wnt-reporter zebrafish line we identify that leptin activates canonical Wnt signalling mediated 
via the leptin receptor and that the glucoregulatory action of leptin is mediated through this pathway. Having 
found that leptin acts through the Wnt pathway in zebrafish, we tested whether this action is preserved in 
mammals. Conditional ablation of β-catenin in the mediobasal hypothalamus of adult mice lead to increased 
weight gain on a high-fat diet, confirming the essential role of the canonical Wnt pathway for mediating 
leptin action and its essential role for the neuroendocrine regulation of glucose homeostasis.  





Leptin activates the canonical Wnt pathway in vivo 
To investigate whether leptin activates the canonical Wnt pathway, we used a transgenic zebrafish line 
(Tg(7xTCF-Xla.Siam:nlsmCherry)ia5) that sensitively detects translocation of the TCF7l2-β-catenin 
complex into the nucleus, thereby indicating canonical Wnt pathway activity [32]. Because the Wnt 
pathway is markedly involved in embryonic patterning, we first established that at 5 days post fertilization 
(dpf), the developmental Wnt pathway activity has subsided to a level where it is mostly confined to the 
heart (figure 1A). This developmental stage can be readily defined as it is characterized by the protrusion 
of the first teeth, which is clearly visible in Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 larvae. The canonical Wnt 
pathway can be pharmacologically activated with lithium chloride (LiCl), which inhibits GSK3β [33], or 
inhibited with pyrvinium pamoate or PNU74654. Pyrvinium pamoate is an anti-helminthic drug that 
potentiates the activity of casein kinase 1α (CK1α), leading to enhanced degradation of β-catenin [34]. 
PNU74654 disrupts the interaction between β-catenin and TCF/LEF transcription factors [35]. We 
demonstrated that pharmacological activation or inhibition of the canonical Wnt pathway reliably increases 
or decreases the fluorescent signal in Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 larvae (figure 1B, C). Strikingly, 
recombinant mouse leptin appeared to be efficacious in zebrafish, and treating 5 dpf Tg(7xTCF-
Xla.Siam:nlsmCherry)ia5 larvae with leptin (100nM) for 2 hours led to robust activation of the fluorescent 
construct (figure 2D). Quantitation of Wnt reporter read-out in the hypothalamus (figure 2E), compared 
with the heart (figure 2F) determined that leptin activates the Wnt pathway specifically in the hypothalamus. 
In the hypothalamus, leptin increased fluorescence intensity significantly compared with vehicle-treated 
larvae, whereas in the heart leptin did not significantly increase fluorescence intensity. 





Figure 1 Wnt pathway activation by leptin in Tg(7xTCFXla.Siam:nlsmCherry)ia5 larvae.  
 
(A) 5dpf Tg(7xTCFXla.Siam:nlsm Cherry)ia5 larvae treated with vehicle (Cortland salt solution). Left: bright field image, with 
anatomical landmarks encircled; Middle: Epifluorescence image, with white arrow indicating teeth protrusion; Right: 
Magnification of yellow box in middle image, with hypothalamus and heart encircled. Scale bar = 500μM. (B) 5dpf 
Tg(7xTCFXla.Siam:nlsm Cherry)ia5 larvae treated with 10μM LiCl for 2 hours. (C) 5dpf Tg(7xTCFXla.Siam:nlsm Cherry)ia5 larvae 
treated with 10μM PNU74654 for 2 hours. (D) 5dpf Tg(7xTCFXla.Siam:nlsm Cherry)ia5 larvae treated with 100nM recombinant 
leptin for 2 hours. (E) Fluorescence intensity in the hypothalamus of differentially treated 5dpf Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 
larvae. A-B=P<0.05, one-way ANOVA. (F) Fluorescence intensity in the heart of differentially treated 5dpf Tg(7xTCF-

































































































Leptin treatment ameliorates hyperglycaemia in leptin deficient and wild type zebrafish 
To further study leptin function in zebrafish we created CRISPR-mediated knockout zebrafish lines on an 
ABz background lacking leptin-a (lepa
nz301), leptin-b (lepbnz302) or the leptin receptor (leprnz303) (figure S1). 
Raising the fish at identical tank densities, we found that body weight and standard length did not differ 
between wild type zebrafish and any of the knockout lines that were created (figure S2, S3), neither in males 
nor females at four, six or twelve months of age. To investigate whether leptin ameliorates hyperglycaemia 
in leptin- or leptin receptor-deficient zebrafish, we induced a hyperglycaemic state by immersing male and 
female zebrafish (n=5) in a 1% glucose solution for four days [36]. Immersion in 1% glucose steadily 
elevated basal blood glucose levels at a rate of 15-20 mg/dl per day, whereas immersion in normal system 
water did not change basal blood glucose levels (figure 2). On the third day of immersion, one hour before 
blood sampling, fish were treated with either recombinant mouse leptin (2 mg/kg) or vehicle (Cortland salt 
solution). Leptin ameliorated hyperglycaemia in wild-type and both leptin-a and leptin-b deficient zebrafish 
(figure 2A-F), but not in leptin receptor-deficient zebrafish (figure 2G,H). Interestingly, the pattern of blood 
glucose elevation, and the effect of leptin on hyperglycaemia was identical between males and females. 
Female zebrafish have a more variable body weight compared with males, due to the fact that they 
continuously produce eggs, which can make up to 25% of their total mass. For these reasons we performed 
all subsequent experiments in males. 





Figure 2 Leptin treatment ameliorates hyperglycemia in leptin deficient and wild type zebrafish. 
 
(A,B) Blood glucose values of male (left) and female (right) wild type zebrafish over time following immersion in a 1% glucose 
solution. On the third day, one hour before blood sampling, fish were injected intraperitoneally with recombinant mouse leptin 
(2mg/kg) or vehicle. *P<0.05, repeated measures one-way ANOVA. Data displayed as meanSEM (C,D) Male (left) and female 
(right) leptin-a deficient “lepanz301” fish. (E, F) Male (left) and female (right) leptin-b deficient “lepbnz302” fish. (G, H) Male (left) 
























































































































































































































































































































































































































































Overfeeding elicits an effect of leptin on body size regulation in zebrafish 
Under normal feeding conditions, leptin regulates glucose homeostasis but not adipostasis in the zebrafish 
[16]. We investigated whether leptin- and leptin receptor-deficient zebrafish are more prone to diet-induced 
obesity (DIO) and impaired glucose tolerance. To this end, we exposed lepanz301 fish, lepbnz302 fish, leprnz303 
fish, or wild-type control fish (n=12) to an overfeeding regime or a normal diet for six weeks. Glucose 
tolerance was tested at the start and end of this period.  Intraperitoneal glucose tolerance tests (ipGTTs) 
revealed that although basal blood glucose levels were not significantly different (figure 3A, B), glucose 
clearance in leptin receptor knockout fish was reduced by 26% compared with wild type fish (figure 3A, 
D). Surprisingly, we found that overfeeding revealed an effect of leptin on body weight. leprnz303 fish 
(0.400.01 g, P<0.001) and lepanz301 fish (0.380.01 g, P<0.001), but not lepbnz302 fish (0.350.01 g) had 
significantly increased body weight compared to overfed wild type controls (0.340.01 g; figure 3E). There 
was also an increase in standard length from 28.40.2mm to 30.50.3mm (P<0.05) in lepanz301 fish and 
28.80.25mm to 31.70.36mm (P<0.05) in leprnz303 fish (figure 3F). Overfeeding increased basal blood 
glucose levels (from 64.13.5 to 100.51.8 mg/dl, P<0.001; figure 3B) and impaired glucose tolerance by 
25%, independent of genotype (figure 3C, D). For the last week of the 6-week overfeeding regimen, we 
treated overfed fish with metformin, a drug thought to have beneficial effects on hepatic glucose 
homeostasis and insulin sensitivity [37] and the first line treatment for T2DM in humans [37]. Metformin 
reduced the area under the curve by 17%, with levels no longer significantly different to levels in non-
overfed wild type fish (figure S4). These results demonstrate that in zebrafish, under normal feeding 
conditions, leptin regulates glucose homeostasis but not body weight. Only in times of nutrient excess does 
leptin impact on both body weight and standard length. 





Figure 3 Regulation of glucose homeostasis and body weight in adult zebrafish.  
(A) Glucose tolerance in normal-fed lepanz301 fish, lepbnz302 fish, leprnz303 fish and wild type controls (n=12). (B) Baseline blood 
glucose levels of normal-fed and overfed lepanz301 fish, lepbnz302 fish, leprnz303 fish and wild type controls. ****P<0.0001, two-way 
ANOVA. (C) Glucose tolerance in overfed lepanz301 fish, lepbnz302 fish, leprnz303 fish and wild type controls (n=12). (D) Area under 
the curve of (A) and (C). *P<0.05, one-way ANOVA; #P<0.05, two-way ANOVA. (E) Body weights of lepanz301 fish, lepbnz302 fish, 
leprnz303 fish and wild type controls on a 6-week normal diet or overfeeding regime. ***P<0.001, repeated measures ANOVA. (F) 
Standard length of normal-fed and overfed lepanz301 fish, lepbnz302 fish, leprnz303 fish and wild type controls at 0,3 and 6 weeks. 
*P<0.05, one-way ANOVA. (G-J) Examples of leptin receptor deficient and wild type zebrafish at the start and end of the 
overfeeding regime.  
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Inhibition of the canonical Wnt pathway blocks the glucoregulatory effect of leptin 
To investigate whether leptin regulates glucose homeostasis via the canonical Wnt pathway, we 
pharmacologically activated or inhibited the canonical Wnt pathway, induced hyperglycaemia acutely or 
persistently and then treated the fish with leptin. During an acute glycaemic challenge in the form of an 
ipGTT, LiCl and leptin treatment reduced the AUC to a similar extent (~20%), whereas combined 
application was not more effective (figure 4A, B). Under artificially-induced hyperglycaemia (figure 4C, 
J) these effects were replicated with a 10% reduction (LiCl), and a 15% reduction (leptin and leptin+LiCl) 
in glucose levels after 3 days. To test whether the glucose-lowering effect of leptin was dependent on Wnt 
pathway activation, we applied PNU74654 two hours before acute leptin treatment. PNU74654 pre-
treatment lead to a return of glucose levels to that observed in control conditions (figure 4D). PNU74654 
alone, on the other hand, lead to a 28% increase in AUC (figure 4E). During persistent hyperglycaemia, 
Wnt pathway inhibition with PNU74654 did not significantly aggravate the rise of blood glucose (1175.7 
mg/dl) when compared with control fish (1134.1 mg/dl). More importantly however, PNU74654 
prevented the ability of leptin to lower blood glucose levels (1075.3 mg/dl), compared with leptin-treated 
fish (973.1 mg/dl; *P<0.05, repeated measures ANOVA; figure 4H). Likewise, the anthelmintic drug 
pyrvinium pamoate impaired glucose tolerance by 39%, and blocked the glucose-lowering effect of acute 
leptin treatment in an ipGTT (figure 4G, H). Under artificially-induced hyperglycaemia, pyrvinium did not 
significantly aggravate the rise of blood glucose (1196.7 mg/dl) when compared with control fish (1134.1 
mg/dl), but prevented the ability of leptin to lower blood glucose levels (1077.9 mg/dl), compared with 
leptin-treated fish (973.1 mg/dl; P<0.05; figure 4I,J). These findings demonstrate that intact canonical 
Wnt signalling is required for the ability of leptin to regulate blood glucose levels. 






Figure 14 Glucose tolerance in wild type zebrafish following WNT pathway manipulation and leptin treatment.  
 
(A) Glucose tolerance of adult wild type male zebrafish (n=6). Fish were treated 10μM LiCl (three hours before glucose injection), 
0.6gr/L of recombinant mouse leptin dissolved in Cortland salt solution (one hour before glucose injection), vehicle only, or a 
combination of LiCl and leptin. Following 0.5mg/g glucose injection, blood samples were taken at 30, 90 and 180 minutes’ post 
injection. (B) Area under the curve of (A). A-B=P<0.05, one-way ANOVA. (C) Blood glucose values of adult wild type male 
zebrafish (n=6) over the course of a 4-day immersion in a 1% glucose solution. On the third day, fish were exposed to 10μM LiCl 
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for three hours before daily blood sampling. One hour before blood sampling, fish were injected intraperitoneally with 0.6gr/L of 
recombinant mouse leptin dissolved in Cortland salt solution, or with vehicle only. (D) Glucose tolerance of adult wild type male 
zebrafish (n=6). Fish were treated 10μM PNU74654 (three hours before glucose injection), 0.6gr/L of recombinant mouse leptin 
dissolved in Cortland salt solution (one hour before glucose injection), vehicle only, or a combination of PNU74654 and leptin. 
(E) Area under the curve of (D). A-B and A-C=P<0.05, one-way ANOVA. (F) Blood glucose values of adult wild type male zebrafish 
(n=6) over the course of a 4-day immersion in a 1% glucose solution with exposure to 10μM PNU74654. (G) Glucose tolerance of 
adult wild type male zebrafish (n=6). Fish were treated 10μM pyrvinium pamoate (three hours before glucose injection), 0.6gr/L 
of recombinant mouse leptin dissolved in Cortland salt solution (one hour before glucose injection), vehicle only, or a combination 
of pyrvinium pamoate and leptin. (H) Area under the curve of (G). A-B and A-C=P<0.05, one-way ANOVA. (I) Blood glucose 
values of adult wild type male zebrafish (n=6) over the course of a 4-day immersion in a 1% glucose solution with exposure to 
10μM pyrvinium pamoate. (J) Comparison of blood glucose levels in (C), (F) and (I), pre-treatment (day 2) and post treatment 
(day 3). *P<0.05, repeated measures ANOVA. 
Activation of the canonical Wnt pathway and glucose lowering effects of leptin are dependent on a 
functional leptin receptor 
We investigated whether the glucoregulatory actions of canonical Wnt signalling are dependent on a 
functional leptin system. To confirm that Wnt reporter activation is mediated through leptin signalling, we 
used CRISPR/Cas9 to create lepR crispants that are mosaic for leptin receptor knockout, and incubated 
them with either recombinant leptin or 10μM LiCl (figure 5A) at 5 dpf. Mosaic knockout of the leptin 
receptor blocked the ability of leptin, but not LiCl to activate WNT signalling (figure 5B). We revisited the 
experimental paradigm described above using lepanz301 fish, lepbnz302 fish and leprnz303 fish. Leptin treatment 
improved glucose tolerance in lepanz301 fish (by 30%, figure 5C, F) and lepbnz302 fish (by 20% figure 6D, 
G). In leprnz303 zebrafish, leptin was unable to improve glucose tolerance with levels identical to the control 
group (figure 6E, H). LiCl treatment improved glucose tolerance in all groups (22% for lepanz301 fish, 15% 
for lepbnz302 fish, and 28% for leprnz303 fish), demonstrating that a functional leptin receptor is not required 
for the glucose lowering effect of LiCl. No additive effect was found between leptin and LiCl. 
In accordance, LiCl treatment attenuated persistent hyperglycaemia in lepanz301 fish (126.06.1 vs 
102.06.5 mg/dl; figure 6I), lepbnz302 fish (121.53.8 vs 95.77.8 mg/dl; figure 6J) and leprnz303 zebrafish 
(130.16.6 vs 102.06.5 mg/dl; figure 6K). The effect of LiCl on blood glucose levels appears to be longer 
lasting than the effect of leptin (figure 2). LiCl-treated fish had significantly lower blood glucose levels not 
only immediately after the treatment ended, but on the following day as well (155.86.1 vs 127.56.7 mg/dl 
for lepanz301 fish; 146.78.2 vs 122.59.4 mg/dl for lepbnz302 fish ; 178.25.3 vs 127.57.2 mg/dl for leprnz303 




fish). Again, we did not identify any combined action of leptin or LiCl on glucose homeostasis. Together, 
these data demonstrate that canonical Wnt pathway activation via LiCl-mediated inhibition of GSK3β 
regulates glucose homeostasis even in the absence of an intact leptin system.  
 
Figure 5 Activation of canonical Wnt signalling improves glucose tolerance in lepanz301 fish, lepbnz302 fish and leprnz303 
zebrafish.  
 
(A) 5dpf CRISPR-mediated leptin receptor-deficient Tg(7xTCFXla.Siam:nlsm Cherry)ia5 larvae treated with 100nM recombinant 
leptin or 10μM LiCl for 2 hours. Scale bar = 500μM. (B) Fluorescence intensity in the hypothalamus of differentially treated 5dpf 
Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 larvae. A-B=P<0.05, one-way ANOVA. (C) Glucose tolerance of adult male lepanz301 zebrafish 
(n=6). Fish were treated with 10μM LiCl (three hours before glucose injection), with 0.6g/L of recombinant mouse leptin dissolved 
in Cortland salt solution (one hour before glucose injection), with vehicle only, or with a combination of LiCl and leptin. Following 
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0.5mg/g glucose injection, blood samples were taken at 30, 90 and 180 minutes’ post injection. (D) Same as (C), but for lepbnz302 
fish. (E) Same as (C) and (B), but for leprnz303 fish. (F) Area under the curve of (C). **P<0.001, one-way ANOVA. (G) Area under 
the curve of (D). *P<0.05, one-way ANOVA. (H) Area under the curve of (E). **P<0.001, one-way ANOVA. (I) Blood glucose 
values of adult male lepanz301 zebrafish (n=6) over the course of a 4-day immersion in a 1% glucose solution. On the third day, fish 
were exposed to 10μM LiCl for three hours before daily blood sampling. One hour before blood sampling, fish were injected 
intraperitoneally with 0.6g/L of recombinant mouse leptin dissolved in Cortland salt solution, or with vehicle only. *P<0.05, 
repeated measures ANOVA. (J) Same as (G), but for lepbnz302 fish. *P<0.05, repeated measures ANOVA. (K) Same as (G) and (H), 
but for leprnz303 fish. *P<0.05, repeated measures ANOVA. 
Conditional deletion of β-catenin in the mediobasal hypothalamus of male mice exacerbates DIO- 
induced body weight gain, food intake and causes leptin resistance 
Because β-catenin is involved in multiple cellular processes, in particular embryogenesis [38], it would be 
impossible to utilise the global knockout approach as it would be embryonically lethal for the offspring. 
Therefore, we employed β-cateninflox mice and bilaterally injected of AAV2-mCherry-iCre into the 
mediobasal hypothalamus to ablate β-catenin in the adult brain. We measured bodyweight and food intake 
daily following the introduction of AAV-iCre into the mediobasal hypothalamus until the conclusion of the 
experiment. When mice were fed low fat diet (LFD), we found that there was no significant difference in 
bodyweight between the control- and β-catenin KO mice fed LFD for most periods except between days 
18 - 22 when we observed a mild increase. After 4 weeks fed LFD, both groups of mice were fed HFD for 
6 weeks, which lead to an increase in bodyweight regardless of treatment. β-catenin KO mice, however, 
exhibited a much larger increase in bodyweight in response to HFD than mice injected with the control 
virus. This effect became significant from the 10th day of HFD feeding (Figure 6A, P<0.01). By the end of 
the study the β-catenin KO mice were 15% heavier than mice that received control injection and were fed 
HFD (P<0.0001). We also observed that while fed LFD, there was no difference in total caloric intake, but 
once fed HFD, the β-catenin KO animals had a higher caloric intake compared with the control mice (Figure 
6B, P<0.05). We also investigated whether deleting β-catenin from cells that express β-catenin in the 
mediobasal hypothalamus led to an impairment in glucose homeostasis. We measured glucose tolerance at 
two time points; four weeks after the AAV-iCRE injection during LFD feeding, and after 6 weeks on HFD 
feeding. β-catenin KO mice on either LFD or HFD had markedly impaired glucose tolerance (Figure 6C, 
D; P<0.05 and P<0.01) relative to controls.  




We next assessed whether β-catenin deletion affects molecular leptin sensitivity by performing 
immunohistochemistry for pSTAT3 in the arcuate nucleus. As expected, acute injection of leptin 
(1.25mg/kg body weight) induced a marked increase in pSTAT3 positive cells in control mice (Figure 6E; 
P<0.01 and P<0.05, respectively) compared with vehicle-treated mice. In β-catenin mice, however, the 
response to leptin was fully ablated (P<0.05), suggesting the establishment of resistance to exogenously 
applied leptin. 
 
Figure 5 Conditional deletion of β-catenin in the mediobasal hypothalamus of male mice exacerbates DIO- induced body weight 
gain, food intake and causes leptin resistance. 
 
(A) Bodyweight of male β-catenin flox mice injected with either the control or inducible Cre expressing virus maintained on LFD 
(ad libitum) for 4 weeks followed by 6 weeks on HFD (ad libitum). Also shown are the bodyweight (g) of β-catenin flox mice 
maintained on LFD throughout the experiment. The bar graphs represent total caloric intake (kcal) of male mice while on LFD 
and HFD. Error bars denote SEM. *, P<0.05; ***, P<0.001; KO compared to control mice. (B) Food intake of mice in (A). (C) 
Glucose tolerance of β-catenin KO- and control mice during intraperitoneal glucose tolerance tests. Glucose tolerance tests were 
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performed 4 weeks after virus injection but maintained on LFD and 6 weeks after switching to HFD (B, E). (D) Area under the 
curve of (C). Error bars denote SEM. *, P<0.05; **, P<0.01; KO compared to control mice. (E) Quantified pSTAT3-
immunoreactive positive cells in the arcuate nucleus after 30 mins of i.p. leptin (1.25 mg/kg) or PBS (vehicle) treatment for the 
different groups. Error bars denote SEM. *, P<0.05; **, P<0.01; leptin- compared to vehicle-treated mice at each group. (F) 
Representative micrographs of arcuate sections showing pSTAT3 expression following PBS or leptin treatment. Scale bar = 100 
μM. 
Discussion 
Most studies investigating the neuroendocrine regulation of body weight, energy and glucose homeostasis 
have been performed in mice, using powerful genetic tools that have been well-established in this species. 
The recent identification of leptin and leptin receptor gene homologs and the invention of the CRISPR-
Cas9 gene editing technology in lower vertebrates such as zebrafish now allows a comparative analysis of 
leptin function. In our study we combined these powerful tools that are specific to the zebrafish (e.g. optical 
transparency in larvae allows clear visualization of Wnt pathway activation) with state of the art tools in 
mice (e.g. larger brain allows conditional region specific genetic ablation of the Wnt pathway). Using 
overfeeding regiments, we first comprehensively studied which physiological role leptin plays in the 
zebrafish, a vertebrate animal model belonging to an evolutionarily older animal class than mammals. This 
was followed by comprehensive assessment of the role Wnt signalling plays as a newly identified leptin 
pathway in zebrafish and mice. 
While raising zebrafish, we took great care to prevent any tank density effects on body weight, which have 
been shown to affect postembryonic development, somatic growth and fat accumulation [39]. Previous 
studies on teleost leptin knockout models have yielded contradicting results, with one study convincingly 
disproving a role for leptin as an adipostat in the zebrafish [16], whereas others reported an effect of leptin 
on adipostasis in zebrafish [40] and medaka [41].  
Because of its ability to readily absorb molecules from the surrounding water, compound exposure is 
relatively straightforward in the zebrafish. We took advantage of this by immersing fish in a 1% glucose 
solution to induce a persistent hyperglycaemic challenge (figure 1). This procedure has previously been 
shown to readily induce hyperglycaemia over time [36]. In line with these previous observations glucose 




levels were significantly elevated after two days of immersion and leptin administration on the third day 
consistently reduced glucose levels in wild type, lepanz301 fish and lepbnz302 fish, but not in leprnz303 fish, 
confirming that the glucose-lowering properties of leptin are mediated by the long from of the leptin 
receptor. This is further substantiated by the fact that glucose levels in the 1% glucose-vehicle treated fish 
were higher after 3 days of immersion in leprnz303 fish compared not only to wild type fish but also to 
lepanz301 fish and lepbnz302 fish. The elevated glucose levels in leprnz303 fish compared with lepanz301 fish and 
lepbnz302 fish suggests that KO of only one of the two leptin paralogs is not sufficient to induce 
hyperglycaemia, but loss of effect of both variants at leptin receptor level is required to reveal the full 
phenotype. The fact that recombinant mouse leptin was active in zebrafish suggests that leptin function is 
highly preserved across species. This finding is in line with other studies that previously demonstrated 
anorexigenic effects of recombinant leptin in trout [42] and goldfish [43]. Interestingly, both the rate at 
which hyperglycaemia was induced, and the potency of leptin to reduce hyperglycaemia was identical in 
male and females. In humans, circulating leptin levels are higher in females [44], and the brains of female 
rats are more sensitive to the catabolic actions of ICV injected leptin than those of age- and weight-matched 
males [45]. Our data suggest that in the zebrafish, leptin acts sexually monomorphic. 
In a landmark study performed by Michel et al. it was shown that leptin regulates glucose homeostasis but 
not adipostasis in zebrafish. We sought to investigate this further by exploring potential catabolic actions 
of leptin under overfeeding conditions. It has been shown that zebrafish become obese when they are 
exposed to an overfeeding regime, and they display metabolic alterations similar to DIO mammals, like 
hypertriglyceridemia, hepatic steatosis, and systemic inflammation [46]. Performing GTTs, under normal 
feeding conditions, we could confirm the results by Michel et al. Knockout of the leptin receptor impaired 
glucose tolerance but had no effect on body weight regulation in the zebrafish, as neither knockout of leptin-
a or leptin-b did. However, this was limited to fish fed normally. Intriguingly, overfeeding elicited an effect 
of leptin on body weight and standard length. Under these conditions leprnz303 fish had elevated body weight 
compared with lepbnz302 fish and wild type zebrafish. Interestingly, lepanz301 fish too showed elevated body 




weight and standard length, suggesting a specific body weight regulatory and somatic effect of leptin-a. In 
silico binding simulation of zebrafish leptin-a and leptin-b predicts significantly lower binding energy to 
the leptin receptor for leptin-b [47]. Previous studies point towards a role for leptin-b in tissue regeneration 
rather than energy homeostasis [48, 49]. Further studies are required to delineate functional differences 
between two leptin paralogues. 
Overfeeding per se led to glucose intolerance in fish independent of genotype. This suggests that this 
treatment maximally impairs the glucoregulatory system as loss of leptin function in addition to overfeeding 
does not impair glucose tolerance any further. One recent study could show that overfeeding of zebrafish 
larvae leads to leptin resistance and reduced hypothalamic pomca levels, leading to activation of the 
melanocortin system, elevation of growth hormone levels, and enhanced somatic growth [50]. Together, 
these data point towards a fundamentally differential physiological role for leptin depending on nutrient 
availability. Under normal feeding conditions, leptin regulates glucose homeostasis. In times of nutrient 
excess on the other hand, an effect of leptin to regulate body weight and somatic growth becomes apparent. 
From an evolutionary perspective, this suggests that leptin originated as a glucoregulatory hormone, and 
that its adipostatic function in mammals may have been acquired at some point during evolution. Most 
aquatic species continue to grow somatically throughout life, whereas growth in terrestrial animals usually 
reaches a plateau due to gravity limitations. Because somatic growth limits movement much less in the 
water than on land, an adipostatic role of leptin may not be as critical as in terrestrial species. This is in line 
with the recent discovery of the gravitostat in mammals [51]. This system has been shown to regulate fat 
mass in obese mice independently of leptin, whereas leptin-mediated regulation of fat mass seems to be 
limited to healthy lean mice [52]. 
The canonical Wnt pathway has been shown to be activated by glucose in a macrophage cell line [53]. In 
mice, we demonstrated that Wnt signalling in the hypothalamus is impaired during obesity [30]. In the 
present study, we take advantage of the optical transparency of zebrafish larvae to provide the first in vivo 




evidence of canonical Wnt pathway activation by leptin. Using LiCl as a positive control, we found that 
leptin-induced Wnt activation was especially prominent in the hypothalamic region in the brain of zebrafish 
larvae. Intriguingly, CRISPR-mediated knockout of the leptin receptor totally abolished this activation, 
suggesting that leptin activation of the Wnt pathway is solely mediated by the leptin receptor. Leptin 
receptor expression in the zebrafish is found not only in the hypothalamus, but also in a variety of peripheral 
organs, including the eye, gut, liver, pancreas, and heart [54]. Another region that showed high intensity of 
fluorescence after Wnt activation by LiCl was the heart. However, leptin did not significantly induce Wnt 
fluorescence in the heart. 
We could demonstrate that pharmacological inhibition of the Wnt pathway blocks the ability of leptin to 
lower blood glucose levels both during acute and persistent hyperglycaemia, suggesting that leptin regulates 
glucose homeostasis predominantly via the Wnt pathway. An antidiabetic action upon activation of the Wnt 
pathway has been confirmed for LiCl treatment, which has been shown to attenuate non-fasting blood 
glucose levels in diabetic Lepob/ob BTBR T+ Itpr3tf/J (BTBR) mice [55]. In accordance, we can show that 
LiCl treatment improves glucose tolerance and normalizes blood glucose levels during a persistent 
hyperglycaemic challenge in zebrafish. Activation of the Wnt pathway with LiCl improved glucose 
homeostasis, even in leptin- or leptin receptor deficient fish, suggesting that LiCl acts independently of 
leptin and that leptin acts upstream of the canonical Wnt signalling cascade. We could previously show that 
leptin induces phosphorylation of LRP6 in the arcuate nucleus of the Djungarian hamster [56].  
The ability of Wnt signalling to regulate blood glucose levels is often ascribed to GSK3β being a site of 
convergence between canonical Wnt signalling and insulin signalling [57]. In a previous study we could 
show that neuron-specific overexpression of GSK3β in the hypothalamus exacerbated the effects of diet-
induced obesity in wild type mice compared with mice fed a standard diet, measured as increased 
hyperphagia, obesity and glucose intolerance [31]. We also found that intracebroventricular injection of a 
GSK3β inhibitor or the WNT pathway antagonist Dickkopf 1 led to very rapid improvement or deterioration 




of glucose homeostasis, respectively.   Here we inhibited the Wnt pathway both upstream (using pyrvinium 
pamoate) and downstream (using PNU74654) of GSK3β, yet both manipulations impaired glucose 
tolerance and blocked the glucoregulatory effect of leptin.  
From these results it is unclear whether the glucoregulatory action of this pathway depends on 
transcriptional events of the canonical Wnt pathway. Since β-catenin as a transcriptional coactivator of the 
pathway is crucial for activation of TCF7l2, we conditionally ablated β-catenin from the mediobasal 
hypothalamus in mice. Intriguingly, this treatment replicated the glucoregulatory effect observed in 
zebrafish suggesting that the canonical Wnt pathway in the brain is a major player in the neuroendocrine 
regulation of whole body glucose homeostasis across different vertebrate species. This manipulation led to 
exogenous leptin resistance confirming that leptin action largely depends on Wnt signalling in the 
hypothalamus.  
Taken together we identify a novel essential role of the central canonical Wnt pathway in the 
neuroendocrine control of glucose homeostasis in zebrafish and mice. Furthermore, our findings highlight 
that leptin may primarily have evolved as a glucoregulatory hormone with its role of an adipostat acquired 
later in evolution. Finally, the glucoregulatory action of leptin is mediated via the Wnt pathway - an 
essential mechanism that appears preserved throughout the vertebrate phylum.   






Procedures involving animals were performed in accordance with national animal ethics legislation and 
received approval by University of Otago Animal Ethics Committee (AUP-18-121).  
Zebrafish Husbandry 
Zebrafish (AB strain) were maintained in 3.5 L tanks on a Palletized Centralized Life Support System 
(Tecniplast). The water in this recirculating system was pumped through mechanical filtration, charcoal 
filtration, and UV-treatment; and 10% of the water was replaced every hour. The water was kept at 26–
30˚C, with pH 7.6–8.0 and a conductivity of 300–600 μS. The facility environment maintained a 14-hour 
light and 10-hour dark cycle. Water quality parameters were automatically measured and adjusted, and 
remained within acceptable limits for the duration of the study. 
CRISPR Cas9 mutagenesis 
Single guide RNA’s (sgRNAs) were synthesized in vitro. Cas9 mRNA was transcribed from a pT3TS-
nCas9n plasmid (Addgene plasmid #46757). Offspring of AB or Tg(7xTCFXla.Siam:nlsmCherry)ia5 
zebrafish were injected at the one cell stage into the cell with ∼1 nL of a solution containing zebrafish 212.2 
ng/μL Cas9 mRNA and 35.4 ng/μL gRNA, based on (Varshney et al., 2016). As a positive control, and to 
test the quality of Cas9mRNA, we used an sgRNA targeting the tyrosinase gene. Mutagenic efficiency was 
analysed using a three-primer fluorescence PCR method. Biallelic mutant founder fish (F0) were inbred, 
giving rise to stable mutant offspring. Target sequences were lepr GGAGCGCCAGTAAAGCCGTGTGG; 
lepa GGAATCTCTGGATAATGTCCTGG; lepb ACAGAACTGAGACCATCAATGGG; tyr 
GGACTGGAGGACTTCTGGGG.  
 





3-month-old male leptin mutant fish and wild type control fish were assigned to either a 6-week overfeeding 
regime, consisting of 6 daily feeds, or a standard diet of 2 feeds per day. Feeds alternated between 20 
mg/fish of ZM-400© fish pellets, and freshly hatched brine shrimp (Artemia nauplii, 30mg cysts/fish). ZM 
dry pellets (Zebrafish Management Ltd.) consisting of  58% protein, 14.5% fat, 11.5% ash, 7.0% moisture, 
30,000 I.U./kg vitamin A, 2,500 I.U./kg vitamin D3, 400 mg/kg vitamin E, 2,000 mg/kg vitamin C, 30 mg/g 
3 highly unsaturated fatty acids. Feeding times were Zeitgeber Time (ZT) 1:00 (with lights turning on at 
ZT 0:00), ZT 3:30, ZT 5:00, ZT 7:30, ZT 9:00 and ZT 11:30h under the overfeeding regime, and ZT 3:30 
and ZT 7:30 in the normal fed group. Feeding was done manually, and leftover food was removed by 
siphoning to prevent an effect of water quality on body weight [58]. Body weights were measured weekly. 
Standard length (SL), defined as the length measured from the tip of the snout to the posterior end of the 
last vertebra, was measured at week 0, week 3 and week 6. Finally, glucose tolerance was measured at the 
end of the dietary intervention 
Zebrafish Compound Exposure  
Metformin (Sigma) was dissolved in fish water to a final concentration of 20 µM. The metformin solution 
was freshly prepared and changed daily. PNU74654 (Abcam) and pyrvinium pamoate (Sigma) were 
dissolved in DMSO and added to tank water or E3 medium at a final concentration of 10µM. LiCl 
(Sigma) was dissolved directly in tank water or E3 medium at a concentration of 10µM. 
Zebrafish Blood sampling 
Borosilicate glass microcapillaries (Harvard Apparatus) were pulled on a Sutter p-97 Flaming Brown glass 
micropipette puller to create needles with a 1.0 mm outer diameter. Using scissors, the needle tips were cut 
obliquely to create a tip diameter of 100-300μm. Next, needles were heparinized (5mg/ml heparin in saline) 
using an aspirator tube assembly. For blood collection, a heparinized needle was inserted in the nosepiece 




end of the aspirator tube assembly. Adult zebrafish were anesthetized with 0.13% tricaine (3-aminobenzoic 
acid ethyl ether methanesulfonate, MS222). Anesthetized fish were carefully transferred onto soft tissue 
paper soaked in tricaine solution. Another soaked tissue was used to cover the fish’s head. The needle was 
then carefully inserted at a 30 – 45° angle into the dorsal aorta (DA), along the body axis and ventral to the 
spine. Generally, blood would rise into the needle in a pulsatile manner. If blood did not rise, gentle suction 
was applied through the mouthpiece, and the needle was moved gently by hand to encourage blood flow. 
The minimal required sample volume (0.6 μl) was collected. The needle was immediately removed, and 
gentle finger pressure with a soaked tissue was applied to the puncture site for ~15 seconds or until bleeding 
stopped. Fish were then transferred to a recovery tank (28.5 °C), and water was gently swirled towards the 
gills. 
Zebrafish Glucose Immersion 
The glucose immersion method was adapted from Capiotti et al. (2014). Fish were placed in standard 
housing tanks containing a 1% glucose solution (55.5 mM). Because the tanks were not on the normal 
recirculation system, solutions were renewed daily after feeding to prevent growth of microorganisms. 
Blood samples were taken daily. 
Zebrafish Intraperitoneal glucose tolerance tests  
Fish were fasted for 72 hours to bring glucose levels down to baseline.  Following anaesthesia, fish were 
weighed and injected intraperitoneally with 0.5 mg glucose/g fish weight and allowed to recover for 30, 90, 
and 180 min after injection. Glucose concentrations were measured using a commercially available 
glucometer (Accu-Chek Performa; Roche) 
Mice 
Mice containing lox-P sites in introns 1&6 of β-catenin (β-cateninflox; B6.129-Ctnnb1tm2Kem/KnwJ, 
Jackson labs; b-catenin gene is flanked by LoxP sites (floxed)) (8 weeks old; n=16-20 per group) were 




obtained from the University of Otago animal breeding facility. They were individually housed under 
12:12h light/dark cycle (lights on 0600h) at a constant temperature (21 + 1 °C) with ad libitum access to 
food and water, except during fasting when only water was available. Mice were fed either a low-fat diet 
(LFD; D12450B Research Diets, New Brunswick, NJ 08901 USA) with 10% fat by energy (kcal) or high-
fat diet (HFD; D12492 Research Diets) with 60% fat by energy (kcal). When required, in female mice the 
estrous cycle was determined by cytological examination of vaginal smears. This was done to ensure 
females were in diestrus when collecting tissue samples. 
Stereotaxic injections 
Both adult male and female β-cateninflox mice were used. Intrahypothalamic injections were performed 
under isofluorane anaesthesia as described previously (23). Stereotaxic co-ordinates to reach the arcuate 
nucleus were 0.125mm posterior, ±0.35mm lateral and 0.59mm ventral relative to Bregma. An AAV-vector 
expressing Cre recombinase (AAV2-mCherry-iCre AAV virus, Penn Vector Core) was injected bilaterally 
using 1 mL Hamilton Syringes (Model 7001 KH SYR, 80100, Hamilton Company, Nevada 89502, USA) 
at volume of 0.5 mL at either side of the arcuate nucleus (Figure 1A). The injection needle was lowered to 
the correct coordinates over a period of 5 min, paused for 2 min, and then the virus was injected over a 
period of 2 min. The injection needle remained in place at each injection site for an additional 10 min to 
allow for diffusion and prevent backflow. The incision was then sutured and the mice were placed under a 
heating lamp in their home cage for recovery. The expectation was that viral-induced expression of the Cre 
would excise the floxed β-catenin gene resulting in a localized deletion of β-catenin at the site of injection. 
For control experiments, β-cateninflox mice were injected with an AAV-vector that did not express the Cre 
recombinase (AAV/DJ-CMV-mCherry AAV virus). For both knockout (KO) and control experiments, 
mice were body weight matched and placed in respective groups (control male mice, KO male mice; control 
female mice and KO female mice). 
 




Onset of obesity, food intake, metabolic measurement and glucose tolerance tests 
Following the injection of the AAV-vector, mice were fed LFD for four weeks. Mice were fasted for 16 h, 
and at zeitgeber time (ZT) 0 (to guarantee a consistent influence of the circadian rhythm), they were injected 
intraperitoneally (ip) with glucose (1.5 g/kg), and a glucose tolerance test was performed. To determine the 
blood glucose levels, drops of blood from tail tips were collected repeatedly and glucose concentrations 
(mg/dL) were measured using a commercially available glucometer (Accu-Check Performa, Roche, Basel, 
Switzerland). For statistical validation, the area under the curve (AUC) was calculated. 
We next investigated the effect of HFD on these mice. They were then fasted for 16 h and an ipGTT was 
performed as described above. Throughout the whole procedure, from viral injection till the conclusion of 
the study, daily body weight and food intake measurements were recorded. In addition, another cohort of 
mice was placed through a similar regime as above, but was fed LFD throughout the experiment. 
Immunohistochemistry – Validation of AAV-vector injections 
To validate successful deletion of β-catenin in the arcuate nucleus, in another set of brain sections, 
immunohistochemical analysis of β-catenin (6B3; Rabbit mAb #9582; 1:100; Cell Signalling) was 
performed as per the manufacturers protocol. Images of the arcuate nucleus were taken, and presence or 
absence of β-catenin was analysed within that region. 
Immunohistochemistry – Onset of leptin resistance  
To determine the onset of either leptin or insulin resistance in mice with β-catenin knocked out in β-catenin 
expressing cells specifically in the ARC, mice were body weight-matched and further subdivided into either 
vehicle- or leptin-or insulin-treated mice. At the conclusion of the study, mice were fasted for 16 h to reduce 
endogenous levels of either leptin or insulin, and at ZT0, were injected ip with either 0.1M PBS (vehicle), 
leptin (1.25 mg/kg; R&D Systems, Minneapolis, MN 55413 USA) or insulin (1 mg/kg; I6634; Sigma-
Aldrich). Thirty mins (leptin-treatment) or 15 mins (insulin-treatment) post-injection, mice were 




anaesthetised (with Pentobarbitol; 30 mg/kg), and once the pedal withdrawal reflex was lost, were 
transcardially perfused with 0.9% heparinized saline followed by 4% paraformaldehyde in 0.1M phosphate 
buffer (pH 7.4). The procedure has been described in detail elsewhere (25). 
The immunohistochemical analysis of phosphorylated signal transducer and activator of transcription3 
(pSTAT3; Tyr705; Rabbit mAb #9145; 1:3000; Cell Signalling, Danvers, MA 01923, USA), a marker for 
leptin receptor signalling (25) or of phosphorylated Akt (Protein Kinase B) (pAkt; Ser 473; Rabbit mAb 
#4060; 1:500; Cell Signalling), a marker for insulin receptor signalling (26) was performed on 30 μm 
coronal brain sections in accordance with a previously described protocol for leptin (27) or insulin (26). 
pSTAT3 or pAkt positive immunoreactive cells were examined using an Olympus AX70 Provis light 
microscope (Olympus, Tokyo, Japan). Images of the arcuate nucleus were taken using the Spot RT Colour 
Camera attached to the microscope with an identical setting throughout the analysis. Two investigators who 
were blinded to the treatment counted immunoreactive cells within one of the bilateral halves of the arcuate 
nucleus (n=4-5 sections per mouse). 
Statistics  
Data were analysed by one- or two-way ANOVA with repeated measurements tests, where appropriate 
followed by a Holm-Sidak post-hoc test to check for significance, as appropriate using Prism software. 
Results are presented as the mean + SEM. P<0.05 was considered statistically significant. For metabolic 
measurements, analysis of covariance (ANCOVA) for two independent samples was performed, whereby 
the body weight was used as the concomitant variable whose effects were brought under statistical control, 
and the energy expenditure was the dependent variable of interest. P<0.05 was considered statistically 
significant.  
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Figure S1 Creation of lepa301, lepb302, lepr303 mutant zebrafish lines. (A) Zebrafish leptin-a gene with target sequence and primers. 
(B) Fluorescence PCR plots of selected lepa301 founder fish with annotated insertion/deletion. (C) Zebrafish leptin-b gene with 
target sequence and primers. (D) Fluorescence PCR plots of selected lepb302 founder fish with annotated insertion/deletion. (E) 
Zebrafish leptin receptor gene with target sequence and primers. (F) Fluorescence PCR plots of selected lepr303 founder fish with 







Left Primer Coordinates chr18:10689883-10689905
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Left Primer Coordinates chr6_KZ115187v1_alt:385386-
385408
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Figure S2 Leptin has no effect on male body weight or body length in the zebrafish. lepanz301 fish, lepbnz302 fish, leprnz303 fish and 
wild type controls (n=24) were raised at identical tank densities. Body weight was measured at 4 months’ post fertilization (A), 6 
months post fertilization (C) and 12 months post fertilization (E). Standard length was measured simultaneously (B, D, F). No 
significant differences were found between any groups at any stage, as measured using one-way ANOVAs. lepA= lepanz301 fish; 
lepB= lepbnz302 fish; lepR= leprnz303 fish; WT=wild type control; data displayed as boxplots with whiskers representing minimum 
and maximum values. 
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Figure S3 Leptin has no effect on female body weight or body length in the zebrafish. lepanz301 fish, lepbnz302 fish, leprnz303 fish 
and wild type controls (n=24) were raised at identical tank densities. Body weight was measured at 4 months post fertilization (A), 
6 months post fertilization (C) and 12 months post fertilization (E). Standard length was measured simultaneously (B, D, F). No 
significant differences were found between any groups at any stage, as measured using one-way ANOVAs. lepA= lepanz301 fish; 
lepB= lepbnz302 fish; lepR= leprnz303 fish; WT=wild type control; data displayed as boxplots with whiskers representing minimum 
and maximum values. 
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Figure S4 Metformin improves glucose tolerance in the zebrafish. After 5 weeks of overfeeding or normal diet, and one week of 
metformin (20 µM) treatment, wild type zebrafish (n=11) were challenged with a 0.5mg/g glucose solution, administered via IP 
injection. Blood samples were taken at 0, 30, 90 and 180 minutes. Overfed fish had significantly impaired glucose tolerance 
(349503211 mg/dl*minutes) compared to normally fed fish (241472192 mg/dl*minutes; *P<0.05, one-way ANOVA with 
multiple comparisons), but not compared to metformin-treated overfed fish (290332169 mg/dl*minutes). Main: blood glucose 
values over time; Insert: area under the curve of glucose tolerance test depicted in main figure. Data displayed as meanSEM. 





Figure S5 Validation of conditional β-catenin knockout in adult mice 
 
(A) Overview of injection site. (B) Representative image of β-catenin staining in the mediobasal hypothalamus of a control-injected 
mouse. (C) Representative image of β-catenin staining in the mediobasal hypothalamus of an AAV-iCre-injected mouse. (D) 
Quantification of β-catenin-positive cells in the arcuate nucleus of AAV-iCre- vs control-injected mice. (E) Quantification of β-
catenin-positive cells in the dorsomedial hypothalamus of AAV-iCre- vs control-injected mice. 
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Energy homeostasis is controlled by an intricate regulatory system centred in the brain. The 
peripheral adiposity signals insulin and leptin play a crucial role in this system by informing the 
brain of the energy status of the body and mediating their catabolic effects through signal 
transduction in hypothalamic areas that control food intake, energy expenditure and glucose 
metabolism. Disruptions of insulin and leptin signalling can result in diabetes and obesity. The 
central signalling crosstalk between insulin and leptin is essential for maintenance of normal 
healthy energy homeostasis. An important role of leptin in glucoregulation has been revealed. 
Typically regarded as controlled by insulin, the control of glucose homeostasis critically depends 
on functional leptin action. Leptin, on the other hand, is able to lower glucose levels in the absence 
of insulin, but insulin is necessary for long-term stabilization of euglycaemia. Evidence from 
rodent models and human patients suggests that leptin improves insulin sensitivity in type 1 
diabetes. The signalling crosstalk between insulin and leptin is likely conveyed by the WNT/β-
catenin pathway. Leptin activates WNT/β-catenin signalling, leading to inhibition of GSK-3β, a 
key inhibitor of insulin action, and thereby facilitating improved insulin signal transduction and 
sensitization of insulin action. Interestingly, insights into the roles of insulin and leptin in insects 
and fish indicate that leptin may have initially evolved as a glucoregulatory hormone and that its 
anorexigenic and body weight regulatory function was acquired throughout evolution. 
Furthermore, the regulation of both central and peripheral control of energy homeostasis is tightly 
controlled by the circadian clock, allowing adaptation of homeostatic processes to environmental 
cues.   




Central regulation of energy homeostasis  
Energy homeostasis in healthy adult individuals functions to a surprisingly precise extend, 
considering that adult mammals, including humans, maintain a relatively stable body weight for 
prolonged time periods despite short-term perturbances in energy balance and even when 
presented with unlimited access to food (1). An extended period of food restriction accompanied 
by loss of body weight in rats resulted in increased energy intake once animals regained ad libitum 
access to food. However, this increase only persisted until rats recovered body weight to baseline 
and at this point, food intake returned to normal levels (2). These findings illuminate a highly 
accurate regulatory mechanism for the homeostatic control of energy balance. More than 60 years 
ago one such mechanism was proposed, postulating a negative feedback model that consists of 
inhibitory signals secreted in proportion to fat depots, acting in the brain to induce a shift towards 
negative energy balance (3). Decades later, this hypothesis was verified, first when a central role 
of insulin in energy homeostasis was identified and next when the adiposity signal leptin was 
discovered (4,5).  
 
Insulin and the central control of energy homeostasis  
The pancreatic peptide hormone insulin was the first hormone to be discovered to be important in 
the control of glucose homeostasis. Insulin concentrations circulate in proportion to body fat mass 
(6). Since the discovery of insulin by Banting, Best and Macleod a century ago, insulin 
administration proved to normalise blood glucose levels and dramatically expand life expectancy 
in patients with type 1 diabetes (T1D). The glucose-lowering effects of insulin had long been 
regarded as being exclusively peripheral, even though French physiologist Bernard discovered as 
early as in 1854 that lesions in the base of the fourth ventricle in rabbits led to glycosuria, 
demonstrating an important role of the CNS in glucose homeostasis (7). It took a further 125 years 
until insulin was shown to mediate its catabolic and anorexigenic effects on energy homeostasis 
via the CNS. Pioneering work by Woods in baboons found that chronic intracerebroventricular 
injections of insulin led to reduced body weight and food intake, which was later confirmed in rats 
(4,8). The creation of the neuron-specific insulin receptor knockout mouse model, which exhibits 
increased food intake, body fat, plasma leptin and insulin levels as well as mild insulin resistance, 




and subsequent studies showing that intracerebroventricular insulin suppresses hepatic glucose 
production and that arcuate nucleus (ARC)-directed inhibition of insulin receptors leads to 
hyperphagia and insulin resistance established that the brain is a target tissue for insulin in the 
control of whole body glucose and energy metabolism (9-12). The insulin receptor is expressed 
throughout the brain with particular abundance in neuropeptide Y/agouti-related peptide 
(NPY/AgRP)- as well as proopiomelanocortin/cocaine and amphetamine regulated transcript 
(POMC/CART)-expressing neurons of the hypothalamic ARC (13-15). Molecularly, insulin 
mediates its effects by binding to its receptor, causing the phosphorylation of insulin receptor 
substrate (IRS) and subsequent activation of the intracellular phosphatidylinositol 3-kinase 
(PI3K)-protein kinase B (AKT) pathway. The serine/threonine-specific protein kinase AKT 
subsequently activates various insulin-sensitive metabolic pathways and gene expression, thereby 
controlling energy and glucose metabolism (15,16). Disruptions to the central insulin pathway lead 
to central insulin resistance and result in the development of type 2 diabetes mellitus (17). The 
enzyme glycogen synthase kinase-3β (GSK-3β) plays a critical role in insulin signal transduction. 
Stimulation of insulin signalling results in inhibition of GSK-3β (18-20). Pharmacological 
inhibition of central GSK-3β has been demonstrated to rescue PI3K-AKT signalling and improve 
glucose homeostasis in obese and glucose-intolerant rodent models, while adeno associated virus-
mediated overexpression in the hypothalamus impaired glucose tolerance (21,22). These findings 
suggest that GSK-3β is a potent modulator of insulin sensitivity (Figure 1). Hypothalamic insulin 
action is crucial for the regulation of hepatic glucose production. Insulin was shown to activate 
ATP-sensitive potassium (KATP) channels in certain hypothalamic areas, with specific evidence 
originating from NPY/AgRP neurons (23,24). KATP channel activation, which is facilitated by 
PI3K, regulates peripheral glucose homeostasis by inhibition of hepatic gluconeogenesis via 
hepatic vagal nerve activation (12) (Figure 1) and intracerebroventricular injections of NPY 
induced hepatic insulin resistance via sympathetic innervation of the liver (25). It should be noted, 
however, that recent findings by Brooks and colleagues demonstrated that insulin in the ARC 
exerts sympathoexcitatory effects via suppression of tonic paraventricular nucleus NPY inhibition 
(26). These results reveal that the intricate control of central insulin action and its effects on 
glucoregulation are a field of ongoing research interest. 
 




Leptin and the central control of energy homeostasis  
In 1994, Jeffrey Friedman and colleagues discovered a novel adipocyte-derived hormone (5), 
which was subsequently named leptin (from Greek leptos for ‘thin’) for its anorexigenic and 
catabolic effects observed in mice (27). The absence of leptin results in increased food intake, 
decreased energy expenditure, hyperglycaemia and severe obesity, as observed in the Lepob/ob 
mouse. This mouse model is leptin deficient due to a mutation in the obese gene (5). Following 
this discovery, leptin was believed to have huge potential as an ‘anti-obesity drug’ to counteract 
the growing obesity epidemic of our modern society. However, this initial euphoria soon abated 
once leptin was shown to be secreted by white adipose tissue and to circulate in proportion to body 
fat mass (28). In fact, most obese individuals display elevated leptin levels, whereas monogenetic 
defects in the leptin system are rare in humans. If present, they, however, result in extreme cases 
of obesity (29). In both leptin deficient mice as well as humans, leptin treatment causes a rapid 
decrease in food intake, increase in energy expenditure as well as weight loss, indicating that these 
subjects remain highly sensitive to leptin (29-32), whereas this does not apply to obese patients 
with elevated serum leptin concentrations (33). This diet-induced obesity (DIO) is characterized 
by hyperleptinemia and central leptin resistance, the failure of leptin to mediate its catabolic effects 
in the brain. In mice, DIO can be induced by feeding of a saturated fatty acid-rich high-fat diet 
(HFD). These mice quickly develop hypothalamic leptin resistance and obesity (34). Interestingly 
however, Ottaway et al. reported that chronic administration of a long-acting leptin receptor 
antagonist leads to hyperphagia and further increase in body weight in DIO mice, but not in obese 
mouse models of leptin deficiency (35). These findings suggest that despite exhibiting impaired 
leptin signalling and resistance to exogenous leptin, DIO mice remain sensitive to endogenous 
leptin to some extent.  
The molecular cause for hypothalamic leptin resistance is still not fully understood. The main 
target tissue for leptin resides in the brain, specifically in the mediobasal hypothalamus. This area 
forms the regulatory centre of hunger and satiety control and plays a key role in energy balance 
regulation (36,37). Intracerebroventricular leptin administration was shown to decrease energy 
intake and body weight, in both wild-type and leptin-deficient Lepob/ob mice (38). Leptin enters the 
brain in proportion to circulating concentrations, up to a point when the transport system is 
saturated (39-41). The long form of the leptin receptor (LepRb) is expressed in abundance in the 




ARC, ventromedial hypothalamus, dorsomedial hypothalamus and lateral hypothalamic area 
(42,43). Of particular interest is the ARC, due to its crucial role in the regulation of energy 
homeostasis and other homeostatic systems (15,44-46). On the molecular level, leptin mediates its 
catabolic effects by binding to LepRb, activating Janus kinase 2 (JAK2), ultimately resulting in 
recruitment and phosphorylation of signal transducer and activator of transcription 3 (STAT3) 
(47,48). Phosphorylated STAT3 (pSTAT3) homodimerises and translocates into the nucleus, 
where it acts as a transcription factor and activates target gene expression (49,50). Among those 
are effector molecules that cause reduced food intake and increased energy expenditure as well as 
the suppressor of cytokine signalling 3 (SOCS3). Through negative feedback regulation, SOCS3 
binds to LepRb and inhibits JAK2 activity, identifying SOCS3 as an effective inhibitor of leptin 
signal transduction via JAK2/STAT3 signalling (51,52). Two distinct neuronal populations in the 
ARC co-express LepRb. Just as described for insulin, these are NPY/AgRP-expressing neurons, 
which are inhibited by leptin (39,53,54), as well as POMC/CART-expressing neurons, which are 
activated by leptin (55,56). Intracerebroventricular injections of NPY and AgRP lead to increased 
food intake, decreased energy expenditure and weight gain (57-60), identifying both neuropeptides 
as anabolic signals. In contrast, catabolic effects were demonstrated for both CART and α-
melanocyte-stimulating hormone, which is cleaved from its precursor POMC (61,62). In wild type 
mice, leptin injections increase pSTAT3 levels, presenting a marker for activated intracellular 
leptin signal transduction. In DIO mice, this response to exogenous leptin is disrupted, particularly 
in the ARC (34). Consequently, this suggests that during obesity the hypothalamus receives 
misinformation about the peripheral energy status and integrates these signals into an inapt neural 
response to control energy homeostasis. Furthermore, increased expression of SOCS3 has been 
shown to cause impairments of leptin signalling in rodent models of leptin resistance and obesity 
(52,63). Notably, SOCS3 is a target gene of inflammatory pathways (64). Our laboratory 
demonstrated that chronic low-grade hypothalamic inflammation, which has been associated with 
the development of metabolic disorders (65), plays a critical role in the dysregulation of normal 
energy and glucose homeostasis and the development of obesity (66,67).  
 
The glucoregulatory role of leptin  




The prominent role of leptin in the maintenance of homeostatic body weight has long been 
discovered. Additionally, leptin is important for glucose homeostasis, as demonstrated in Lepob/ob 
mice that are severely hyperglycaemic and glucose intolerant, but in which leptin administration 
acutely restores glucose metabolism (31). Unilateral restoration of leptin signalling in the ARC of 
obese, hyperphagic and hyperglycaemic leptin receptor null mice had only minor corrective effects 
on body weight and food intake. Circulating glucose and insulin levels were, however, markedly 
improved in mice with partially rescued ARC leptin function (68). These results indicate that 1) 
ARC leptin signalling is sufficient to mediate the glucoregulatory effects of leptin; 2) leptin is 
more efficient at lowering blood glucose than at regulating food intake and body weight and 3) 
leptin regulates glucose homeostasis independent of body weight. This notion is further supported 
by the finding that leptin treatment in Lepob/ob mice acutely restores euglycaemia without affecting 
body fat mass (69). Two decades ago, leptin was shown to activate PI3K in the hypothalamus (70). 
It was later demonstrated that the glucoregulatory effects of leptin depend on functional PI3K, but 
are independent of AKT (69,71,72). It appears more likely that leptin’s glucose homeostatic 
properties are integrated upstream of PI3K at the level of IRS. Leptin treatment was shown to 
reduce the number of pIRS1 (Ser612)-immunoreactive cells in the ARC of Lepob/ob mice (69). This 
phosphorylation site of IRS1 is commonly associated with disrupted insulin signalling (73), 
suggesting that the glucose-lowering effects of leptin are due to hypothalamic sensitization of 
insulin signalling. Interestingly, the glucoregulatory action of leptin is reportedly not attributed to 
the LepRb-STAT3 pathway. This was demonstrated in the Leprs/s mouse model, which expresses 
a mutant leptin receptor with a selective disruption of STAT3 signal transduction and exhibits 
hyperphagia and obesity similar to the Leprdb/db mouse model, which exhibits a complete 
abrogation of leptin receptor signalling. Buettner et al. reported that Leprs/s mice display severe 
hepatic insulin resistance similar to that observed in Leprdb/db mice (74). Conversely, Bates et al. 
demonstrated that Leprs/s compared with Leprdb/db mice display improved glucose tolerance and 
insulin sensitivity, suggesting that leptin mediates its effects on glucose homeostasis partially 
independent of STAT3 signalling (75). This was confirmed in a pair-feeding study showing that 
Leprs/s had improved glycaemic control, but Leprdb/db mice of similar body weight and adiposity 
remained glucose intolerant (75).  




In mice with a global leptin receptor mutation, POMC-directed re-expression of LepRb restored 
euglycemia and insulin sensitivity (76,77). In Lepob/ob mice, however, loss of leptin receptors 
solely in POMC neurons did not reverse the glucoregulatory effects of leptin (78), indicating that 
POMC leptin signalling is sufficient to control glucose homeostasis in mice, but other integration 
sites for leptin exist. In a similar experiment, reintroducing LRb expression only in AgRP neurons 
of Leprdb/db mice reversed hyperglycaemia, while loss of LRb exclusively in AgRP neurons of 
Lepob/ob mice prevented the glucoregulatory effects of leptin (78). Furthermore, AgRP neuron 
directed elimination of both NPY and GABA, which are co-secreted by AgRP neurons, did not 
affect leptin’s glucose lowering effects (78). These findings suggest that leptin signalling in AgRP 
neurons is both sufficient and essential for leptin-induced control of glucose homeostasis and that 
these effects may directly be mediated by AgRP neuropeptides. Furthermore, we discovered that 
leptin inactivates GSK-3β in particular in NPY/AgRP neurons in the ARC of mice (79). Insulin 
receptor deletion exclusively in AgRP neurons resulted in impaired hepatic insulin action and a 
reduction in insulin-induced suppression of hepatic glucose production, but did not affect adipose 
tissue lipolysis (80). Conversely, in mice lacking the insulin receptor in POMC neurons, insulin 
maintained its ability to lower hepatic gluconeogenesis, but failed to suppress lipolysis (80). Taken 
together, these findings elucidate the critical role of insulin and leptin action in NPY/AgRP 
neurons in the control of glucose homeostasis (Figure 1).  
The fact that insulin’s glucoregulatory action is deteriorated in the absence of functional leptin 
signalling, as observed in Lepob/ob, Leprdb/db and Leprs/s mice, all of which exhibit hyperglycaemia 
and hyperinsulinemia, implies that intact leptin action is required for insulin to function. Whether 
this also applies vice versa and insulin is required for leptin to function has long been a matter of 
debate. To answer this question, Neumann et al. conducted a study in mice in which insulin 
signalling was maximally blocked. Mice with streptozotocin (STZ)-induced insulin deficiency that 
were additionally treated with insulin receptor antagonists, as well as mice with global insulin 
knockout were treated with leptin. In both models, Neumann et al. reported that leptin was still 
efficacious at lowering glucose levels, even though insulin knockout mice displayed volatile 
changes in glucose levels (81). These data demonstrate that leptin is able to restore glucose 
homeostasis in the total absence of insulin, but minimal insulin is still required to stabilize glucose 
levels indefinitely. The finding that leptin can effectively restore euglycemia in STZ-induced 




rodent models of insulin-deficient type 1 diabetes (T1D) (82) sparked interest in leptin as a 
therapeutical replacement for insulin in the treatment of T1D in hope to avoid the recurring 
hypoglycaemic episodes caused by insulin therapy. In a small clinical trial testing the effect of 
metreleptin on glycaemic control in human T1D patients it was demonstrated that leptin led to a 
subtle decrease in body weight (83). This effect might be due to mild hypoleptinemia that is 
observed in T1D patients, who display a reduction in leptin levels of approximately 50% (84,85). 
Although the authors furthermore reported a significant reduction in the daily insulin dose required 
to maintain glycaemic control, they concluded that leptin did not improve any parameters for 
glycaemic control (83). It is plausible, however, that comparable to results from rodent models of 
T1D (86,87), these findings suggest that leptin promotes insulin sensitivity in human T1D patients. 
This needs to be confirmed in larger scale clinical trials. The molecular mechanisms underlying 
the interaction of central insulin and leptin are not entirely understood. However, the WNT/β-
catenin pathway appears as a potential integration site for these metabolic signals, as discussed in 
the next section.  
 
WNT/β-catenin signalling as an integrator of central insulin and leptin action on energy 
homeostasis 
The WNT pathway is an evolutionary highly conserved signal transduction pathway that is present 
in species throughout all of animal kingdom, from sponges and worms to insects and mammals. 
WNT signalling controls numerous cellular processes and is well characterized in embryogenesis 
and carcinogenesis (88-90). Much of our early knowledge about the WNT pathway originates from 
developmental studies conducted in the fruit fly Drosophila melanogaster. The term WNT is 
composed of the gene names wg (wingless), characterized in the fruit fly, and int-1 (integration-
1), characterized in mice (91,92). Both were found to relate to the same highly conserved ligand, 
therefore later named WNT-1. The canonical, β-catenin-dependent WNT pathway is most 
prominently associated with proliferation, differentiation and cell survival during development, 
whereas aberrant pathway activation is involved in tumorigenesis and the pathogenesis of other 
diseases, such as Alzheimer’s disease (93,94). In mammals, the WNT protein family consists of 
19 different WNT ligands (WNTs). The WNT/β-catenin pathway involves several regulatory steps 




for its activation. In the absence of WNT stimulation a β-catenin destruction complex exists in the 
cytoplasm, which contains the pathway’s key regulatory enzyme GSK-3β, casein kinase-1α 
(CK1α), adenomatous polyposis coli (APC), dishevelled (Dsh), as well as the scaffolding protein 
Axin (95-97). Cytoplasmic β-catenin is bound to this destruction complex and phosphorylated by 
GSK-3β, thereby targeting β-catenin for ubiquitination and proteasomal degradation (98,99). The 
WNT/β-catenin pathway is activated when extracellular WNTs bind to Frizzled receptors, leading 
to heterodimerisation between those and the co-receptor LRP-5/6 and resulting in the recruitment 
of the destruction complex and the phosphorylation and activation of LRP5/6 (100). 
Phosphorylated LRP-5/6 in turn inhibits the destruction complex and GSK-3β is targeted for 
negative phosphorylation and is thereby inhibited (101). Consequently, hypophosphorylated β-
catenin accumulates in the cytoplasm and translocates into the nucleus. Here, it acts as a co-
transcription factor by activating the transcription factors T-cell factor-7 (TCF-7) and lymphoid 
enhancer factor (LEF). This leads to the transcription of WNT target genes, such as Cyclin-D1 and 
Axin-2 (102) (Figure 1). In the last decade, strong evidence linked the WNT/β-catenin pathway to 
the pathogenesis of type 2 diabetes and other metabolic disorders. Polymorphisms in the genes 
encoding for TCF-7 and low-density lipoprotein receptor-related protein-6 (LRP-6) were shown 
to be associated with a higher risk of developing type 2 diabetes in humans (103-106). 
Traditionally regarded as involved in embryonic development, WNT/β-catenin signalling was 
recently shown to be active in the developed hypothalamus and to play an important role in adult 
neurogenesis as well as the cellular and structural remodelling of the hypothalamus (79,107-109). 
The emerging role of WNT/β-catenin signalling in the neuroendocrine control of glucose 
homeostasis was first highlighted by the in vitro finding that glucose activates the Wnt pathway 
(110). Our laboratory provided strong evidence suggesting that hypothalamic WNT signalling is 
impaired in genetically obese and glucose intolerant Lepob/ob mice and that leptin treatment can 
rescue WNT action and thereby improve glucose homeostasis (22,79). We demonstrated that leptin 
acutely leads to activation of the WNT/β-catenin pathway through activation of LRP-6 and 
increased WNT target gene expression in different rodent models, identifying this pathway as an 
integration site of the leptin signal (79,107). The key enzyme of the WNT/β-catenin pathway is 
GSK-3β. Inhibition of GSK-3β ameliorates insulin-stimulated glucose metabolism, identifying 
GSK-3β as a negative modulator of insulin signalling and glucose homeostasis (21,111,112). 




Indeed, leptin was shown to inactivate GSK-3β in NPY/AgRP neurons in the ARC of mice (79). 
Because canonical WNT signalling leads to inactivation of GSK-3β (102), leptin-induced WNT/β-
catenin activation offers an explanation for the insulin-sensitizing effects of leptin (Figure 1).  
 
Comparative physiology of energy and glucose homeostasis in different animal classes 
In light of the importance of leptin for glucose homeostasis in mammals, it is of interest to consider 
how glucoregulation is organised in other animal classes. As an intensely studied example of the 
class of insects, the fruit fly Drosophila melanogaster displays striking homologies to mammals 
in the molecular insulin signalling pathway. The insulin receptor of fruit flies was demonstrated to 
be activated by mammalian insulin (113,114). Disruption of insulin signalling led to a diabetic 
phenotype in D. melanogaster (114). Neurosecretory cells (NSCs) are located in the fly brain and 
release Drosophila insulin-like peptides (Dilps). Despite structural differences, Dilps exert similar 
effects to mammalian insulin and control systemic growth and energy homeostasis (115). The fat 
body of fruit flies, a functional analogue to the mammalian adipose tissue, secretes Unpaired 2 
(Upd2), an adiposity signal. Upd2 binds to its receptor on NSCs and activates the intracellular 
JAK/STAT signalling pathway, causing increased secretion of Dilps (115). Knockdown of upd2 
in D. melanogaster resulted in increased circulating trehalose levels, a disaccharide of glucose and 
the principal sugar in the haemolymph of insects. Strikingly, human leptin was shown to rescue 
this phenotype through activation of JAK/STAT signalling in these flies, indicating that Upd2 is a 
functional homologue of leptin (115). Much like fruit flies, zebrafish (Danio rerio) are a popular 
non-mammalian research model. However, as vertebrates, fish are evolutionary much closer to 
mammals than flies. Insulin in fish regulates growth, energy metabolism and glucose balance 
through insulin receptor-PI3K-AKT signalling in the brain, just like it does in mammals (116,117). 
In fish, leptin receptors are found in the brain, but leptin is secreted mainly in the liver, not the 
adipose tissue (118). Leptin receptor deletion was shown to have negligible effects on body mass 
and body fat (119), challenging the role of leptin as an adipostat in fish. In a different study leptin 
receptor deletion in zebrafish was demonstrated to result in alterations in glucose homeostasis but 
to not have any effects on adipostasis (120). Collectively, these findings suggest that leptin has 




primarily been a glucoregulatory hormone and that its mammalian role in energy homeostasis as 
an adipostat might have developed secondarily throughout evolution (Figure 2).  
 
Circadian control of adiposity signals and energy homeostasis  
Emerging evidence suggests that regulation of energy homeostasis is tightly controlled by the 
circadian clock as demonstrated in numerous studies (121-124). Various metabolic phenotypes 
have been described for clock gene mutation studies in rodents (125,126). The circadian clock, 
whose central pacemaker resides in the hypothalamic suprachiasmatic nucleus (SCN), orchestrates 
an organism’s physiology and behaviour in a rhythmic fashion to adapt to the 24-hour day. These 
endogenously generated rhythms are entrainable by external cues, such as light and food 
(127,128). Circadian disruptions can lead to the development of the metabolic syndrome, including 
increased body weight, hyperglycaemia, impaired glucose tolerance and hepatic insulin resistance 
(123,129). We recently discovered that hypothalamic sensitivity to leptin is regulated in a circadian 
manner in mice and that DIO leads to impairments of leptin sensitivity only at specific times 
throughout the day, whereas at other times leptin sensitivity remains normal. Restricting food 
intake in DIO mice to the identified leptin sensitive times proved to be beneficial for metabolic 
health (122). Furthermore, we and others demonstrated that chronic light disruptions caused 
impairments of leptin signalling accompanied by dramatic deterioration of glucose metabolism 
(123,130). Peripheral glucose homeostasis exhibits a strong daily rhythm controlled by the 
circadian clock (reviewed in detail in (131)). The SCN contains two separate populations of pre-
sympathetic and pre-parasympathetic neurons providing the anatomical basis for the circadian 
oscillation in autonomic output to peripheral organs like the liver (132). Here, plasma glucose 
levels were demonstrated to be controlled by GABAergic inputs from the SCN, controlling hepatic 
gluconeogenesis (133) (Figure 1). Furthermore, SCN neuronal activity was shown to affect hepatic 
insulin sensitivity (134). These findings highlight the importance of circadian regulation of factors 
involved in the control of energy homeostasis and the detrimental effects of disruption of these 
rhythms.  
 





The brain is important for the control of many aspects of whole-body energy and glucose 
homeostasis. The crosstalk between insulin and leptin signalling in the hypothalamus plays a 
critical role in this process. Evidence for an integral role of leptin in the homeostatic control of 
euglycaemia has been provided. The studies reviewed here suggest that the integration of the 
insulin and leptin signal is facilitated by the activation of the WNT/β-catenin signalling pathway 
by leptin, leading to inhibition of GSK-3β and thereby the sensitization of insulin signalling. 
Without functional leptin action, insulin is unable to maintain glucoregulation. We furthermore 
discuss the essential contribution of STAT3 independent leptin signal transduction, as well as 
insulin and leptin action specifically in NPY/AgRP neurons, to the control of glucose homeostasis. 
Future research must attempt to expand our understanding of the neuronal circuits that control 
glucose homeostasis in order to provide therapeutic interventions that counteract disruptions of 
these processes.  
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